 EXHIBIT 2.1      



  

Exhibit 2.1

  



    



  



  

AGREEMENT AND PLAN OF MERGER

  



  

by and among

  



  

H. LUNDBECK A/S,

  



  

CHARLIE ACQUISITION CORP.,

  



  

and

  



  

CHELSEA THERAPEUTICS INTERNATIONAL, LTD.

  



  

Dated as of May 7, 2014

  



  



  



    


--- 

 


--- 

    



  

 _Table of Contents_

  



       |   |   |   | _Page_ 
---|---|---|---|--- 
     |   |   |   | 
   ARTICLE I  |   | DEFINITIONS and INTERPRETATIONS  | 2 
     |   |   | 
     | 1.1  |   | Certain Definitions  | 2 
     |   |   |   | 
     | 1.2  |   | Certain Interpretations  | 10 
     |   |   |   | 
     | 1.3  |   | Index of Defined Terms  | 11 
     |   |   |   | 
   ARTICLE II  |   | THE OFFER  | 12 
     |   |   | 
     | 2.1  |   | The Offer  | 12 
     |   |   |   | 
     | 2.2  |   | Company Actions  | 15 
     |   |   |   | 
     | 2.3  |   | Notices of Guaranteed Delivery  | 16 
     |   |   |   | 
   ARTICLE III  |   | THE MERGER  | 16 
     |   |   | 
     | 3.1  |   | The Merger  | 16 
     |   |   |   | 
     | 3.2  |   | The Closing  | 16 
     |   |   |   | 
     | 3.3  |   | The Effective Time  | 16 
     |   |   |   | 
     | 3.4  |   | Effect of the Merger  | 16 
     |   |   |   | 
     | 3.5  |   | Certificate of Incorporation and By-Laws  | 16 
     |   |   |   | 
     | 3.6  |   | Directors and Officers  | 17 
     |   |   |   | 
     | 3.7  |   | Effect on Capital Stock  | 17 
     |   |   |   | 
     | 3.8  |   | Exchange of Certificates  | 19 
     |   |   |   | 
     | 3.9  |   | Necessary Further Actions  | 21 
     |   |   |   | 
   ARTICLE IV  |   | REPRESENTATIONS AND WARRANTIES OF THE COMPANY  | 21 
     |   |   | 
     | 4.1  |   | Organization; Good Standing  | 21 
     |   |   |   | 
     | 4.2  |   | Corporate Power; Enforceability  | 21 
     |   |   |   | 
     | 4.3  |   | Board Actions  | 22 
     |   |   |   | 
     | 4.4  |   | Voting Requirements  | 22 
     |   |   |   | 
     | 4.5  |   | Non-Contravention  | 22 
     |   |   |   | 
     | 4.6  |   | Required Governmental Approvals  | 23 
     |   |   |   | 
     | 4.7  |   | Company Capitalization  | 23 
     |   |   |   | 
     | 4.8  |   | Subsidiaries  | 25 
     |   |   |   | 
     | 4.9  |   | Company SEC Reports  | 25 
     |   |   |   | 
     | 4.10  |   | Company Financial Statements  | 26 
     |   |   |   | 
     | 4.11  |   | Disclosure Documents  | 27 
     |   |   |   | 
     | 4.12  |   | No Undisclosed Liabilities  | 27 
   



  

   

i 
--- 

 


--- 

    



  

 _Table of Contents (cont 'd)_

  



       |   |   |   | _Page_ 
---|---|---|---|--- 
     |   |   |   | 
     | 4.13  |   | Absence of Certain Changes  | 28 
     |   |   |   | 
     | 4.14  |   | Material Contracts  | 28 
     |   |   |   | 
     | 4.15  |   | Real Property  | 30 
     |   |   |   | 
     | 4.16  |   | Personal Property and Assets  | 31 
     |   |   |   | 
     | 4.17  |   | Intellectual Property  | 31 
     |   |   |   | 
     | 4.18  |   | Tax Matters  | 31 
     |   |   |   | 
     | 4.19  |   | Employee Plans  | 33 
     |   |   |   | 
     | 4.20  |   | Labor Matters  | 35 
     |   |   |   | 
     | 4.21  |   | Permits  | 35 
     |   |   |   | 
     | 4.22  |   | Compliance with Laws  | 36 
     |   |   |   | 
     | 4.23  |   | Environmental Matters  | 37 
     |   |   |   | 
     | 4.24  |   | Litigation  | 38 
     |   |   |   | 
     | 4.25  |   | Insurance  | 38 
     |   |   |   | 
     | 4.26  |   | Related Party Transactions  | 38 
     |   |   |   | 
     | 4.27  |   | Brokers  | 38 
     |   |   |   | 
     | 4.28  |   | Opinion of Financial Advisor  | 38 
     |   |   |   | 
     | 4.29  |   | Milestone and Royalty Payments  | 38 
     |   |   |   | 
   ARTICLE V  |   | REPRESENTATIONS AND WARRANTIES OF PARENT AND
ACQUISITION SUB  | 39 
     |   |   | 
     | 5.1  |   | Organization; Good Standing  | 39 
     |   |   |   | 
     | 5.2  |   | Corporate Power; Enforceability  | 39 
     |   |   |   | 
     | 5.3  |   | Non-Contravention  | 39 
     |   |   |   | 
     | 5.4  |   | Required Governmental Approvals  | 40 
     |   |   |   | 
     | 5.5  |   | Litigation  | 40 
     |   |   |   | 
     | 5.6  |   | Information Supplied  | 40 
     |   |   |   | 
     | 5.7  |   | Ownership of Company Capital Stock  | 41 
     |   |   |   | 
     | 5.8  |   | Brokers  | 41 
     |   |   |   | 
     | 5.9  |   | Operations and Ownership of Acquisition Sub  | 41 
     |   |   |   | 
     | 5.10  |   | Available Funds  | 41 
     |   |   |   | 
     | 5.11  |   | Stockholder and Management Arrangements  | 42 
     |   |   |   | 
     | 5.12  |   | No Other Company Representations or Warranties  |
42 
     |   |   |   | 
     | 5.13  |   | Non-Reliance on Company Estimates, Projections,
Forecasts, Forward-Looking Statements and Business Plans  | 42 
     |   |   |   | 
   ARTICLE VI  |   | COVENANTS OF THE COMPANY  | 43 
   



  

   

ii 
--- 

 


--- 

    



  

 _Table of Contents (cont 'd)_

  



       |   |   |   | _Pages_ 
---|---|---|---|--- 
     |   |   |   | 
     | 6.1  |   | Interim Conduct of Business  | 43 
     |   |   |   | 
     | 6.2  |   | No Solicitation  | 46 
     |   |   |   | 
     | 6.3  |   | Company Board Recommendation  | 47 
     |   |   |   | 
     | 6.4  |   | Access  | 49 
     |   |   |   | 
     | 6.5  |   | Section 16(b) Exemption  | 49 
     |   |   |   | 
     | 6.6  |   | Stock Exchange Delisting  | 49 
     |   |   |   | 
   ARTICLE VII  |   | COVENANTS OF PARENT AND ACQUISITION SUB  | 50 
     |   |   | 
     | 7.1  |   | Directors' and Officers' Indemnification and
Insurance  | 50 
     |   |   |   | 
     | 7.2  |   | Employee Matters  | 53 
     |   |   |   | 
     | 7.3  |   | Obligations of Acquisition Sub  | 54 
     |   |   |   | 
     | 7.4  |   | Other Actions by Parent and Acquisition Sub  | 54 
     |   |   |   | 
     | 7.5  |   | Tax Matters  | 55 
     |   |   |   | 
     | 7.6  |   | CVRs  | 55 
     |   |   |   | 
   ARTICLE VIII  |   | ADDITIONAL COVENANTS OF ALL PARTIES  | 55 
     |   |   | 
     | 8.1  |   | Reasonable Best Efforts to Complete  | 55 
     |   |   |   | 
     | 8.2  |   | Regulatory Filings  | 55 
     |   |   |   | 
     | 8.3  |   | No Company Stockholders Meeting  | 57 
     |   |   |   | 
     | 8.4  |   | Anti-Takeover Laws  | 57 
     |   |   |   | 
     | 8.5  |   | Public Statements and Disclosure  | 58 
     |   |   |   | 
     | 8.6  |   | Confidentiality  | 58 
     |   |   |   | 
     | 8.7  |   | Certain Litigation  | 58 
     |   |   |   | 
     | 8.8  |   | Rule 14d-10(d) Matters  | 58 
     |   |   |   | 
     | 8.9  |   | Directors  | 59 
     |   |   |   | 
   ARTICLE IX  |   | CONDITIONS TO THE MERGER  | 60 
     |   |   | 
     | 9.1  |   | Conditions to Each Party's Obligation to Effect the
Merger  | 60 
     |   |   |   | 
     | 9.2  |   | Conditions to Company's Obligation to Effect the
Merger  | 60 
     |   |   |   | 
   ARTICLE X  |   | TERMINATION, AMENDMENT AND WAIVER  | 60 
     |   |   | 
     | 10.1  |   | Termination  | 60 
     |   |   |   | 
     | 10.2  |   | Notice of Termination; Effect of Termination  | 63 
     |   |   |   | 
     | 10.3  |   | Fees and Expenses  | 63 
     |   |   |   | 
     | 10.4  |   | Amendment  | 64 
     |   |   |   | 
     | 10.5  |   | Extension; Waiver  | 64 
     |   |   |   | 
   ARTICLE XI  |   | GENERAL PROVISIONS  | 65 
   



  

   

iii 
--- 

 


--- 

    



  

 _Table of Contents (cont 'd)_

  



       |   |   |   | _Page_ 
---|---|---|---|--- 
     |   |   |   | 
     | 11.1  |   | Survival of Representations, Warranties and
Covenants  | 65 
     |   |   |   | 
     | 11.2  |   | Notices  | 65 
     |   |   |   | 
     | 11.3  |   | Assignment  | 66 
     |   |   |   | 
     | 11.4  |   | Entire Agreement  | 66 
     |   |   |   | 
     | 11.5  |   | Third Party Beneficiaries  | 66 
     |   |   |   | 
     | 11.6  |   | Severability  | 66 
     |   |   |   | 
     | 11.7  |   | Specific Performance  | 67 
     |   |   |   | 
     | 11.8  |   | Governing Law  | 67 
     |   |   |   | 
     | 11.9  |   | Consent to Jurisdiction  | 67 
     |   |   |   | 
     | 11.10  |   | WAIVER OF JURY TRIAL  | 68 
     |   |   |   | 
     | 11.11  |   | Company Disclosure Letter References  | 68 
     |   |   |   | 
     | 11.12  |   | Counterparts  | 68 
  



  

 _List of Exhibits_

  



     Exhibit A   | -  | Form of Amended and Restated Certificate of
Incorporation 
---|---|--- 
   Exhibit B  | -  | Form of Contingent Value Rights Agreement 
    



  

   

iv 
--- 

 


--- 

    



  

 _AGREEMENT AND PLAN OF MERGER_

  



  

This AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of May 7,
2014, is entered into by and among H. Lundbeck A/S, a Danish corporation
("Parent"), Charlie Acquisition Corp., a Delaware corporation and an indirect
wholly-owned Subsidiary of Parent ("Acquisition Sub"), and Chelsea
Therapeutics International, Ltd., a Delaware corporation (the "Company").
Each of Parent, Acquisition Sub and the Company are referred to herein as a
"Party" and together as the "Parties." Capitalized terms used but not
otherwise defined in this Agreement shall have the respective meanings
ascribed thereto in _ARTICLE I_.

  



  

WITNESSETH:

  



  

WHEREAS, (a) the respective boards of directors of each of Parent,
Acquisition Sub and the Company have approved this Agreement and
the transactions contemplated hereby, including the Offer and the Merger, on
the terms and subject to the conditions set forth in this Agreement and (b)
the respective boards of directors of each of the Company and Acquisition Sub
have determined that this Agreement and the transactions contemplated hereby,
including the Offer and the Merger, are advisable, fair to and in the
best interests of their stockholders;

  



  

WHEREAS, Parent proposes to cause Acquisition Sub to commence a tender offer
(as it may be amended from time to time as permitted under this Agreement,
the "Offer") to purchase any and all of the outstanding shares of Company
Common Stock for (a) $6.44, without interest (such amount, or any other
amount per share of Company Common Stock paid pursuant to the Offer and this
Agreement, the "Cash Consideration"), net to the seller thereof in cash, and
(b) one contingent value right of Parent pursuant to the CVR Agreement (a
"CVR" and, together with the Cash Consideration, the "Merger Consideration"),
in each case, per share of Company Common Stock on the terms and subject to
the conditions set forth in this Agreement;

  



  

WHEREAS, upon the terms and subject to the conditions set forth in this
Agreement, Acquisition Sub will merge with and into the Company, with the
Company continuing as the surviving corporation in the merger (the "Merger")
in accordance with the General Corporation Law of the State of Delaware (the
"DGCL") (with the Merger being governed by and effected pursuant to Section
251(h) of the DGCL), and as a result of the Merger, except as expressly
provided in _Section 3.7(a)(ii)_ ,  _Section 3.7(a)(iii)_ and _Section
3.7(c)_ , each issued and outstanding share of Company Common Stock
immediately prior to the effective time of the Merger will be converted into
the right to receive the Merger Consideration; and

  



  

WHEREAS, Parent, Acquisition Sub and the Company desire to make certain
representations, warranties, covenants and agreements in connection with this
Agreement and the transactions contemplated hereby and to prescribe certain
conditions with respect to the consummation of the transactions contemplated
by this Agreement.

  



  

NOW, THEREFORE, in consideration of the foregoing premises and the
representations, warranties, covenants and agreements set forth herein, as
well as other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged and accepted, and intending to be legally bound
hereby, Parent, Acquisition Sub and the Company hereby agree as follows:

  



  

   

\- 1 - 
--- 

 


--- 

    



  

ARTICLE I 
  _DEFINITIONS and INTERPRETATIONS_

  



  

1.1 _Certain Definitions_. For all purposes of and under this Agreement, the
following capitalized terms shall have the following respective meanings:

  



  

"Acceptable Confidentiality Agreement" shall mean a customary confidentiality
agreement on terms not less favorable to the Company in the aggregate than
those contained in the Confidentiality Agreement; _provided_ , _however_ ,
such agreement may omit or contain provisions that are less favorable to the
Company than those contained in the Confidentiality Agreement and in
such event the Confidentiality Agreement shall be deemed correspondingly
amended.

  



  

"Acquisition Proposal" shall mean any inquiry, offer or proposal (other than
an inquiry, offer or proposal by Parent or Acquisition Sub) to engage in an
Acquisition Transaction.

  



  

"Acquisition Transaction" shall mean any transaction or series of related
transactions (other than the transactions contemplated by this Agreement)
involving: (i) the purchase or other acquisition by any Person (or the equity
holders of such Person) or "group" (as defined in or under Section 13(d) of
the Exchange Act), directly or indirectly, of more than twenty percent (20%)
of the Company Common Stock outstanding or shares of any other class of
voting securities of the Company outstanding as of the consummation of such
purchase or other acquisition, or any tender offer or exchange offer by any
Person or "group" (as defined in or under Section 13(d) of the Exchange Act)
that, if consummated in accordance with its terms, would result in such Person
(or the equity holders of such Person) or "group" beneficially owning more
than twenty percent (20%) of the Company Common Stock outstanding or shares
of any other class of voting securities of the Company outstanding as of the
consummation of such tender or exchange offer; (ii) a merger, consolidation,
joint venture, business combination or other similar transaction
involving the Company pursuant to which any Person (or the equity holders of
such Person) or "group" (as defined in or under Section 13(d) of the Exchange
Act) would hold, directly or indirectly as of the consummation of such
transaction, more than twenty percent (20%) of any class of the voting equity
interests in the surviving or resulting entity of such transaction or the
direct or indirect parent of such entity; (iii) a sale, transfer,
acquisition, lease, exchange or disposition of more than twenty percent (20%)
of the consolidated assets of the Company and its Subsidiaries taken as a
whole (measured by any of the fair market value, consolidated net revenue,
consolidated net income or consolidated book value thereof or represented
thereby); (iv) the issuance by the Company of securities representing more
than 20% of the Company Common Stock outstanding or shares of any other class
of voting securities of the Company outstanding; or (v) a liquidation,
dissolution or other winding up of the Company and its Subsidiaries, taken as
a whole.

  



  

"Affiliate" shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by or is under common control
with such Person. For purposes of the immediately preceding sentence, the term
"control" (including, with correlative meanings, the terms "controlling,"
"controlled by" and "under common control with"), as used with respect to any
Person, means the possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of such Person, whether
through ownership of voting securities, by contract or otherwise.

  



  

"Antitrust Law" shall mean the Sherman Antitrust Act of 1890, as amended, the
Clayton Act of 1914, as amended, the HSR Act, the Federal Trade Commission
Act, as amended, and all other Laws that are designed or intended to prohibit,
restrict or regulate actions having the purpose or effect of monopolization
or restraint of trade or significant impediments or lessening of competition
or the creation or strengthening of a dominant position through merger or
acquisition, including any foreign merger control, antitrust, or foreign
investment Laws, in any case that are applicable to the transactions
contemplated by this Agreement.

  



  

   

\- 2 - 
--- 

 


--- 

    



  

"Business Day" shall mean any day, other than a Saturday, Sunday and any day
which is a legal holiday under the laws of the State New York or is a day on
which banking institutions located in the State of New York are authorized or
required by Law or other governmental action to close.

  



  

"Code" shall mean the Internal Revenue Code of 1986, as amended, and the
rules and regulations promulgated thereunder.

  



  

"Company Balance Sheet" shall mean the audited consolidated balance sheet of
the Company and its Subsidiaries as of December 31, 2013.

  



  

"Company Balance Sheet Date" shall mean December 31, 2013.

  



  

"Company Board" shall mean the Board of Directors of the Company.

  



  

"Company By-Laws" shall mean the by-laws of the Company.

  



  

"Company Capital Stock" shall mean the Company Common Stock and the Company
Preferred Stock.

  



  

"Company Certificate of Incorporation" shall mean the Certificate of
Incorporation of the Company, as amended through the date hereof.

  



  

"Company Common Stock" shall mean the Common Stock, par value $0.0001 per
share, of the Company.

  



  

"Company Intellectual Property Rights" means Intellectual Property rights
owned, used or held for use by the Company or any of its Subsidiaries.

  



  

"Company Material Adverse Effect" shall mean any change, effect, event or
development (each a "Change", and collectively, "Changes") that, individually
or taken together with all other Changes, has had or would reasonably be
likely to have a material adverse effect on the business, financial condition
or results of operations of the Company and its Subsidiaries, taken as a
whole; _provided _,_ however _,__ that none of the following and no Change (by
itself or when aggregated or taken together with any and all other Changes)
directly or indirectly resulting from, relating to or arising out of any of
the following shall be deemed to be or constitute a "Company Material Adverse
Effect," and none of the following and no Change (by itself or when
aggregated or taken together with any and all other such Changes) directly or
indirectly resulting from, relating to or arising out of any of the following
shall be taken into account when determining whether a "Company Material
Adverse Effect" has occurred or may, would or could occur:

  



  

(i) general economic conditions (or changes in such conditions) in the United
States or any other country or region in the world, or conditions in the
global economy generally;

  



  

(ii) conditions (or changes in such conditions) in the securities markets,
capital markets, credit markets, currency markets or other financial markets
in the United States or any other country or region in the world, including
(A) changes in interest rates in the United States or any other country or
region in the world and changes in exchange rates for the currencies of any
countries and (B) any suspension of trading in securities (whether equity,
debt, derivative or hybrid securities) generally on any securities
exchange or over-the-counter market operating in the United States or any
other country or region in the world;

  



  

   

\- 3 - 
--- 

 


--- 

    



  

(iii) conditions (or changes in such conditions) in the industries or markets
in which the Company and its Subsidiaries conduct business;

  



  

(iv) political conditions (or changes in such conditions) in the United
States or any other country or region in the world or acts of war,
sabotage or terrorism (including any escalation or general worsening of any
such acts of war, sabotage or terrorism) in the United States or any other
country or region in the world;

  



  

(v) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild
fires or other natural disasters, weather conditions and other force majeure
events in the United States or any other country or region in the world;

  



  

(vi) the results of any clinical trial of one or more products or product
candidates of any Person other than the Company;

  



  

(vii) the determination by, or the delay of a determination by, the FDA, or
any panel or advisory board empowered or appointed thereby, with respect to
the approval, non-approval or disapproval of any products similar to or
competitive with the Company's product candidates;

  



  

(viii) changes in Law or other legal or regulatory conditions (or the
interpretation thereof) or changes in GAAP or other accounting standards (or
the interpretation thereof);

  



  

(ix) the announcement of this Agreement or the pendency or consummation of
the transactions contemplated hereby _(provided_ that this clause (ix) shall
not apply to any representation or warranty contained in this Agreement to the
extent that the purpose thereof is to address the consequences resulting from
the announcement of this Agreement or the pendency or consummation of the
transactions contemplated by this Agreement), including (A) the identity of
Parent, (B) the loss or departure of officers or other employees of the
Company or any of its Subsidiaries directly or indirectly resulting from,
arising out of, attributable to, or related to the transactions contemplated
by this Agreement, and (C) any other negative development in the Company's
relationships with any of its customers, suppliers, distributors or other
business partners, directly or indirectly resulting from, arising out
of, attributable to, or related to the transactions contemplated by this
Agreement;

  



  

(x) any actions taken or failure to take action, in each case, by Parent or
any of its Subsidiaries, or which Parent has approved, consented to or
requested; compliance with the terms of, or the taking of any action required
or contemplated by, this Agreement, other than _Section 6.1_ ( _provided_
that this clause (x) shall not apply to any representation or warranty
contained in this Agreement to the extent that the purpose thereof is to
address the consequences resulting from the compliance with, and
actions contemplated by, this Agreement); or the failure to take any action
prohibited by this Agreement;

  



  

(xi) changes in the Company's stock price or the trading volume of the
Company's stock, in and of itself, or any failure by the Company to meet any
public estimates or expectations of the Company's revenue, earnings or other
financial performance or results of operations for any period, in and of
itself, or any failure by the Company to meet any internal budgets, plans or
forecasts of its revenues, earnings or other financial performance or results
of operations, in and of itself (but not, in each case, the underlying cause
of such changes or failures, unless such changes or failures would otherwise
be excepted from this definition); and

  



  

   

\- 4 - 
--- 

 


--- 

    



  

(xii) (A) the legal proceedings set forth on _Section 1.1(a)_ of the Company
Disclosure Letter and (B) any legal proceedings against the Company arising
out of this Agreement, the Offer, the Merger or in connection with any other
transactions contemplated by this Agreement.

  



  

Notwithstanding the foregoing proviso, to the extent a Change (by itself or
when aggregated or taken together with any and all other Changes) both (A)
results from, arises out of, or is attributable or related to, any of the
matters described in _clauses (i)_ through  _(vi)_ , _(vii)_ or _(viii)_
above, and (B) adversely and disproportionately affects the Company and its
Subsidiaries, taken as a whole, as compared to other companies in the
industries in which the Company and its Subsidiaries conduct business, the
disproportionate aspect of such Change may be taken into account when
determining whether a "Company Material Adverse Effect" has occurred.

  



  

"Company Option Amounts" shall mean, collectively, all amounts payable
pursuant to _Section 3.7(d)_.

  



  

"Company Options" shall mean any options to purchase shares of Company Common
Stock outstanding under the Company Stock Plan or otherwise.

  



  

"Company Preferred Stock" shall mean the Preferred Stock, par value $0.0001
per share, of the Company.

  



  

"Company Registered Intellectual Property Rights" shall mean all of the
Registered Intellectual Property owned by, filed in the name of, or applied
for by the Company or any of its Subsidiaries.

  



  

"Company Stock Plan" shall mean the 2004 Stock Plan, as amended or restated
from time to time in accordance with the terms thereof.

  



  

"Company Stockholders" shall mean holders of shares of Company Common Stock,
in their capacities as such.

  



  

"Confidentiality Agreement" shall mean the confidentiality agreement between
the Company and Parent, dated April 18, 2013, as amended or modified from
time to time in accordance with the terms thereof.

  



  

"Continuing Employees" shall mean all employees of the Company and its
Subsidiaries as of the Effective Time.

  



  

"Contract" shall mean any binding written or oral contract, subcontract,
agreement, commitment, note, bond, mortgage, indenture, lease,
understanding, arrangement, obligation, letter of intent, memorandum of
understanding, purchase order, license, sublicense or other legally
binding instrument or arrangement.

  



  

"CVR Agreement" shall mean that certain Contingent Value Rights Agreement
between Parent and a rights agent selected by Parent and reasonably
acceptable to the Company (the "Rights Agent"), substantially in the form
attached hereto as  _Exhibit B_ (subject to any reasonable revisions
requested by the Rights Agent and _Section 7.6(b)_ ).

  



  

"Delaware Law" shall mean the DGCL and any other applicable law (including
common law) of the State of Delaware.

  



  

"DOJ" shall mean the United States Department of Justice or any successor
thereto.

  



  

"EMA" shall mean the European Medicines Agency.

  



  

   

\- 5 - 
--- 

 


--- 

    



  

"Environmental Law" shall mean any and all applicable Laws relating to the
protection of the environment (including ambient air, surface water,
groundwater or land) or exposure of any individual to Hazardous Substances or
otherwise relating to the production, use, emission, storage, treatment,
transportation, recycling, disposal, discharge, release or other handling of
any Hazardous Substances or the investigation, cleanup or other remediation
or analysis thereof.

  



  

"Equity Interest" shall mean any share, capital stock, partnership, limited
liability company, member or similar interest in any Person, and any option,
warrant, right or security convertible, exchangeable or exercisable therefor
or other instrument, obligation or right the value of which is based on any
of the foregoing, in each case issued, granted, entered into, agreed to or
authorized by such Person.

  



  

"ERISA" shall mean the Employee Retirement Income Security Act of 1974, as
amended, and the rules and regulations promulgated thereunder, or any
successor statue, rules and regulations thereto.

  



  

"ERISA Affiliate" shall mean each trade or business (whether or not
incorporated) that together with the Company or any Subsidiary of the Company
would be deemed to be a single employer within the meaning of Section 414 of
the Code.

  



  

"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder, or any successor
statute, rules and regulations thereto.

  



  

"FDA" means the United States Food and Drug Administration or any successor
thereto.

  



  

"FTC" shall mean the United States Federal Trade Commission or any successor
thereto.

  



  

"GAAP" shall mean generally accepted accounting principles, as applied in the
United States.

  



  

"Governmental Authority" shall mean any government, any governmental or
regulatory entity or body, department, commission, board, agency or
instrumentality, and any court, tribunal or judicial body of competent
jurisdiction, in each case whether federal, state, county, provincial, and
whether local or foreign.

  



  

"Hazardous Substance" shall mean any substance, material or waste that is
regulated under any Environmental Law, including those characterized or
defined as "hazardous," "pollutant," "contaminant," "toxic" or words of
similar meaning or effect, and including petroleum and petroleum products,
polychlorinated biphenyls and asbestos.

  



  

"HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, and the rules and regulations promulgated thereunder, or
any successor statute, rules and regulations thereto.

  



  

"Indebtedness" means, with respect to any Person, (i) all obligations of such
Person, whether or not contingent, for borrowed money, or with respect to
deposits or advances of any kind to such Person, (ii) all obligations of such
Person evidenced by notes, bonds, debentures or other similar instruments,
(iii) all obligations of such Person for the deferred purchase price of
property or services, (iv) all obligations of such Person under currency,
interest rate or other swaps, and all hedging and other obligations of such
Person under other derivative instruments, (v) all Indebtedness created or
arising under any conditional sale or other title retention agreement with
respect to property acquired by such Person, (vi) all obligations of such
Person as lessee under leases that have been or should be, in accordance with
GAAP, recorded as capital leases, (vii) all obligations, contingent or
otherwise, of such Person under acceptance, letter of credit or similar
facilities or pursuant to securitization or factoring programs or
arrangements, (viii) all obligations of such Person to purchase, redeem,
retire, defease or otherwise acquire for value any share capital of such
Person or any warrants, rights or options to acquire such share capital,
valued, in the case of redeemable preferred shares, at the greater of its
voluntary or involuntary liquidation preference plus accrued and unpaid
dividends, (ix) all "keep well" or similar agreements of such Person or
obligations or undertakings of such Person to maintain or cause to be
maintained the financial position or covenants of others or to purchase the
obligations or property of others, (x) all Indebtedness of others referred to
in clauses (i) through (ix) guaranteed directly or indirectly in any manner by
such Person and (xi) all Indebtedness referred to in clauses (i) through (ix)
secured by (or for which the holder of such Indebtedness has an existing
right, contingent or otherwise, to be secured by) any Liens on property
(including accounts and contract rights) owned by such Person, even
though such Person has not assumed or become liable for the payment of such
Indebtedness.

  



  

   

\- 6 - 
--- 

 


--- 

    



  

"Intellectual Property" shall mean all intellectual property and other
similar proprietary rights in any jurisdiction, including: (i) all patents
(including all reissues, divisionals, provisionals, continuations and
continuations-in-part, re-examinations,  _inter partes_ reviews, renewals,
substitutions and extensions thereof), applications for patents, patent
disclosures or other patent rights, (ii) all market authorizations,
exclusivities or designations, including orphan designations, or requests for
the same, (iii) all inventions, discoveries, trade secrets, business and
technical information and know-how, databases, data collections and other
confidential and proprietary information and all rights therein, (iv) all
copyright registrations, applications for copyright registrations and
unregistered copyrights, (v) all trademarks, service marks and other indicia
of origin together with all goodwill associated therewith, and all
registrations, applications for registration, renewals for any of the
foregoing and unregistered trademarks, and (vi) Internet domain names, and
all rights to any of the foregoing.

  



  

"Intervening Event" shall mean a material event or circumstance that was not
known to the Company Board on the date of this Agreement (or if known, the
consequences of which (or the magnitude of such consequences) were not known
to the Company Board as of the date of this Agreement), which event or
circumstance, or the consequence (or magnitude) thereof, becomes known to the
Company Board prior to the Offer Closing; _provided_ , _however_ , that in no
event shall any Acquisition Proposal or any inquiry, offer or proposal that
constitutes or would reasonably be expected to lead to an Acquisition Proposal
constitute an Intervening Event.

  



  

"IRS" shall mean the United States Internal Revenue Service or any successor
thereto.

  



  

"Key Product" shall mean droxidopa (including any other formulation thereof).

  



  

"Knowledge" of the Company, with respect to any matter in question, shall
mean the actual knowledge after reasonable inquiry of any of the Persons set
forth in _Section 1.1(b)_ of the Company Disclosure Letter as of the date of
this Agreement.

  



  

"Law" shall mean any and all applicable federal, state, local, municipal,
foreign or other law, statute, constitution, principle of common law,
ordinance, code, rule, regulation, ruling or other legal requirement issued,
enacted, adopted, promulgated, implemented or otherwise put into effect by or
under the authority of any Governmental Authority.

  



  

"Legal Proceeding" shall mean any action, investigation, claim, lawsuit,
litigation or other proceeding brought by or pending before any Governmental
Authority.

  



  

"Liabilities" shall mean any liability, obligation or commitment of any kind
(whether accrued, absolute, contingent, matured, unmatured or otherwise and
whether or not required to be recorded or reflected on a balance sheet
prepared in accordance with GAAP).

  



  

   

\- 7 - 
--- 

 


--- 

    



  

"Lien" shall mean any lien, pledge, hypothecation, charge, mortgage, security
interest, encumbrance, option, right of first refusal, preemptive right or
community property interest (including any restriction on the voting of any
security, any restriction on the transfer of any security or other asset, any
restriction on the possession, exercise or transfer of any other attribute of
ownership of any asset).

  



  

"Nasdaq" shall mean The NASDAQ Global Market.

  



  

"Order" shall mean any order, judgment, decision, decree, injunction, ruling,
writ or assessment of any Governmental Authority (whether temporary,
preliminary or permanent) that is binding on any Person or its property under
applicable Law.

  



  

"Permitted Liens" shall mean any of the following: (i) Liens for Taxes,
assessments and governmental charges or levies either not yet delinquent or
which are being contested in good faith by appropriate proceedings and for
which appropriate reserves have been established on the consolidated
financial statements of the Company and its Subsidiaries in accordance with
GAAP as adjusted in the ordinary course of business through the Effective
Time; (ii) mechanics, carriers', workmen's, warehousemen's, repairmen's,
materialmen's or other Liens that are not yet due or that are being contested
in good faith and by appropriate proceedings; (iii) pledges or deposits to
secure obligations under workers' compensation Laws or similar legislation
or to secure public or statutory obligations; (iv) pledges and deposits to
secure the performance of bids, trade contracts, leases, surety and appeal
bonds, performance bonds and other obligations of a similar nature, in each
case in the ordinary course of business; (v) defects, imperfections or
irregularities in title, easements, covenants and rights of way (unrecorded
and of record) and other similar restrictions, and zoning, building and other
similar codes or restrictions, in each case that do not adversely affect in
any material respect the value or the current use of the applicable property
owned, leased, used or held for use by the Company or any of its
Subsidiaries; (vi) Liens that individually or in the aggregate do not
materially and adversely affect the use or operation of the property subject
thereto; (vii) statutory, common law or contractual liens of landlords,
provided the same are not currently violated or in breach; (viii) with
respect to Intellectual Property, restrictions associated with nonexclusive
licenses and (ix) Liens described in _Section 1.1(c)_ of the Company
Disclosure Letter.

  



  

"Person" shall mean any individual, corporation (including any nonprofit
corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any limited
liability company or joint stock company), firm or other enterprise,
association, organization, entity or Governmental Authority.

  



  

"Registered Intellectual Property Rights" shall mean all Intellectual
Property that is the subject of an application, certificate, filing,
registration, or other document issued by, filed with, or recorded by, any
Governmental Authority in any jurisdiction, including all applications,
reissues, divisions, re-examinations, renewals, extensions, provisionals,
continuations, and continuations-in-part associated with patent rights.

  



  

"Registrations" shall mean any investigational new drug applications, new
drug applications, or similar regulatory applications of the Company or any
of its Subsidiaries that have been submitted to or approved by the FDA or any
applicable Governmental Authority.

  



  

"Release" shall mean any actual or threatened release, spill, emission,
leaking, dumping, injection, pouring, deposit, disposal,
discharge, dispersal, leaching or migration into or through the environment
or within any building, structure, facility or fixture.

  



  

"Sarbanes-Oxley Act" shall mean the Sarbanes-Oxley Act of 2002, as amended,
and the rules and regulations promulgated thereunder, or any successor
statute, rules or regulations thereto.

  



  

   

\- 8 - 
--- 

 


--- 

    



  

"SEC" shall mean the United States Securities and Exchange Commission or any
successor thereto.

  



  

"Securities Act" shall mean the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder, or any successor statute, rules
or regulations thereto.

  



  

"Subsidiary" of any Person shall mean (i) a corporation more than fifty
percent (50%) of the combined voting power of the outstanding voting stock of
which is owned, directly or indirectly, by such Person or by one or more other
Subsidiaries of such Person or by such Person and one or more other
Subsidiaries thereof, (ii) a partnership of which such Person, or one or more
other Subsidiaries of such Person or such Person and one or more other
Subsidiaries thereof, directly or indirectly, is the general partner and
has the power to direct the policies, management and affairs of such
partnership, (iii) a limited liability company of which such Person or one or
more other Subsidiaries of such Person or such Person and one or more other
Subsidiaries thereof, directly or indirectly, is the managing member and has
the power to direct the policies, management and affairs of such company or
(iv) any other Person (other than a corporation, partnership or limited
liability company) in which such Person, or one or more other Subsidiaries of
such Person or such Person and one or more other Subsidiaries thereof,
directly or indirectly, has at least a majority ownership and power to direct
the policies, management and affairs thereof.

  



  

"Substantial Detriment" shall mean (i) any prohibition or limitation on, or
other commitments as to, the ownership, conduct or operation by the Company,
Parent or any of their respective Affiliates of any portion of the business,
rights, properties or assets of Parent or any of its Affiliates or of the
Company relating to Key Products, (ii) the Company, Parent or any of their
respective Affiliates being compelled to sell, divest, license, transfer or
dispose of or hold separate any portion of the business, rights, properties
or assets of Parent or any of its Affiliates or of the Company relating to Key
Products, (iii) any prohibition or limitation on, or other commitments as to,
the ability of Parent or any of its Affiliates to acquire or hold, or
exercise full right of ownership of, any shares of Company Common Stock or
other securities of the Company (including the acquisition of the Company
Common Stock pursuant to the Offer), (iv) any prohibition or limitation on,
or other commitments as to, Parent or any of its Affiliates effectively
controlling the assets, business or operations of the Company relating to Key
Products or (v) any agreement to do or permitting to be done any of the
foregoing.

  



  

"Superior Proposal" shall mean any bona fide written Acquisition Proposal for
an Acquisition Transaction on terms that the Company Board (or any committee
thereof) shall have determined in good faith (after consultation with its
outside financial advisor and outside legal counsel), (i) is more favorable
from a financial point of view to the Company Stockholders than the Offer and
the Merger and (ii) is reasonably capable of being completed if accepted, in
each case, taking into account all terms and conditions of the proposal and
this Agreement and all relevant circumstances, including financial,
regulatory, legal and other aspects of such proposal; _provided, however,_
that for the purposes of the definition of "Superior Proposal" all
references to "20%" in the definition of Acquisition Transaction shall be
deemed to be references to "50%".

  



  

"Tax" shall mean any and all U.S. federal, state, local and non-U.S. taxes,
including taxes based upon or measured by gross receipts, income, profits,
sales, use and occupation, and value added, ad valorem, transfer, franchise,
withholding, payroll, recapture, employment, excise and property taxes,
together with all interest, penalties and additions imposed with respect to
such amounts.

  



  

   

\- 9 - 
--- 

 


--- 

    



  

1.2 _Certain Interpretations_.

  



  

(a) Unless otherwise indicated, all references herein to Articles, Sections,
Annexes, Exhibits or Schedules, shall be deemed to refer to Articles,
Sections, Annexes, Exhibits or Schedules of or to this Agreement, as
applicable.

  



  

(b) Unless otherwise indicated, the words "include," "includes" and
"including," when used herein, shall be deemed in each case to be followed by
the words "without limitation."

  



  

(c) The table of contents and headings set forth in this Agreement are for
convenience of reference purposes only and shall not affect or be deemed to
affect in any way the meaning or interpretation of this Agreement or any term
or provision hereof.

  



  

(d) Unless otherwise indicated, all references herein to the Subsidiaries of
a Person shall be deemed to include all direct and indirect Subsidiaries of
such Person unless otherwise indicated or the context otherwise requires.

  



  

(e) Whenever the context may require, any pronouns used in this Agreement
shall include the corresponding masculine, feminine or neuter forms, and the
singular form of nouns and pronouns shall include the plural, and vice versa.

  



  

(f) Any dollar or percentage thresholds set forth herein shall not be used as
a benchmark for the determination of what is or is not "material" or a
"Company Material Adverse Effect" under this Agreement.

  



  

(g) When used herein, the word "extent" and the phrase "to the extent" shall
mean the degree to which a subject or other thing extends, and such word or
phrase shall not simply mean "if."

  



  

(h) The Parties hereto agree that they have been represented by counsel
during the negotiation and execution of this Agreement and, therefore, waive
the application of any Law, holding or rule of construction providing that
ambiguities in an agreement or other document will be construed against the
Party drafting such agreement or document.

  



  

(i) Unless otherwise indicated, all references herein to "dollars", "cash"
and "$" shall be construed to refer to U.S. dollars.

     



  

   

\- 10 - 
--- 

 


--- 

    



  

1.3 _Index of Defined Terms_.

  



     409A Authorities  | 34  |   | Contract  | 5 
---|---|---|---|--- 
   Acceptable Confidentiality Agreement  | 2  |   | Covered
Securityholder  | 34 
   Acquisition Proposal  | 2  |   | CVR  | 1 
   Acquisition Sub  | 1  |   | CVR Agreement  | 5 
   Acquisition Transaction  | 2  |   | DandO Insurance  | 51 
   Affiliate  | 2  |   | Delaware Law  | 5 
   Agreement  | 1  |   | Deutsche Bank  | 38 
   Antitrust Law  | 2  |   | DGCL  | 1 
   Appraisal Shares  | 18  |   | DOJ  | 5 
   Assets  | 31  |   | Effective Time  | 16 
   Business Day  | 3  |   | EMA  | 5 
   Cash Consideration  | 1  |   | Employee Plans  | 33 
   Certificate  | 17  |   | Employment Compensation Arrangement  | 34 
   Certificate of Merger  | 16  |   | Enforceability Exception  | 22 
   Change  | 3  |   | Environmental Law  | 6 
   Changes  | 3  |   | Equity Interest  | 6 
   Code  | 3  |   | ERISA  | 6 
   Collective Bargaining Agreement  | 35  |   | ERISA Affiliate  | 6 
   Company  | 1  |   | Exchange Act  | 6 
   Company Balance Sheet  | 3  |   | Exchange Fund  | 19 
   Company Balance Sheet Date  | 3  |   | Fairness Opinion  | 38 
   Company Board  | 3  |   | FDA  | 6 
   Company Board Recommendation  | 22  |   | FTC  | 6 
   Company Board Recommendation Change  | 47  |   | Fully Diluted
Shares  | A-2 
   Company By-Laws  | 3  |   | GAAP  | 6 
   Company Capital Stock  | 3  |   | Governmental Authority  | 6 
   Company Certificate of Incorporation  | 3  |   | Hazardous
Substance  | 6 
   Company Common Stock  | 3  |   | HSR Act  | 6 
   Company Compensation Committee  | 34  |   | Indebtedness  | 6 
   Company Disclosure Documents  | 27  |   | Indemnified Persons  | 50 
   Company Disclosure Letter  | 21  |   | Independent Directors  | 59 
   Company Intellectual Property Rights  | 3  |   | Information
Statement  | 23 
   Company Material Adverse Effect  | 3  |   | Initial Expiration Date 
| 13 
   Company Option Amounts  | 5  |   | Intellectual Property  | 7 
   Company Options  | 5  |   | Intervening Event  | 7 
   Company Plans  | 53  |   | IRS  | 7 
   Company Preferred Stock  | 5  |   | Key Product  | 7 
   Company Registered Intellectual Property Rights  | 5  |   |
Knowledge  | 7 
   Company SEC Reports  | 25  |   | Law  | 7 
   Company Securities  | 24  |   | Leased Real Property  | 30 
   Company Stock Plan  | 5  |   | Leases  | 30 
   Company Stockholders  | 5  |   | Legal Proceeding  | 7 
   Comparable Plans  | 53  |   | Liabilities  | 7 
   Confidentiality Agreement  | 5  |   | Lien  | 8 
   Consent  | 23  |   | Material Contract  | 28 
   Continuing Employees  | 5  |   | Merger  | 1 
  



  

   

\- 11 - 
--- 

 


--- 

    



     Merger Closing  | 16  |   | Person  | 8 
---|---|---|---|--- 
   Merger Closing Date  | 16  |   | Post-Signing Arrangement  | 59 
   Merger Consideration  | 1  |   | Recommendation Change Notice  | 48 
   Minimum Tender Condition  | A-1  |   | Registered Intellectual
Property Rights  | 8 
   Nasdaq  | 8  |   | Registrations  | 8 
   New Plans  | 54  |   | Release  | 8 
   Offer  | 1  |   | Representatives  | 46 
   Offer Closing  | 14  |   | Rights Agent  | 5 
   Offer Closing Date  | 14  |   | Sarbanes-Oxley Act  | 8 
   Offer Conditions  | 12  |   | Schedule 14D-9  | 15 
   Offer Documents  | 14  |   | Schedule TO  | 14 
   Old Plans  | 54  |   | SEC  | 9 
   Order  | 8  |   | Securities Act  | 9 
   Outside Date  | 61  |   | Subsidiary  | 9 
   Parent  | 1  |   | Subsidiary Securities  | 25 
   Parent Disclosure Documents  | 40  |   | Substantial Detriment  | 9 
   Parent Expenses  | 64  |   | Superior Proposal  | 9 
   Parent Plans  | 53  |   | Superior Proposal Notice  | 61 
   Parties  | 1  |   | Surviving Corporation  | 16 
   Party  | 1  |   | Takeover Laws  | 22 
   Paying Agency Agreement  | 19  |   | Tax  | 9 
   Paying Agent  | 19  |   | Tax Returns  | 32 
   Permits  | 36  |   | Termination Fee  | 63 
   Permitted Liens  | 8  |   | Transfer Taxes  | 55 
  



  

ARTICLE II 
  _THE OFFER_

  



  

2.1 _The Offer_.

  



  

(a) _Commencement of the Offer_. As promptly as reasonably practicable (and,
in any event, within ten (10) Business Days) after the date of
this Agreement, Acquisition Sub shall, and Parent shall cause Acquisition Sub
to, commence (within the meaning of Rule 14d-2 under the Exchange Act) the
Offer to purchase any and all of the outstanding shares of Company Common
Stock at a per share consideration equal to the Merger Consideration (as
adjusted as provided in _Section 2.1(c)_ , if applicable); _provided_ that,
if the Company is not prepared to file the Schedule 14D-9 on the same date as
the commencement of the Offer, then such ten (10) Business Day deadline shall
automatically be extended for five (5) Business Days (or such earlier date
that the Company is prepared to file the Schedule 14D-9).

  



  

(b) _Terms and Conditions of the Offer_. The obligations of Acquisition Sub
to, and of Parent to cause Acquisition Sub to, accept for payment, and pay
for, any shares of Company Common Stock validly tendered and not validly
withdrawn pursuant to the Offer are subject to the conditions set forth in
_Annex A_ (the "Offer Conditions"). The Offer Conditions, other than the
Minimum Tender Condition, are for the sole benefit of Parent and Acquisition
Sub, and Parent and Acquisition Sub may waive, in whole or in part, any Offer
Condition at any time and from time to time, in their sole discretion, other
than the Minimum Tender Condition, which may be waived by Parent and
Acquisition Sub only with the prior written consent of the Company.
Parent and Acquisition Sub expressly reserve the right to increase the Merger
Consideration or to waive or make any other changes in the terms and
conditions of the Offer; _provided_ , _however_ , that unless otherwise
provided in this Agreement or previously approved by the Company in writing,
Acquisition Sub shall not, and Parent shall not permit Acquisition Sub to, (i)
reduce the number of shares of Company Common Stock sought to be purchased in
the Offer, (ii) reduce the Cash Consideration or the number of CVRs to be
issued per share of Company Common Stock or amend the terms of the CVR or the
CVR Agreement in a manner that is adverse to the interests of the holders of
CVRs, (iii) change the form of consideration payable in the Offer, (iv) amend,
modify or waive the Minimum Tender Condition, (v) add to the Offer Conditions
or amend, modify or supplement any Offer Condition in a manner adverse to any
holder of Company Common Stock, (vi) terminate the Offer, or extend or
otherwise amend or modify the expiration date of the Offer, in any manner
other than in compliance with the terms of this Agreement or (vii) provide any
"subsequent offering period" within the meaning of Rule 14d-11 promulgated
under the Exchange Act.

  



  

   

\- 12 - 
--- 

 


--- 

    



  

(c) _Adjustments to Merger Consideration_. Without limiting the restrictions
set forth in _Section 6.1_ and the other provisions of this Agreement, the
Merger Consideration shall be adjusted appropriately to reflect the effect of
any stock split, reverse stock split, stock dividend (including any dividend
or distribution of securities convertible into Company Common Stock),
reorganization, recapitalization, reclassification, combination, exchange of
shares or other like change with respect to Company Common Stock occurring on
or after the date hereof and prior to Acquisition Sub's acceptance for
payment of, and payment for, Company Common Stock tendered in the Offer, and
such adjustment to the Merger Consideration shall provide to the holders of
Company Common Stock the same economic effect as contemplated by this
Agreement prior to such action.

  



  

(d) _Expiration and Extension of the Offer_. Unless extended as provided in
this Agreement, the Offer shall expire on the date (the "Initial Expiration
Date") that is twenty (20) Business Days (calculated as set forth in Rule
14d-1(g)(3) and Rule 14e-1(a) under the Exchange Act) after the commencement
of the Offer. Notwithstanding the foregoing, subject, in each case, to
Parent's and the Company's right to terminate this Agreement pursuant to
_Section 10.1,_ if, on the Initial Expiration Date or any subsequent date as
of which the Offer is scheduled to expire, any Offer Condition is not
satisfied and has not been waived (to the extent waivable in accordance with
the terms hereof), then Acquisition Sub shall extend (and re-extend) the Offer
and its expiration date beyond the Initial Expiration Date for one or more
periods, in consecutive increments of up to ten (10) Business Days each,
ending no later than the Outside Date, to permit such Offer Condition to be
satisfied; _provided_ , _however_ , if, on the Initial Expiration Date or any
subsequent date as of which the Offer is scheduled to expire, the Minimum
Tender Condition and conditions which by their nature are to be satisfied at
the expiration date are the only Offer Conditions that have not
been satisfied or waived (to the extent waivable in accordance with the terms
hereof), (i) Acquisition Sub shall, if and as requested by the Company in
writing, extend (and re-extend) the Offer and its expiration date beyond the
Initial Expiration Date for one or more periods, in consecutive increments of
up to ten (10) Business Days each, ending no later than the Outside Date or
(ii) if the Company shall not have requested such an extension in writing,
Acquisition Sub may extend (and re-extend) the Offer and its expiration date
beyond the Initial Expiration Date for one or more periods, in consecutive
increments of up to ten (10) Business Days each, ending no later than the
Outside Date. Notwithstanding anything herein to the contrary, Acquisition Sub
shall, without the consent of the Company, extend the Offer for any period
required by any rule, regulation, interpretation or position of the SEC or
its staff, any rule or regulation of the Nasdaq, or any applicable Law or
Order, in each case, applicable to the Offer;  _provided_ , for the avoidance
of doubt, that if Acquisition Sub elects to increase the Merger Consideration,
it shall be required to extend the Initial Expiration Date or such other
subsequent date as of which the Offer is scheduled to expire for the minimum
period required under the securities Laws.

  



  

(e) _Acceptance for Payment and Payment_. On the terms and subject to the
conditions of the Offer and this Agreement, Acquisition Sub shall, and Parent
shall cause Acquisition Sub to, irrevocably accept for payment, and pay for,
all shares of Company Common Stock validly tendered and not validly withdrawn
pursuant to the Offer in compliance with Rule 14e-1(c) promulgated under the
Exchange Act but in any event no later than 9 a.m. New York time on the third
Business Day following the applicable expiration date of the Offer (as it may
be extended in accordance with _Section 2.1(d)_ ). At or prior to such time,
the Merger Consideration payable in respect of each share of Company Common
Stock validly tendered and not validly withdrawn pursuant to the Offer shall
be paid to the holder thereof, subject to reduction for any Taxes required by
Law to be withheld or deducted. The irrevocable acceptance for payment of
shares of Company Common Stock pursuant to and subject to the conditions of
the Offer is referred to in this Agreement as the "Offer Closing", and the
date on which the Offer Closing occurs is referred to in this Agreement
as the "Offer Closing Date".

  



  

   

\- 13 - 
--- 

 


--- 

    



  

(f) _Termination of Offer_. The Offer may not be terminated prior to the
Initial Expiration Date, or any subsequent date as of which the Offer is
scheduled to expire, unless this Agreement is validly terminated in accordance
with _Section 10.1_. If this Agreement is validly terminated pursuant to
_Section 10.1_ , Acquisition Sub shall, and Parent shall cause Acquisition Sub
to, (i) promptly (and in any event within one (1) Business Day of such
termination) terminate the Offer and in any event shall not acquire
any shares of Company Common Stock pursuant thereto and (ii) promptly return,
and shall cause any depositary acting on behalf of Acquisition Sub to return,
in accordance with applicable Law, all tendered shares of Company Common Stock
to the registered holders thereof.

  



  

(g) _Offer Documents_. On the date of commencement of the Offer, Parent and
Acquisition Sub shall file with the SEC a Tender Offer Statement on Schedule
TO with respect to the Offer (together with all amendments and supplements
thereto, and including all exhibits thereto, the "Schedule TO"), which shall
include, as exhibits, an offer to purchase and a related letter of
transmittal, a summary advertisement and other ancillary Offer documents
pursuant to which the Offer will be made (such Schedule TO and the documents
attached as exhibits thereto, together with any supplements or amendments
thereto, the "Offer Documents") and promptly thereafter shall cause the
proper dissemination of the Offer Documents to the holders of the Company
Common Stock as required by applicable Law. The Company shall promptly
furnish to Parent and Acquisition Sub all information concerning the Company
that may be required by applicable Laws or reasonably requested by Parent or
Acquisition Sub for inclusion in the Offer Documents. Each of Parent,
Acquisition Sub and the Company shall promptly correct any information
provided by it for use in the Offer Documents if and to the extent that such
information shall have become false or misleading in any material respect and
provide additional information for use in the Offer Documents if and to the
extent that such Party determines that failure to include such information
would cause the Offer Documents to omit to state any material fact required to
be stated therein. Parent and Acquisition Sub shall take all steps necessary
to cause the Offer Documents, as so corrected, to be filed with the SEC and
the Offer Documents, as so corrected, to be disseminated to the holders of
Company Common Stock, in each case as and to the extent required by
applicable Laws. Parent and Acquisition Sub shall promptly notify the Company
upon the receipt of any comments from the SEC or the staff of the SEC or any
request from the SEC or the staff of the SEC for amendments or supplements to
the Offer Documents, and shall provide the Company with copies of all
correspondence between Parent, Acquisition Sub and their
respective Representatives, on the one hand, and the SEC or the staff of the
SEC, on the other hand. Parent and Acquisition Sub shall use reasonable best
efforts to respond as promptly as reasonably practicable to any comments of
the SEC or the staff of the SEC with respect to the Offer Documents, and
Parent and Acquisition Sub shall provide the Company and its counsel a
reasonable opportunity to participate in the formulation of any written
response to any such written comments of the SEC or the staff of the SEC.
Prior to the filing of the Offer Documents (or any amendment or supplement
thereto) or the dissemination thereof to the holders of Company Common Stock,
or responding to any comments of the SEC or the staff of the SEC with respect
thereto, Parent and Acquisition Sub shall provide the Company and its counsel
a reasonable opportunity to review and to propose comments on such document or
response.

  



  

   

\- 14 - 
--- 

 


--- 

    



  

(h) _Funds_. Subject in all respects to the other terms and conditions of
this Agreement and the Offer Conditions, Parent shall provide or cause to be
provided to Acquisition Sub on a timely basis the funds necessary to purchase
any shares of Company Common Stock that Acquisition Sub becomes obligated to
purchase pursuant to the Offer.

  



  

2.2 _Company Actions_.

  



  

(a) _Schedule 14D-9_. On the date the Offer Documents are filed with the SEC,
the Company shall file with the SEC a Solicitation/Recommendation Statement
on Schedule 14D-9 with respect to the Offer (such Schedule 14D-9, together
with any supplements or amendments thereto, and including all exhibits
thereto, the "Schedule 14D-9") containing the Company Board Recommendation
(subject to _Section 6.3(a)_ ), and promptly thereafter shall mail the
Schedule 14D-9 to the holders of the Company Common Stock. Parent and
Acquisition Sub shall promptly furnish to the Company all information
concerning Parent and Acquisition Sub that may be required by applicable Laws
or reasonably requested by the Company for inclusion in the Schedule 14D-9.
Each of Parent, Acquisition Sub and the Company shall promptly correct any
information provided by it for use in the Schedule 14D-9 if and to the extent
that such information shall have become false or misleading in any material
respect and provide additional information for use in the Schedule 14D-9 if
and to the extent that such Party determines that failure to include such
information would cause the Schedule 14D-9 to omit to state any material fact
required to be stated therein. The Company shall take all steps necessary to
cause the Schedule 14D-9, as so corrected, to be filed with the SEC and the
Schedule 14D-9, as so corrected, to be disseminated to the holders of Company
Common Stock, in each case as and to the extent required by applicable Laws.
The Company shall promptly notify Parent and Acquisition Sub upon the receipt
of any comments from the SEC or the staff of the SEC or any request from the
SEC or the staff of the SEC for amendments or supplements to the Schedule
14D-9, and shall provide Parent and Acquisition Sub with copies of
all correspondence between the Company and its Representatives, on the one
hand, and the SEC or the staff of the SEC, on the other hand. The Company
shall use reasonable best efforts to respond as promptly as reasonably
practicable to any comments of the SEC or the staff of the SEC with respect
to the Schedule 14D-9, and the Company shall provide Parent and Acquisition
Sub and their respective counsel a reasonable opportunity to participate in
the formulation of any written response to any such written comments of the
SEC or the staff of the SEC. Prior to the filing of the Schedule 14D-9 (or any
amendment or supplement thereto) or the dissemination thereof to the holders
of Company Common Stock, or responding to any comments of the SEC or the staff
of the SEC with respect thereto, the Company shall provide Parent and
Acquisition Sub and their respective counsel a reasonable opportunity to
review and to propose comments on such document or response. The Company
hereby approves of and consents to the Offer and consents to the inclusion in
the Offer Documents of the Company Board Recommendation (subject to _Section
6.3(a)_ ).

  



  

(b) _Stockholder Lists_. In connection with the Offer and the Merger, the
Company shall cause its transfer agent to furnish Acquisition Sub promptly
with mailing labels containing the names and addresses of the record holders
of Company Common Stock as of a recent date, together with copies of all
lists of stockholders, security position listings, computer files and all
other information in the Company's possession or control regarding the
beneficial owners of Company Common Stock, and shall furnish to
Acquisition Sub such information (including updated lists of stockholders,
security position listings and computer files) and assistance as Parent or
Acquisition Sub may reasonably request in communicating the Offer to the
record and beneficial holders of the Company Common Stock. Subject to the
requirements of applicable Law, and except for such steps as are necessary to
disseminate the Offer Documents and any other documents necessary to
consummate the transactions contemplated by this Agreement, Parent and
Acquisition Sub shall not use or disclose the information contained in any
such labels, lists, listings and files other than in connection with the
Offer and the Merger and, if this Agreement shall be terminated, shall, upon
request, deliver to the Company or destroy all copies of such information
then in their possession or control in accordance with the Confidentiality
Agreement.

  



  

   

\- 15 - 
--- 

 


--- 

    



  

2.3 _Notices of Guaranteed Delivery_. For purposes of this Agreement,
including the Offer, unless otherwise mutually agreed to by the Company and
Parent, any shares of Company Common Stock subject to notices of guaranteed
delivery shall be deemed not to be validly tendered into the Offer unless and
until the shares of Company Common Stock underlying such notices of guaranteed
delivery are delivered to or on behalf of Acquisition Sub.

  



  

ARTICLE III 
  _THE MERGER_

  



  

3.1 _The Merger_. Upon the terms and subject to the conditions set forth in
this Agreement, and in accordance with the DGCL, Acquisition Sub shall be
merged with and into the Company at the Effective Time. Following the
Effective Time, the separate corporate existence of Acquisition Sub shall
cease, and the Company shall continue as the surviving corporation in the
Merger (the "Surviving Corporation"). The Merger shall be governed by Section
251(h) of the DGCL.

  



  

3.2 _The Closing_. The closing of the Merger (the "Merger Closing") will take
place as soon as practicable (but in no event later than the next Business
Day) following the Offer Closing, provided that the conditions set forth in
_ARTICLE IX _ have been satisfied or (to the extent permitted by Law) waived
(other than those conditions that by their terms are to be satisfied at the
Merger Closing, but subject to the satisfaction or (to the extent permitted by
Law) waiver of those conditions) at such time, at the offices of Morgan,
Lewis and Bockius LLP, located at 101 Park Avenue, New York, NY 10178, unless
another time, date or place is agreed to in writing by Parent and the
Company. The date on which the Merger Closing occurs is referred to in this
Agreement as the "Merger Closing Date".

  



  

3.3 _The Effective Time_. Subject to the provisions of this Agreement, as
promptly as practicable on the Merger Closing Date, the Company shall file a
certificate of merger (the "Certificate of Merger") in such form as is
required by, and executed and acknowledged in accordance with, the relevant
provisions of the DGCL, and shall make all other filings and recordings
required under the DGCL to effectuate the Merger. The Merger shall become
effective on such date and time as the Certificate of Merger is filed with
the Secretary of State of the State of Delaware or at such later date and time
as Parent and the Company shall agree and specify in the Certificate of
Merger. The date and time at which the Merger becomes effective is referred to
in this Agreement as the "Effective Time".

  



  

3.4 _Effect of the Merger_. The Merger shall have the effects set forth
herein and in the applicable provisions of the DGCL. Without limiting the
generality of the foregoing, from and after the Effective Time, the Surviving
Corporation shall possess all properties, rights, privileges, powers and
franchises of the Company and Acquisition Sub, and all of the claims,
obligations, liabilities, debts and duties of the Company and Acquisition Sub
shall become the claims, obligations, liabilities, debts and duties of the
Surviving Corporation.

  



  

3.5 _Certificate of Incorporation and By-Laws_.

  



  

(a) At the Effective Time, the Company Certificate of Incorporation as in
effect immediately prior to the Effective Time shall be amended so as to read
in its entirety as set forth in _Exhibit A_ attached hereto and, as so
amended, shall be the certificate of incorporation of the Surviving
Corporation, until thereafter changed or amended as provided therein or by
applicable Law, subject to _Section 7.1_.

  



  

   

\- 16 - 
--- 

 


--- 

    



  

(b) The By-laws of Acquisition Sub as in effect immediately prior to the
Effective Time shall be the By-laws of the Surviving Corporation until
thereafter changed or amended as provided therein or by applicable Law,
subject to _Section 7.1_.

  



  

3.6 _Directors and Officers_.

  



  

(a) _Directors_. The Parties shall take all necessary action such that the
directors of Acquisition Sub immediately prior to the Effective Time shall be
the directors of the Surviving Corporation until the earlier of their death,
resignation or removal or until their respective successors are duly elected
and qualified, as the case may be.

  



  

(b) _Officers_. The Parties shall take all necessary action such that the
officers of the Acquisition Sub immediately prior to the Effective Time shall
be the officers of the Surviving Corporation, until the earlier of their
death, resignation or removal or until their respective successors are duly
elected or appointed and qualified, as the case may be.

  



  

3.7 _Effect on Capital Stock_.

  



  

(a) _Capital Stock_. Upon the terms and subject to the conditions set forth
in this Agreement, at the Effective Time, by virtue of the Merger and without
any action on the part of Parent, Acquisition Sub, the Company, or the holders
of any of the following securities, the following shall occur:

  



  

(i) _Capital Stock of Acquisition Sub_. Each share of capital stock of
Acquisition Sub that is outstanding immediately prior to the Effective Time
shall be converted into one validly issued, fully paid and nonassessable share
of common stock, par value $0.01 per share, of the Surviving Corporation.
Each certificate evidencing ownership of such shares of common stock of
Acquisition Sub shall thereafter evidence ownership of shares of common stock
of the Surviving Corporation.

  



  

(ii) _Company Common Stock_. Each share of Company Common Stock that is
issued and outstanding immediately prior to the Effective Time (other than
(A) shares of Company Common Stock owned by Parent, Acquisition Sub or the
Company (or held in the Company's treasury), or by any direct or indirect
wholly-owned Subsidiary of Parent, Acquisition Sub or the Company, in each
case immediately prior to the Effective Time, and (B) except as provided in
_Section 3.7(c)_ , the Appraisal Shares) shall be automatically
converted, subject to _Section 3.7(b)_ , into the right to receive the Merger
Consideration. At the Effective Time, all such shares of Company Common Stock
shall no longer be outstanding and shall automatically cease to exist, and
each holder of a certificate (or evidence of shares in book-entry form) that
immediately prior to the Effective Time represented any such shares of Company
Common Stock (each, a "Certificate") shall cease to have any rights with
respect thereto, except the right to receive the Merger Consideration in
accordance with this _ARTICLE III_.

  



  

(iii) _Owned Company Common Stock_. Each share of Company Common Stock owned
by Parent, Acquisition Sub or the Company (or held in the Company's treasury)
or by any direct or indirect wholly-owned Subsidiary of Parent, Acquisition
Sub or the Company, in each case immediately prior to the Effective Time,
shall automatically be cancelled and extinguished without any conversion
thereof or consideration paid therefor.

  



  

(b) _Adjustment to the Merger Consideration_. Without limiting the
restrictions set forth in _Section 6.1_ and the other provisions of this
Agreement but without duplication of the provisions of _Section 2.1(c)_ , if
at any time during the period between the date of this Agreement and the
Effective Time, there shall be any stock split, reverse stock split, stock
dividend (including any dividend or distribution of securities convertible
into Company Common Stock), reorganization, recapitalization,
reclassification, combination, exchange of shares or other like change with
respect to Company Common Stock occurring on or after the date hereof and
prior to the Effective Time, the Merger Consideration as provided in _Section
3.7(a)(ii)_ shall be equitably adjusted to reflect the effect thereof, and
such adjustment to the Merger Consideration shall provide to the holders of
Company Common Stock the same economic effect as contemplated by this
Agreement prior to such action.

  



  

   

\- 17 - 
--- 

 


--- 

    



  

(c) _Appraisal Rights_. Notwithstanding anything in this Agreement to the
contrary, shares of Company Common Stock issued and outstanding immediately
prior to the Effective Time that are held by any holder who is entitled to
demand and properly demands appraisal of such shares pursuant to, and who
complies in all respects with, the provisions of Section 262 of the DGCL (the
"Appraisal Shares") shall not be converted into the right to receive the
Merger Consideration as provided in _Section 3.7(a)(ii)_ , but instead such
holder shall be entitled to payment of the fair value of such shares in
accordance with the provisions of Section 262 of the DGCL, subject to
reduction for any Taxes required by Law to be withheld or deducted. At the
Effective Time, the Appraisal Shares shall no longer be outstanding and shall
automatically cease to exist, and each holder of Appraisal Shares shall
cease to have any rights with respect thereto, except the right to receive
the fair value of such Appraisal Shares in accordance with the provisions of
Section 262 of the DGCL, subject to reduction for any Taxes required by Law to
be withheld or deducted. Notwithstanding the foregoing, if any such holder
shall fail to perfect or otherwise shall waive, validly withdraw or lose the
right to appraisal under Section 262 of the DGCL with respect to any of such
holder's Appraisal Shares or a court of competent jurisdiction shall
determine that such holder is not entitled to the right of appraisal provided
by Section 262 of the DGCL with respect to any of such holder's Appraisal
Shares, then the right of such holder to be paid the fair value of such
Appraisal Shares under Section 262 of the DGCL shall cease and such Appraisal
Shares shall be deemed to have been converted at the Effective Time into, and
shall have become, the right to receive the Merger Consideration as provided
in _Section 3.7(a)(ii)_ , without any interest thereon. The Company shall
give prompt notice to Parent of any demands for appraisal of any shares of
Company Common Stock, withdrawals of such demands and any other instruments
served pursuant to the DGCL and received by the Company, and Parent shall
have the right to participate in and direct all negotiations and proceedings
with respect to such demands. Prior to the Effective Time, the Company shall
not, without the prior written consent of Parent, voluntarily make any payment
with respect to, or settle or offer to settle, any such demands, or agree to
do or commit to do any of the foregoing.

  



  

(d) _Company Options_. Neither Parent nor Acquisition Sub shall assume any
Company Options in connection with the Offer, Merger or any
other transactions contemplated by this Agreement. Effective upon the Offer
Closing, each outstanding unvested, unexpired and unexercised Company Option
shall vest and become exercisable. To the extent not exercised prior to the
Effective Time, then upon the Effective Time, each Company Option shall be
cancelled. Each former holder of any such cancelled Company Option shall be
entitled to receive, at the Effective Time or as soon as practicable
thereafter, (i) an amount in cash, without interest and subject to
_Section 3.8(h)_ , equal to (A) the excess of (1) the Cash Consideration over
(2) the exercise price per share of Company Common Stock subject to such
Company Option multiplied by (B) the total number of shares of Company Common
Stock subject to such Company Option and (ii) a CVR for each share of Company
Common Stock subject to such Company Option; provided, that, for the avoidance
of doubt, the amount payable shall be zero with respect to a Company Option
that has a per share exercise price that is equal to or exceeds the Cash
Consideration and such Company Option shall be cancelled and terminated
without any payment being made in respect thereof (whether in the form of
cash or a CVR), and the holder of any such Company Option shall have no
further rights with respect thereto. CVRs in respect of Company Options shall
be subject to the same terms and conditions as apply to CVRs in respect of
Company Common Stock generally. As soon as practicable following the date of
this Agreement, the Company shall take all actions necessary to effect the
transactions contemplated by this _Section 3.7(d)_ under the Company Stock
Plan and all Company Option agreements and any other plan or arrangement of
the Company, including delivering all required notices and making any
determinations and/or resolutions of the Company Board or a committee
thereof. The Company shall ensure, prior to the Effective Time, that
following the Effective Time, no holder of a Company Option (or former holder
of a Company Option) or any current or former participant in any Company
Stock Plan or Employee Plan shall have any right thereunder to (A) acquire any
capital stock of the Company, the Surviving Corporation or their Subsidiaries
or any other equity interest therein or (B) receive any other consideration in
respect of such Company Option.

  



  

   

\- 18 - 
--- 

 


--- 

    



  

3.8 _Exchange of Certificates_.

  



  

(a) _Payment Agent_. Prior to the Merger Closing Date, Parent shall appoint a
bank or trust company reasonably acceptable to the Company to act as paying
agent (the "Paying Agent") for the payment of the Cash Consideration in
accordance with this  _ARTICLE III_ and, in connection therewith, shall enter
into an agreement with the Paying Agent in a form reasonably acceptable to
the Company (the "Paying Agency Agreement"). At or prior to the Effective
Time, Parent shall deposit with the Paying Agent cash in an amount sufficient
to pay the aggregate Cash Consideration as required to be paid or issued
pursuant to this Agreement (such deposit hereinafter referred to as the
"Exchange Fund"). For avoidance of doubt, Parent shall not be required to
deposit any funds related to any CVR with the Rights Agent unless and until
such deposit is required pursuant to the terms of the CVR Agreement. If any
holder of Appraisal Shares shall fail to perfect or otherwise shall
waive, validly withdraw or lose the right to appraisal under Section 262 of
the DGCL with respect to any of such holder's Appraisal Shares, or a court of
competent jurisdiction shall determine that such holder is not entitled to the
relief provided by Section 262 of the DGCL with respect to any of such
holder's Appraisal Shares, then Parent shall deposit with the Paying Agent
cash in an amount sufficient to pay the aggregate Cash Consideration as
required to be paid pursuant to this Agreement with respect to such Appraisal
Shares, and the Exchange Fund shall be deemed to include the cash so
deposited.

  



  

(b) _Certificate Exchange Procedures_. As promptly as reasonably practicable
after the Effective Time, Parent shall cause the Paying Agent to mail to each
holder of record of a Certificate (i) a letter of transmittal (which shall
specify that delivery shall be effected, and risk of loss and title to the
Certificates shall pass, only upon proper delivery of the Certificates to the
Paying Agent and which shall otherwise be in customary form (including
customary provisions with respect to delivery of an "agent's message" with
respect to shares held in book-entry form)), and (ii) instructions for use in
effecting the surrender of the Certificates in exchange for the Merger
Consideration. Upon surrender to the Paying Agent of such Certificate,
together with such letter of transmittal, duly executed, and such other
documents as may reasonably be required by the Paying Agent, the holder
of record of such Certificate shall be entitled to receive in exchange
therefor the Cash Consideration (subject to _Section 3.8(h)_ ) with respect
to the number of shares of Company Common Stock previously represented by such
Certificate shall have been converted into the right to receive pursuant to
_Section 3.7(a)(ii)_ , and the Certificate so surrendered shall forthwith be
cancelled. In the event of a transfer of ownership of Company Common Stock
which is not registered in the transfer records of the Company, payment of
the Merger Consideration may be made to a Person other than the Person in
whose name the Certificate so surrendered is registered if such Certificate
shall be properly endorsed or otherwise be in proper form for transfer and the
Person requesting such payment shall pay any transfer or other similar taxes
required by reason of the payment of the Merger Consideration to a Person
other than the registered holder of such Certificate or establish to the
reasonable satisfaction of Parent that such tax has been paid or is not
applicable. Until surrendered as contemplated by this _Section 3.8(b)_ , each
Certificate shall be deemed at any time after the Effective Time to represent
only the right to receive upon such surrender the Merger Consideration which
the holder thereof has the right to receive in respect of such Certificate
pursuant to this _ARTICLE III_. No interest shall be paid or will accrue on
any cash payable to holders of Certificates pursuant to the provisions of this
_ARTICLE III_.

  



  

   

\- 19 - 
--- 

 


--- 

    



  

(c) _No Further Ownership Rights in Company Common Stock_. All cash paid upon
the surrender of Certificates in accordance with the terms of this _ARTICLE
III_ shall be deemed to have been paid in full satisfaction of all rights
pertaining to the shares of Company Common Stock formerly represented by such
Certificates. At the close of business on the day on which the Effective Time
occurs, the stock transfer books of the Company shall be closed, and there
shall be no further registration of transfers on the stock transfer books of
the Surviving Corporation of the shares of Company Common Stock that were
outstanding immediately prior to the Effective Time. If, after the Effective
Time, any Certificate is presented to the Surviving Corporation for any
reason, it shall be cancelled against delivery of cash to the holder thereof
as provided in this _ARTICLE III_.

  



  

(d) _Termination of the Exchange Fund_. Any portion of the Exchange Fund that
remains undistributed to the holders of the Certificates for twelve (12)
months after the Effective Time shall be delivered to Parent, upon demand, and
any holders of the Certificates who have not theretofore complied with this
_ARTICLE III_ shall thereafter look only to Parent for, and Parent shall
remain liable for, payment of their claims for the Merger Consideration
pursuant to the provisions of this _ARTICLE III_.

  



  

(e) _No Liability_. None of Parent, Acquisition Sub, the Company, the
Surviving Corporation or the Paying Agent shall be liable to any Person in
respect of any cash from the Exchange Fund delivered to a public official in
compliance with any applicable state, federal or other abandoned property,
escheat or similar Law. If any Certificate has not been surrendered prior to
the date on which Merger Consideration in respect of such Certificate would
otherwise escheat to or become the property of any Governmental Authority,
any Merger Consideration in respect of such Certificate shall, to the extent
permitted by applicable Law, immediately prior to such time become the
property of the Surviving Corporation, free and clear of all claims or
interest of any person previously entitled thereto.

  



  

(f) _Investment of Exchange Fund_. The Paying Agent shall invest the cash in
the Exchange Fund as directed by Parent; _provided_ , _however_ , that such
investments shall be in obligations of or guaranteed by the United States of
America or any agency or instrumentality thereof and backed by the full faith
and credit of the United States of America, in commercial paper obligations
rated A-1 or P-1 or better by Moody's Investors Service, Inc. or Standard and
Poor's Corporation, respectively, or in certificates of deposit, bank
repurchase agreements or banker's acceptances of commercial banks with capital
exceeding $5.0 billion (based on the most recent financial statements of such
bank that are then publicly available). Any interest and other income
resulting from such investments shall be paid solely to Parent, and any Taxes
resulting therefrom shall be paid by Parent. Nothing contained herein and no
investment losses resulting from investment of the Exchange Fund shall
diminish the rights of any holder of Certificates to receive the Merger
Consideration as provided herein. To the extent that there are any losses with
respect to any investments of the Exchange Fund, or the Exchange Fund
diminishes for any reason below the level required for the Paying Agent to
promptly pay the Cash Consideration to all holders of Certificates, Parent
shall, or shall cause the Surviving Corporation to, promptly replace or
restore the cash in the Exchange Fund so as to ensure that the Exchange Fund
is at all times maintained at a level sufficient for the Paying Agent to make
such payments.

  



  

(g) _Lost Certificates_. If any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact by the Person
claiming such Certificate to be lost, stolen or destroyed and, if required by
Parent, the posting by such Person of a bond in such reasonable amount as
Parent may direct as indemnity against any claim that may be made against it
with respect to such Certificate, the Paying Agent shall deliver in exchange
for such lost, stolen or destroyed Certificate the applicable Merger
Consideration.

  



  

(h) _Withholding Rights_. Notwithstanding anything in this Agreement to the
contrary, Parent, Acquisition Sub, the Surviving Corporation or the Paying
Agent shall be entitled to deduct and withhold from the Merger Consideration,
Company Option Amounts and any amounts otherwise payable pursuant to this
Agreement to any holder of shares of Company Common Stock or any holder of a
Company Option, as applicable, such amounts as Parent, Acquisition Sub, the
Surviving Corporation or the Paying Agent are required to deduct and withhold
with respect to the making of such payment under the Code or any provision of
applicable Tax Law. To the extent that amounts are so withheld and paid over
to the appropriate taxing authority by Parent, Acquisition Sub, the Surviving
Corporation or the Paying Agent, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to the holder of the
shares of Company Common Stock or the holder of a Company Option, as the case
may be, in respect of which such deduction and withholding was made by
Parent, Acquisition Sub, the Surviving Corporation or the Paying Agent.

  



  

   

\- 20 - 
--- 

 


--- 

    



  

3.9 _Necessary Further Actions_. If, at any time after the Effective Time,
any further action is necessary or desirable to carry out the purposes of
this Agreement and to vest the Surviving Corporation with full right, title
and possession to all assets, property, rights, privileges, powers and
franchises of the Company and Acquisition Sub, the directors and officers of
the Company and Acquisition Sub shall take all such lawful and necessary
action.

  



  

ARTICLE IV 
  _REPRESENTATIONS AND WARRANTIES OF THE COMPANY_

  



  

Except (i) as set forth in the disclosure letter delivered by the Company to
Parent on the date of this Agreement (the "Company Disclosure Letter"), or
(ii) as set forth in the Company SEC Reports filed by the Company on or after
January 2, 2012 and prior to the date hereof (other than in any "risk factor"
disclosure or any other forward-looking statements or other disclosures
included in such documents that are generally cautionary, predictive or
forward-looking in nature), the Company hereby represents and warrants to
Parent and Acquisition Sub as follows:

  



  

4.1 _Organization; Good Standing_. The Company is a corporation duly
organized and validly existing under Delaware Law, and has the
requisite corporate power and authority to conduct its business as it is
presently being conducted and to own, lease or operate its properties and
assets. The Company is duly qualified to do business and is in good standing
(to the extent either such concept is recognized under applicable Law) in
each jurisdiction where the character of its properties owned or leased or the
nature of its activities make such qualification necessary, except where the
failure to be so qualified or in good standing has not had, individually
or in the aggregate, a Company Material Adverse Effect. The Company has
publicly filed with the SEC or made available to Parent complete and correct
copies of the Company Certificate of Incorporation and Company By-Laws, as
amended to date. The Company is not in violation of any provisions of the
Company Certificate of Incorporation and Company By-Laws.

  



  

4.2 _Corporate Power; Enforceability._ Assuming the accuracy of the
representations and warranties of Parent and Acquisition Sub in
_Section 5.7(a)_ , the Company has all requisite corporate power and
authority to execute and deliver this Agreement, to perform its covenants and
obligations hereunder and to consummate the transactions contemplated hereby.
Assuming the accuracy of the representations and warranties of Parent and
Acquisition Sub in _Section 5.7(a)_ , the execution and delivery by the
Company of this Agreement, the performance by the Company of its covenants
and obligations hereunder and the consummation by the Company of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of the Company and no additional
corporate proceedings on the part of the Company are necessary to authorize
the execution and delivery by the Company of this Agreement, the performance
by the Company of its covenants and obligations hereunder or the consummation
of the transactions contemplated hereby, other than, in the case of the
Merger, filing the Certificate of Merger with the Secretary of State of the
State of Delaware in accordance with the DGCL. This Agreement has been duly
executed and delivered by the Company and, assuming the due
authorization, execution and delivery by Parent and Acquisition Sub, and the
accuracy of the representations and warranties of Parent and Acquisition Sub
in _Section 5.7(a)_ , constitutes a legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, except
that such enforceability (x) may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other similar laws affecting or
relating to creditors' rights generally, and (y) is subject to general
principles of equity ( _clause (x)_ and _(y)_ collectively, the
"Enforceability Exception").

  



  

   

\- 21 - 
--- 

 


--- 

    



  

4.3 _Board Actions_. The Company Board, at a meeting duly called and held,
duly and unanimously adopted resolutions (i) authorizing and approving the
execution, delivery and performance of this Agreement by the Company and the
transactions contemplated hereby, (ii) approving and declaring advisable this
Agreement, the Offer, the Merger and the other transactions contemplated
hereby, (iii) declaring that this Agreement and the transactions contemplated
hereby, including the Offer and the Merger, on the terms and subject to the
conditions set forth herein, are fair to and in the best interests of the
Company and the Company Stockholders, (iv) resolving that this Agreement and
the Merger shall be governed by Section 251(h) of the DGCL and that the Merger
shall be consummated as soon as practicable following the Offer Closing, (v)
recommending that the Company Stockholders accept the Offer and tender
their shares of Company Common Stock pursuant to the Offer _(clauses (ii)_ ,
_(iii)_ and _(v)_ , the "Company Board Recommendation") and (vi) assuming the
accuracy of the representations and warranties of Parent and Acquisition Sub
in _Section 5.7(a)_ , causing any restrictions of any "moratorium," "control
share acquisition," "business combination," "fair price" or other form of
anti-takeover Laws (collectively, "Takeover Laws") of any jurisdiction that
may purport to be applicable to the Company, Parent, Acquisition Sub or any of
their respective Affiliates or the CVR Agreement or this Agreement or the
transactions contemplated thereby or hereby (including the Offer and the
Merger) with respect to any of the foregoing not to apply or to have been
satisfied with respect to each of Parent, Acquisition Sub and their
respective Affiliates solely with respect to this Agreement and the CVR
Agreement and the transactions contemplated hereby and thereby (including the
Offer and the Merger), which resolutions, as of the date of this Agreement,
have not been rescinded, modified or withdrawn.

  



  

4.4 _Voting Requirements_. Assuming the accuracy of the representations and
warranties of Parent and Acquisition Sub set forth in _Section 5.7(a)_ , (a)
no vote of the holders of any class or series of capital stock or other Equity
Interests of the Company is necessary to adopt this Agreement, and to approve
and consummate the transactions contemplated hereby and (b) the Company has
taken all necessary action to exempt this Agreement and the transactions
contemplated hereby, including the Offer and the Merger, from
the restrictions of Section 203 of the DGCL.

  



  

4.5 _Non-Contravention_. The execution and delivery by the Company of this
Agreement, the performance by the Company of its covenants and obligations
hereunder and the consummation of the Offer, the Merger and the other
transactions contemplated hereby will not (a) violate or conflict with any
provision of (i) the Company Certificate of Incorporation or the Company By-
Laws or (ii) the comparable organizational documents of any of the Company's
Subsidiaries, (b) subject to obtaining the Consents set forth in _Section 4.5_
of the Company Disclosure Letter, violate, conflict with, or result in the
breach of or constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or result in the termination or
modification of, or the acceleration of the performance or obligation
required by, or result in a right of termination, modification or acceleration
under any Contract to which the Company or any of the Company's Subsidiaries
is a party or by which Company, its Subsidiaries or any of their properties
or assets may be bound, (c) assuming the Consents referred to in _Section 4.5_
of the Company Disclosure Letter are obtained or made, and assuming the
accuracy of the representations and warranties of Parent and Acquisition Sub
in _Section 5.7(a)_ , violate or conflict with any Law or Order applicable to
the Company or any of its Subsidiaries or by which any of their properties or
assets are bound, or (d) result in the creation of any Lien (other than
Permitted Liens) upon any of the properties or assets of the Company or any
of its Subsidiaries, except in the case of each of _clauses (a)(ii), (b), (c)_
and _(d) _ above, for such violations, conflicts, defaults, terminations,
modifications, accelerations or Liens which would not have, individually or
in the aggregate, a Company Material Adverse Effect or prevent or materially
delay the consummation by the Company of the transactions contemplated
hereby.

  



  

   

\- 22 - 
--- 

 


--- 

    



  

4.6 _Required Governmental Approvals_. No consent, permit, approval, Order or
authorization of, or filing or registration with, or notification to (any of
the foregoing being referred to herein as a "Consent"), any Governmental
Authority is required on the part of the Company or any of its Subsidiaries
in connection with the execution and delivery by the Company of this
Agreement, the performance by the Company of its covenants and obligations
hereunder and the consummation by the Company of the
transactions contemplated hereby, except (a) the filing of the Certificate of
Merger with the Secretary of State of the State of Delaware and such filings
with Governmental Authorities to satisfy the applicable Laws of states in
which the Company and its Subsidiaries are qualified to do business, (b) such
filings and approvals as may be required by any federal or state securities
Laws, including compliance with any applicable requirements of the Exchange
Act, including the Schedule 14D-9 and if necessary, any information statement
(the "Information Statement") required under Rule 14f-1 in connection with the
Offer, (c) Consents required under, and compliance with any other applicable
requirements of the HSR Act and any applicable foreign Antitrust Laws, (d)
any filings or notices required under the rules and regulations of the Nasdaq
and (e) such other Consents, the failure of which to obtain would not have,
individually or in the aggregate, a Company Material Adverse Effect or prevent
or materially delay the consummation by the Company of the transactions
contemplated hereby or the performance by the Company of its covenants
and obligations hereunder.

  



  

4.7 _Company Capitalization_.

  



  

(a) The authorized capital stock of the Company consists of (i) 200,000,000
shares of Company Common Stock and (ii) 5,000,000 shares of Company Preferred
Stock. As of the close of business on May 2, 2014, (1) 78,935,852 shares of
Company Common Stock were issued and outstanding and 7,607,273 shares of
Company Common Stock were issuable upon exercise of outstanding
Company Options, whether granted pursuant to the Company Stock Plan or
otherwise, (2) no shares of Company Preferred Stock were issued and
outstanding and (3) 10,400,000 shares of Company Common Stock were reserved
for issuance under the Company Stock Plan (which number includes the shares
of Company Common Stock issued to date or issuable upon exercise of
outstanding Company Options, as described in clause (1)). All outstanding
shares of Company Common Stock are, and all such shares that may be issued
prior to the Effective Time will be when issued, duly authorized, validly
issued, fully paid, nonassessable and free of any preemptive rights, right of
repurchase, right of participation, right of maintenance, right of first
refusal, or similar rights and not subject to any vesting conditions or
forfeiture restrictions.

  



  

(b) Since December 31, 2013, the Company has not (i) issued any shares of
Company Capital Stock other than pursuant to the exercise of Company Options
or (ii) granted, committed to grant or otherwise created or assumed any
obligation with respect to any Company Options, stock appreciation rights,
phantom stock or other rights or other commitments or agreements to acquire
from the Company or that obligates the Company to issue, any capital stock
of, or other Equity Interest or voting interest in, the Company.
_Section 4.7(b)_ of the Company Disclosure Letter sets forth, with respect to
each Company Option, (1) the name of each holder of such Company Option and
an indication of whether such holder is a current or former employee, director
or consultant of the Company or its Subsidiaries, (2) the date each such
Company Option was granted, (3) the number of shares of Company Common Stock
subject to each such Company Option, (4) the expiration date of each such
Company Option, (5) the exercise price of each such Company Option, (6)
whether each such Company Option was granted under the Company Stock Plan and
(7) whether or not each such Company Option is intended to qualify as an
"incentive stock option" under Section 422 of the Code.

  



  

   

\- 23 - 
--- 

 


--- 

    



  

(c) Except as set forth in this _Section 4.7_ , there are (i) no outstanding
shares of capital stock of, or other Equity Interest or voting interest in,
the Company, (ii) no outstanding securities of the Company or its Subsidiaries
convertible into or exchangeable for shares of capital stock of, or other
Equity Interest or voting interest in, the Company, (iii) no outstanding
options, stock appreciation rights, warrants, phantom stock, rights or other
commitments or agreements to acquire from the Company or any of its
Subsidiaries, or that obligates the Company or any of its Subsidiaries to
issue, transfer or sell, or cause to be issued, transferred or sold, any
capital stock of, or other Equity Interest or voting interest in, or any
securities convertible into or exchangeable for shares of capital stock of,
or other Equity Interest or voting interest in, the Company, (iv) no
obligations of the Company or any of its Subsidiaries to grant, extend or
enter into any subscription, warrant, right, convertible or
exchangeable security or other similar agreement or commitment relating to
any capital stock of, or other Equity Interest or voting interest (including
any voting debt) in, the Company (the items in _clauses (i), (ii), (iii)_ and
_(iv),_ together with the capital stock of the Company, being referred to
collectively as "Company Securities") and (v) no other obligations by the
Company or any of its Subsidiaries to make any payments based on the price or
value of any Company Securities. Neither the Company nor any of its
Subsidiaries is a party to any Contract which obligates the Company or any of
its Subsidiaries to repurchase, redeem or otherwise acquire any Company
Securities. _Section 4.7(c)_ of the Company Disclosure Letter sets forth, as
of the date of this Agreement, the immediately available cash held by the
Company and its Subsidiaries free of any Lien in bank accounts of the Company
or its Subsidiaries, net of all Indebtedness outstanding as of the date hereof
and any issued but uncleared checks and drafts, in each case on a
consolidated basis.

  



  

(d) Neither the Company nor any of its Subsidiaries is a party to any
agreement relating to the voting of, requiring registration of, or
granting any preemptive rights, anti-dilutive rights or rights of first
refusal or other similar rights with respect to any securities of the
Company.

  



  

(e) With respect to the Company Options, except as has not had, and would not
reasonably be expected to have, individually or in the aggregate, a material
impact on the Company or its Subsidiaries, (i) each Company Option intended to
qualify as an "incentive stock option" under Section 422 of the Code so
qualifies, (ii) each grant of a Company Option was made in accordance with
the terms of the Company Stock Plan, the Exchange Act and all other
applicable Laws and regulatory rules or requirements, including the rules of
Nasdaq and any other exchange on which Seller securities are traded and (iii)
the per share exercise price of each Company Option was not less than the
fair market value (within the meaning of Section 409A of the Code or, if
intended to qualify as an incentive stock option, within the meaning of
Section 422 of the Code) of a share of Company Common Stock on the date
on which such Company Option was granted. The Company has not knowingly
granted, and there is no and has been no policy or practice of the Company of
granting, Company Options prior to, or otherwise coordinating the grant of
Company Options with, the release or other public announcement of material
information regarding the Company or its Subsidiaries or their results of
operations or prospects. The Company has delivered or otherwise made
available to Parent copies of all equity plans covering the Company Options
and the forms of all stock option agreements evidencing such Company Options
and any award agreement evidencing any Company Option that contains material
terms that are inconsistent with, or in addition to, such forms (except with
respect to the number of shares of Company Common Stock covered thereby, the
grant date, the exercise price, the vesting schedule or the expiration date,
as applicable).

  



  

   

\- 24 - 
--- 

 


--- 

    



  

4.8 _Subsidiaries_.

  



  

(a) _Section 4.8_ of the Company Disclosure Letter lists each of the
Company's Subsidiaries, its jurisdiction of organization and its
capitalization. Each of the Company's Subsidiaries is duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
respective organization (to the extent either such concept is recognized under
applicable Law), except where the failure to be in good standing has not had,
individually or in the aggregate, a Company Material Adverse Effect. Each of
the Company's Subsidiaries has the requisite corporate power and authority to
carry on its respective business as it is presently being conducted and to
own, lease or operate its respective properties and assets. Each of the
Company's Subsidiaries is duly qualified to do business and is in good
standing in each jurisdiction where the character of its properties owned or
leased or the nature of its activities make such qualification necessary (to
the extent either such concept is recognized under applicable Law), except
where the failure to be so qualified or in good standing has not had,
individually or in the aggregate, a Company Material Adverse Effect.

  



  

(b) All of the outstanding capital stock of, or other Equity Interest or
voting interest in, each Subsidiary of the Company (i) have been duly
authorized, validly issued and are fully paid and nonassessable and (ii) are
set forth in _Section 4.8_ of the Company Disclosure Letter and owned,
directly or indirectly, by the Company, free and clear of all Liens and free
of any other restriction (including any restriction on the right to vote,
sell or otherwise dispose of such capital stock or other equity or voting
interest) that would prevent the operation by the Surviving Corporation of
such Subsidiary's business as presently conducted. Except as set forth in
_Section 4.8_ of the Company Disclosure Letter, there are (A) no outstanding
shares of capital stock of, or other Equity Interest or voting interest in,
any of the Company's Subsidiaries, (B) no outstanding securities
convertible into or exchangeable for shares of capital stock of, or other
Equity Interest or voting interest in, any of the Company's Subsidiaries, (C)
no outstanding options, stock appreciation rights, warrants, phantom stock,
rights or other commitments or agreements to acquire from the Company or any
of its Subsidiaries, or that obligates the Company or any of its Subsidiaries
to issue, transfer or sell, or cause to be issued, transferred or sold, any
capital stock of, or other Equity Interest or voting interest in, or any
securities convertible into or exchangeable for shares of capital stock of, or
other Equity Interest or voting interest in, any of the Company's
Subsidiaries, (D) no obligations of the Company or any of its Subsidiaries to
grant, extend or enter into any subscription, warrant, right, convertible or
exchangeable security or other similar agreement or commitment relating to
any capital stock of, or other Equity Interest or voting interest (including
any voting debt) in, any of the Company's Subsidiaries (the items in _clauses
(A), (B), (C)_ and _(D),_ together with the capital stock of each of the
Company's Subsidiaries, being referred to collectively as "Subsidiary
Securities") and (v) no other obligations by the Company or any of its
Subsidiaries to make any payments based on the price or value of any
Subsidiary Securities.

  



  

(c) Except for its interest in the Company's Subsidiaries, the Company does
not own, directly or indirectly, any Equity Interest in any Person and
neither the Company or the Company's Subsidiaries has agreed or is obligated
to make, or is bound by any Contract under which it may become obligated to
make, any future investment or capital contribution to any other Person.

  



  

4.9 _Company SEC Reports_. Since January 2, 2012, the Company has filed on a
timely basis all forms, reports, schedules, statements and documents with the
SEC that have been required to be filed by it under applicable Laws prior to
the date hereof. References herein to the term "Company SEC Reports" shall
mean all information filed or incorporated by reference in (but
not information furnished under) any Form 10-K, Form 10-Q, Form 8-K or
Schedule 14A since January 2, 2012, including any exhibits and amendments
thereto. Since January 2, 2012, as of its filing date (or, if amended or
superseded by a filing prior to the date of this Agreement, on the date of
such amended or superseded filing), (a) each Company SEC Report complied as to
form in all material respects with the applicable requirements of the
Securities Act or the Exchange Act, as the case may be, each as in effect
on the date such Company SEC Report was filed, and (b) each Company SEC
Report did not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not
misleading. None of the Company's Subsidiaries is required to file any forms,
reports, or other documents with the SEC. No executive officer of the Company
has failed to make the certifications required of him or her under Section
302 or 906 of the Sarbanes-Oxley Act with respect to any Company SEC Report,
except as disclosed in certifications filed with the Company SEC Reports.
Neither the Company nor any of its executive officers has received notice from
any Governmental Authority challenging or questioning the accuracy,
completeness, form or manner of filing of such certifications. The
Company and each of its officers, and, to the Knowledge of the Company, each
of its directors, is in compliance in all material respects with (i) the
applicable provisions of the Sarbanes-Oxley Act and the rules and regulations
promulgated thereunder and (ii) the applicable listing and corporate
governance rules and regulations of the Nasdaq.

  



  

   

\- 25 - 
--- 

 


--- 

    



  

4.10 _Company Financial Statements_.

  



  

(a) The consolidated financial statements of the Company and its Subsidiaries
filed with the Company SEC Reports complied as to form with applicable
accounting requirements and published rules and regulations of the SEC and
have been prepared in accordance with GAAP consistently applied during the
periods and at the dates involved (except as may be indicated in the notes
thereto or as otherwise permitted by Form 10-Q with respect to any financial
statements filed on Form 10-Q), and fairly present in all material
respects the consolidated financial position of the Company and its
Subsidiaries as of the dates thereof and the consolidated results
of operations and cash flows for the periods then ended (subject, in the case
of unaudited quarterly statements, to normal year-end adjustments).

  



  

(b) The Company maintains "disclosure controls and procedures" (as such term
is defined in Rules 13a-15 and 15d-15 under the Exchange Act) that satisfy
the requirements of Rule 13a-15 under the Exchange Act. Such disclosure
controls and procedures are effective and reasonably designed to ensure that
all information required to be disclosed in the Company SEC Reports is
recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC and that all such information is
accumulated and communicated to the Company's management as appropriate to
allow timely decisions regarding required disclosure and to enable each of
the principal executive officer of the Company and the principal financial
officer of the Company to make the certifications required under the Exchange
Act with respect to such reports.

  



  

(c) The Company maintains "internal control over financial reporting" (as
such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act)
sufficient to provide reasonable assurance: (i) that transactions are executed
in accordance with management's general or specific authorizations; (ii) that
transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability;
(iii) that access to assets is permitted only in accordance with management's
general or specific authorization; (iv) that the recorded accountability for
assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences; and (v) regarding
prevention or timely detection of the unauthorized acquisition, use or
disposition of the Company's assets that could have a material effect on the
Company's financial statements. The Company has disclosed, based on the most
recent evaluation of internal controls prior to the date hereof, to the
Company's auditors and the audit committee of the Company Board (1) any
significant deficiencies or material weaknesses in the design or operation of
its internal control over financial reporting that would reasonably be
expected to adversely affect the Company's ability to record, process,
summarize and report financial information and (2) any fraud, whether or not
material, that involves management or other employees who have a significant
role in the Company's internal control over financial reporting.

  



  

   

\- 26 - 
--- 

 


--- 

    



  

(d) Since the enactment of the Sarbanes-Oxley Act, neither the Company nor
any of its Subsidiaries has made or permitted to remain outstanding any
prohibited loans or other extensions of credit to any executive officer of the
Company (as defined in Rule 3b-7 under the Exchange Act) or director of the
Company or any of its Subsidiaries.

  



  

(e) Neither the Company nor any of its Subsidiaries is a party to, or has any
obligation or other commitment to become a party to, any joint venture,
securitization transaction, "off-balance sheet arrangement" (as defined in
Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act) or
any similar Contract where the result, purpose or intended effect of such
arrangement is to avoid disclosure of any transaction involving, or
liabilities of, the Company or any of its Subsidiaries in the Company's or
such Subsidiary's published financial statements or other Company SEC Report.

  



  

(f) The Company has made available to Parent accurate and complete copies of
all material correspondence since January 2, 2012 through the date hereof
between the SEC, on the one hand, and the Company, on the other hand,
including comment letters from the staff of the SEC relating to the Company
SEC Reports containing unresolved comments and all written responses of the
Company thereto. To the Knowledge of the Company, as of the date hereof, no
Company SEC Report is the subject of ongoing review, comment or
investigation by the SEC.

  



  

4.11 _Disclosure Documents_.

  



  

(a) Each document required to be filed by the Company with the SEC in
connection with the Offer (the "Company Disclosure Documents") (including the
Schedule 14D-9 and, if necessary, the Information Statement), and any
amendments or supplements thereto, when filed, distributed or disseminated,
as applicable, will comply as to form in all material respects with the
applicable requirements of the Exchange Act. If requested by Parent or
Acquisition Sub, the Schedule 14D-9, as first mailed to the Company
Stockholders, will constitute a valid notice of appraisal rights under
Section 262(d)(2) of the DGCL and contain all information required thereby.

  



  

(b) The Company Disclosure Documents, at the time of the filing of such
Company Disclosure Documents or any supplement or amendment thereto and at
the time of any distribution or dissemination thereof and at the time of the
consummation of the Offer, will not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make
the statements made therein, in the light of the circumstances under which
they were made, not misleading. The representations and warranties contained
in this _Section 4.11_ will not apply to statements included in, or omissions
from, the Company Disclosure Documents based upon information furnished to
the Company by or on behalf of Parent or Acquisition Sub or any Affiliate of
Parent or Acquisition Sub or known to Parent or Acquisition Sub but not known
to the Company.

  



  

(c) The information with respect to the Company or any of the Company's
Subsidiaries that the Company furnishes to Parent or Acquisition Sub
expressly for use in the Schedule TO, the Offer Documents and the other Parent
Disclosure Documents, at the time such document is filed with the SEC, at any
time such document is amended or supplemented or at the time such document is
first published, sent or given to the Company Stockholders, will not contain
any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of
the circumstances under which they were made, not misleading.

  



  

4.12 _No Undisclosed Liabilities_. Neither the Company nor any of its
Subsidiaries has any Indebtedness or any Liabilities of any nature (whether
or not accrued, absolute, contingent or otherwise), other than (a) Liabilities
reflected or otherwise reserved against in the Company Balance Sheet or in
the consolidated financial statements and notes thereto of the Company and its
Subsidiaries included in the Company SEC Reports filed prior to the date of
this Agreement, (b) Liabilities arising under this Agreement or, except as
otherwise expressly prohibited by this Agreement, incurred in connection with
the transactions contemplated by this Agreement, (c) Liabilities incurred
since the Company Balance Sheet Date in the ordinary course of business
consistent with past practice, and (d) Liabilities that, individually or in
the aggregate, are not material to the Company and its Subsidiaries, taken as
a whole. No representation or warranty is made in this _Section 4.12_ with
respect to (a) compliance with the Exchange Act, to the extent such
compliance is covered in _Section 4.6_ and _Section 4.9_ , (b) intellectual
property and related matters, (c) applicable laws with respect to Taxes, (d)
ERISA and other employee benefit-related matters, (e) labor law matters, or
(f) Environmental Laws.

  



  

   

\- 27 - 
--- 

 


--- 

    



  

4.13 _Absence of Certain Changes_.

  



  

(a) Since the Company Balance Sheet Date through the date hereof, except for
actions taken or not taken in connection with the transactions contemplated
by this Agreement, the business of the Company and its Subsidiaries has been
conducted, in all material respects, in the ordinary course of business
consistent with past practice. There has not been or occurred, and there does
not exist, any Company Material Adverse Effect that is continuing.

  



  

(b) Since the Company Balance Sheet Date through the date hereof, neither the
Company nor any of its Subsidiaries has taken any action that would be
prohibited by _Section 6.1(b)_ if proposed to be taken after the date hereof.

  



  

4.14 _Material Contracts_.

  



  

(a) For all purposes of and under this Agreement, a "Material Contract" shall
mean:

  



  

(i) any "material contract" (as such term is defined in Item 601(b)(10) of
Regulation S-K of the SEC);

  



  

(ii) any Contract to which the Company or any of its Subsidiaries is a party
that contains any covenant by the Company or any of its Subsidiaries to not
(A) engage in any line of business, (B) engage in its business in any
geographic location, (C) compete with any other Person, (D) acquire any
product or other asset from any other Person, (E) develop, sell, supply,
distribute, offer, support or service any product or any technology or other
asset to or for such Person, or (F) obtain services from or perform services
for any other Person, in each case other than any such Contracts that (1) may
be cancelled without liability to the Company or its Subsidiaries upon notice
of sixty (60) days or less or (2) are not, individually or in the aggregate,
material to the Company and its Subsidiaries, taken as a whole;

  



  

(iii) any Contract entered into after January 2, 2012 or, if entered into on
or prior to January 2, 2012, that contains covenants, indemnities or other
obligations of the Company in respect of which a future payment by the Company
or any of its Subsidiaries may be made and (A) relating to the disposition or
acquisition (directly or indirectly) by the Company or any of its Subsidiaries
of a material amount of assets (including equipment purchases) other than in
the ordinary course of business consistent with past practice, or (B)
pursuant to which the Company or any of its Subsidiaries acquired or will
acquire any material interest in any other Person, for each of subsection (A)
and (B), for an amount in excess of $250,000, in each instance;

  



  

(iv) any Contract that relates to the formation, creation, operation,
management or control of any legal partnership or any joint venture entity
pursuant to which the Company has an obligation (contingent or otherwise) to
make a material investment in or material extension of credit to any Person;

  



  

   

\- 28 - 
--- 

 


--- 

    



  

(v) any Contract that involves or relates to Indebtedness or guarantees of
Indebtedness for borrowed money (whether incurred, assumed, guaranteed or
secured by any asset);

  



  

(vi) any Contract with a sole-source or single-source supplier of material
tangible products, services or raw materials that are not readily available
from other suppliers;

  



  

(vii) any Contract that requires the Company or any of its Subsidiaries to
(A) use any supplier or third party for all or substantially all of the
requirements or needs for the operation of the business of the Company or any
of its Subsidiaries, (B) conduct business on a "most favored nations" basis
with a third party, (C) market or co-market any product or services of a third
party or with a third party or (D) be bound by a "take-or-pay" or other
similar agreement or arrangement requiring the Company or any of its
Subsidiaries to make a minimum payment for goods or services from third party
suppliers irrespective of usage;

  



  

(viii) each Contract that involves future expenditures or receipts by the
Company or any Subsidiary of the Company of more than $100,000 in any one-
year period and that cannot be terminated by the Company or its Subsidiaries
on less than sixty (60) days' notice without payment or penalty;

  



  

(ix) each Contract between the Company or any of its Subsidiaries, on the one
hand, and any director, officer, employee, independent contractor, consultant
or Affiliate (other than a wholly owned Subsidiary) of the Company or any of
its Subsidiaries or any of their respective "associates" or "immediate
family" members (as such terms are defined in Rule 16a-1 of the Exchange
Act), on the other hand, including any Contract pursuant to which the Company
or any of its Subsidiaries has an obligation to indemnify such director,
officer, employee, independent contractor, consultant, Affiliate or family
member, but not including any Employee Plans;

  



  

(x) any Contract (excluding (A) licenses for commercial off-the-shelf
computer software that are generally available on nondiscriminatory pricing
terms and (B) service contracts to the extent the licenses contained therein
are incidental to such contracts, immaterial, non-exclusive and granted in
the ordinary course of business consistent with past practice) under which the
Company or any of its Subsidiaries is granted by a third party or grants to a
third party any material license, option or other right or
immunity (including a covenant not to be sued or right to enforce or
prosecute any patents) with respect to any Intellectual Property right;

  



  

(xi) any Contract not described in any other subsection of this _Section
4.14(a)_ that relates to the research, development, distribution, marketing,
supply, license, collaboration, co-promotion or manufacturing of any Key
Product, which, if terminated or not renewed, would reasonably be expected to
have a material and adverse effect on the Company's Key Products;

  



  

(xii) any stockholders, investors rights, registration rights or similar
agreement or arrangement;

  



  

(xiii) any Contract pursuant to which the Company or any of its Subsidiaries
has continuing obligations or interests involving (A) milestone or similar
payments, including upon the achievement of regulatory or commercial
milestones or (B) payment of royalties or other amounts calculated based upon
any revenues or income of the Company or any of its Subsidiaries, in each case
that cannot be terminated by the Company or its Subsidiaries without penalty
and without more than sixty (60) days' notice;

  



  

   

\- 29 - 
--- 

 


--- 

    



  

(xiv) any Contract that relates to any swap, forward, futures, warrant,
option or other derivative transaction;

  



  

(xv) any Contract relating to any loan or other extension of credit (other
than trade credits and accounts receivable in the ordinary course of business
consistent with past practice) made by the Company or any of its Subsidiaries;
or

  



  

(xvi) any Contract, or group of Contracts with a Person (or group of
affiliated Persons), the termination or breach of which would have a Company
Material Adverse Effect and is not disclosed pursuant to _clauses (i)_ through
_(xv)_ above.

  



  

(b) _Section 4.14(b)_ of the Company Disclosure Letter contains a complete
and accurate list of all Material Contracts to which the Company or any of
its Subsidiaries is a party as of the date of this Agreement (listed by
specific subsection of _Section 4.14(a)_ ). As of the date hereof, true and
complete copies of all Material Contracts (including all exhibits and
schedules thereto) have been (i) publicly filed with the SEC or (ii) made
available to Parent.

  



  

(c) Each Material Contract is valid and binding on the Company (and/or each
such Subsidiary of the Company party thereto) and, to the Knowledge of the
Company, each other party thereto, and is in full force and effect,
enforceable against the Company or each such Subsidiary of the Company party
thereto, as the case may be, in accordance with its terms, subject to the
Enforceability Exception, and neither the Company nor any of its Subsidiaries
that is a party thereto, nor, to the Knowledge of the Company, any other party
thereto, is in breach of, or default under, any such Material Contract, and
no event has occurred that with notice or lapse of time or both would
constitute such a breach or default thereunder by the Company or any of its
Subsidiaries, or, to the Knowledge of the Company, any other party thereto,
except for such failures to be in full force and effect and such breaches and
defaults that have not had, individually or in the aggregate, a Company
Material Adverse Effect. Except as set forth on _Section 4.14(c)_  of the
Company Disclosure Letter, as of the date of this Agreement, neither the
Company nor any of its Subsidiaries has received any written notice of any
intent or threat to terminate any Material Contract or seeking to amend any
provision of any Material Contract in a manner materially adverse to the
Company or any of its Subsidiaries, nor has the Company or any of its
Subsidiaries waived any rights under any Material Contract, the waiver of
which would be materially adverse to the Company or any of its Subsidiaries.

  



  

4.15 _Real Property_.

  



  

(a) The Company and its Subsidiaries do not own any real property. _Section
4.15(a)_ of the Company Disclosure Letter contains a complete and accurate
list of all of the real property in which the Company holds an existing
material lease, sublease, license or other agreement to which the Company or
any of its Subsidiaries are a party as of the date of this Agreement
(collectively, the "Leases") and under which the Company or any of its
Subsidiaries uses or occupies or has the right to use or occupy, now or in
the future, any material real property (such property, the "Leased Real
Property"). The Company has publicly filed with the SEC or made available to
Parent a complete and accurate copy of all Leases of Leased Real Property.
The Company and/or its Subsidiaries have and own valid leasehold estates in
the Leased Real Property, free and clear of all Liens other than Permitted
Liens, except as have not had, individually or in the aggregate, a Company
Material Adverse Effect.

  



  

   

\- 30 - 
--- 

 


--- 

    



  

(b) _Section 4.15(b)_ of the Company Disclosure Letter contains a complete
and accurate list of all of the existing Leases granting to any Person, other
than the Company or any of its Subsidiaries, any right to use or occupy, now
or in the future, any material portion of the Leased Real Property.

  



  

(c) All of the Leases set forth in _Section 4.15(a)_ or _Section 4.15(b)_ of
the Company Disclosure Letter are each in full force and effect and neither
the Company nor any of its Subsidiaries is in breach of or default under, or
has received written notice of any breach of or default under, any Lease,
and, to the Knowledge of the Company, no event has occurred that with
notice or lapse of time or both would constitute a breach or default
thereunder by the Company or any of its Subsidiaries or any other party
thereto, except in each case, for such breaches or defaults that has not had,
individually or in the aggregate, a Company Material Adverse Effect.

  



  

4.16 _Personal Property and Assets_. The machinery, equipment, furniture,
fixtures and other tangible personal property and assets owned, leased or
used by the Company or any of its Subsidiaries (the "Assets") are, in the
aggregate, sufficient and adequate to carry on their respective businesses in
all material respects as presently conducted, and the Company and its
Subsidiaries are in possession of and have good title to, or valid leasehold
interests in or valid rights under contract to use, such Assets that are
material to the Company and its Subsidiaries, taken as a whole, free and clear
of all Liens other than Permitted Liens.

  



  

4.17 _Intellectual Property_.

  



  

(a) _Section 4.17(a)_ of the Company Disclosure Letter contains a complete
and accurate list, as of the date of this Agreement, of all
Company Registered Intellectual Property Rights and, if applicable, the
jurisdiction in which each item of Company Registered Intellectual Property
Rights has been issued, filed, or recorded. Each item of Company Registered
Intellectual Property Rights is subsisting and, to the Knowledge of the
Company, valid and enforceable.

  



  

(b) As of the date hereof, (i) the Company or one of its Subsidiaries is the
exclusive owner of, or has a valid and enforceable right to use, the Company
Intellectual Property Rights, free and clear of any Liens, other than
Permitted Liens, (ii) the Company and its Subsidiaries are not subject to any
Order that restricts or impairs the use of any material Company Intellectual
Property Rights, (iii) there are no other claims, suits, actions, or
proceedings pending or threatened in writing with respect to any
material Company Intellectual Property Rights and (iv) the Company
Intellectual Property Rights constitute all of the Intellectual Property used
or held for use in the conduct of the Company's business. The consummation of
the transactions contemplated hereunder will not result in the loss or
impairment of or payment of additional amounts with respect to, nor require
the consent of any other Person in respect of, the Company's or its
Subsidiaries' right to own, use or hold for use any material
Company Intellectual Property Rights.

  



  

(c) Except as set forth on _Section 4.17(c)_ of the Company Disclosure
Letter, (i) to the Knowledge of the Company, the conduct of the Company's
business as currently conducted or as currently proposed to be conducted does
not infringe, misappropriate, or otherwise violate the Intellectual Property
rights of a third Person and (ii) since January 2, 2012, neither the Company
nor any of its Subsidiaries has received written notice of a claim that the
conduct of the Company's business infringes, misappropriates, or otherwise
violates the Intellectual Property rights of a third Person. To the Knowledge
of the Company, no third Person is infringing, misappropriating, or otherwise
violating the Company Intellectual Property Rights.

  



  

4.18 _Tax Matters_.

  



  

(a) The Company and each of its Subsidiaries (i) have timely filed (taking
into account any extensions of time in which to file) all material U.S.
federal, state, local and non-U.S. returns, estimates, claims for refund,
information statements and reports or other similar documents with respect to
Taxes (including amendments, schedules, or attachments thereto) relating to
any and all Taxes ("Tax Returns") required to be filed with any Governmental
Authority by any of them and all such filed Tax Returns are true, correct and
complete and were prepared in compliance with all applicable Laws, (ii) have
paid, or have adequately reserved (in accordance with GAAP) on the most
recent financial statements contained in the Company SEC Reports for the
payment of, all material Taxes required to be paid through the Company
Balance Sheet Date, and (iii) have not incurred any liability for material
Taxes since the Company Balance Sheet Date other than in the ordinary course
of business consistent with past practice. No deficiencies for any material
Taxes have been proposed, asserted or assessed, in each case in writing
against the Company or any of its Subsidiaries that are not subject to
adequate reserves on the consolidated financial statements of the Company and
its Subsidiaries (in accordance with GAAP) as adjusted in the ordinary course
of business consistent with past practice through the Effective Time, nor has
the Company or any of its Subsidiaries executed any waiver of any statute of
limitations on or extending the period for the assessment or collection of
any material Tax. There are no Liens (other than Permitted Liens) on any of
the assets of the Company or its Subsidiaries for Taxes.

  



  

   

\- 31 - 
--- 

 


--- 

    



  

(b) The Company and each of its Subsidiaries have timely paid or withheld
with respect to their service providers, creditors, stockholders or other
third parties (and paid over any amounts withheld to the appropriate Taxing
authority) all material federal and state income taxes required to be paid or
withheld.

  



  

(c) No audit of any material Tax Return of the Company or any of its
Subsidiaries is presently in progress, nor has the Company or any of its
Subsidiaries been notified in writing of any request for such an audit.

  



  

(d) The Company is not and has not been during the applicable period
specified in Section 897(c)(1)(A)(ii) of the Code, a "United States Real
Property Holding Corporation" within the meaning of Section 897(c)(2) of the
Code.

  



  

(e) Neither the Company nor any of its Subsidiaries has constituted either a
"distributing corporation" or a "controlled corporation" in a distribution of
stock intended to qualify for tax-free treatment under Section 355 of the Code
(A) in the two years prior to the date of this Agreement or (B) in a
distribution which otherwise constitutes part of a "plan" or "series of
related transactions" (within the meaning of Section 355(e) of the Code) that
includes the Merger.

  



  

(f) Neither the Company nor any of its Subsidiaries has engaged in a
"reportable transaction," as set forth in Treas. Reg.  1.6011-4(b)(2).

  



  

(g) None of the Company nor any of its Subsidiaries has (i) ever been a
member of an affiliated group (within the meaning of Code 1504(a)) filing a
consolidated federal income Tax Return (other than a group the common parent
of which was the Company), (ii) ever been a party to any material Tax
sharing, indemnification or allocation agreement (other than any such
agreement with customers, vendors or real property lessors, the principal
purpose of which is not to address Tax matters), nor does the Company or any
of its Subsidiaries owe any material amount under any such agreement and
(iii) any material liability for the Taxes of any person under Treas. Reg. 
1.1502-6 (or any similar provision of state, local or non-U.S. Tax Law,
including any arrangement for group or consortium relief or similar
arrangement), as a transferee or successor, by contract, or otherwise.

  



  

   

\- 32 - 
--- 

 


--- 

    



  

4.19 _Employee Plans_.

  



  

(a) _Section 4.19(a)_ of the Company Disclosure Letter sets forth a complete
and accurate list of each (i) "employee benefit plan" (as defined in Section
3(3) of ERISA), whether or not subject to ERISA and (ii) other bonus, stock
option, stock purchase or other equity-based, benefit, incentive
compensation, profit sharing, savings, retirement, medical, disability,
vacation, paid time off, loan, deferred compensation, workers' compensation,
severance, termination, retention, change of control, employment,
consulting or other similar fringe, welfare or other employee benefit plan,
program, policy, agreement or arrangement maintained or contributed to, or
required to be maintained or contributed to, by the Company, any of its
Subsidiaries or any ERISA Affiliate for the benefit of any current or former
officer, employee, director, independent contractor or consultant of the
Company or any of its Subsidiaries (clauses (i) and (ii) collectively, the
"Employee Plans").

  



  

(b) With respect to each Employee Plan, the Company has delivered or made
available to Parent complete and accurate copies, if applicable, of (i) such
Employee Plan, including any amendment thereto (or, in the case of any
unwritten Employee Plan, a written description thereof), (ii) each trust,
insurance, annuity or other funding Contract related thereto, (iii) the most
recent summary plan description and any summary of material modifications
prepared for each Employee Plan, (iv) the most recent financial statements and
actuarial or other valuation reports prepared with respect thereto, (v) the
most recent determination or opinion letter from the IRS and (vi) the most
recent annual report on Form 5500 required to be filed with the IRS with
respect thereto.

  



  

(c) No Employee Plan is (i) a "defined benefit plan" (as defined in Section
414 of the Code), (ii) a "multiemployer plan" (as defined in Section 3(37) of
ERISA) or (iii) a "multiple employer plan" (as defined in Section 4063 or
4064 of ERISA), and none of the Company, any of its Subsidiaries or any ERISA
Affiliate has sponsored, maintained, contributed to or has any liability with
respect to any such plan described in _clause (i), (ii)_ or _(iii)_ of this
_Section 4.19(c)_.

  



  

(d) Each Employee Plan has been maintained, operated and administered in
compliance in all material respects with its terms and with all applicable
Law, including the applicable provisions of ERISA and the Code. Each of the
Company and its Subsidiaries is in compliance in all material respects with
ERISA, the Code and all other Laws applicable to the Employee Plans.

  



  

(e) Except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a material impact on the Company or its
Subsidiaries, none of the Company, any of its Subsidiaries, or, to the
Knowledge of the Company, any of their respective directors, officers,
employees or agents has, with respect to any Employee Plan, engaged in or been
a party to any non-exempt "prohibited transaction," as such term is defined
in Section 4975 of the Code or Section 406 of ERISA, which could reasonably
be expected to result in the imposition of a penalty assessed pursuant to
Section 502(i) of ERISA or a tax imposed by Section 4975 of the Code, in each
case applicable to the Company, any of its Subsidiaries or any Employee Plan
or for which the Company or any of its Subsidiaries has any indemnification
obligation.

  



  

(f) Each Employee Plan that is intended to be "qualified" under Section 401
of the Code may rely on a prototype opinion letter or has received a
favorable determination letter from the IRS to such effect with respect to all
Tax law changes for which a determination letter may be sought and, to the
Knowledge of the Company, no fact, development or event has occurred or exists
since the date of such determination or opinion letter that has adversely
affected the qualified status of any such Employee Plan.

  



  

   

\- 33 - 
--- 

 


--- 

    



  

(g) All material contributions, premiums and other payments required to be
made with respect to any Employee Plan have been timely made, accrued or
reserved for.

  



  

(h) No Employee Plan provides for post-retirement life, medical, health or
other welfare benefits with respect to any current or former employees (or
their beneficiaries) of the Company or any of its Subsidiaries, except for
coverage or benefits required to be provided under Part 6 of Title I of ERISA
or Section 4980B(f) of the Code, and no circumstances exist that would
reasonably be expected to result in the Company or any of its Subsidiaries
becoming obligated to provide such benefits. No current or former
officer, employee, director, consultant or independent contractor of the
Company or any of its Subsidiaries (i) is currently receiving any severance
or separation pay or any workers' compensation or disability benefits from the
Company or any of its Subsidiaries, (ii) has received any loan from the
Company or any of its Subsidiaries that has an outstanding balance, (iii) has
a right (A) to take more than four weeks of vacation per year or (B) to
receive a guaranteed bonus from the Company or any of its Subsidiaries, (v)
is based outside of the United States, (vi) has received or is reasonably
expected to receive any payment or benefit from the Company or any of its
Subsidiaries that would not be deductible by such entity (including as a
result of Section 162(m) or 280G of the Code) or (vii) is entitled to receive
any gross-up, make-whole or other additional payment by reason of any Tax
being imposed on such Person (including as a result of Section 409A or 4999
of the Code).

  



  

(i) Each Employee Plan that is a "nonqualified deferred compensation plan"
within the meaning of Treasury Regulation Section 1.409A-1(a)(i) (i) was
operated in compliance with Section 409A of the Code between January 1, 2005
and December 31, 2008, based upon a good faith, reasonable interpretation of
(A) Section 409A of the Code or (B) guidance issued by the IRS thereunder
(including IRS Notice 2005-1), to the extent applicable and effective
(clauses (A) and (B), together, the "409A Authorities"), (ii) has been
operated in compliance with the 409A Authorities and the final Treasury
Regulations issued thereunder since January 1, 2009 and (iii) has been in
documentary compliance with the 409A Authorities and the final Treasury
Regulations issued thereunder since January 1, 2009.

  



  

(j) None of the execution and delivery of this Agreement or the consummation
of the Merger and the other transactions contemplated hereby (alone or in
conjunction with any other event, including any termination of employment)
will (i) entitle any current of former director, officer, employee,
independent contractor or consultant to any material compensation or benefit,
(ii) accelerate the time of payment or vesting, or trigger any payment or
funding, of any material compensation or benefits or trigger any other
material obligation under any Employee Plan or (iii) result in any breach or
violation of or default under, or limit the Company's right to amend, modify
or terminate, any Employee Plan.

  



  

(k) All payments made or to be made or benefits granted or to be granted to
any holder of Company Common Stock or other securities of the Company (each,
a "Covered Securityholder") pursuant to any employment, consulting, bonus,
incentive or deferred compensation, equity or equity-based compensation,
severance, change in control, retention, termination, pension, welfare or
other compensation or benefit plan, program, policy, arrangement or Contract,
including each Employee Plan, (i) have been or will be paid or granted as
compensation for past services performed, future services to be performed, or
future services to be refrained from performing (and matters incidental
thereto) by the applicable Covered Securityholder and (ii) have not been
and will not be calculated based on the number of shares of Company Common
Stock tendered or to be tendered into the Offer by the applicable Covered
Securityholder. The compensation committee of the Board (the "Company
Compensation Committee") (x) has prior to the date of this Agreement duly and
unanimously adopted resolutions approving as an "employment
compensation, severance or other employee benefit arrangement" within the
meaning of Rule 14d-10(d)(1) under the Exchange Act (an
"Employment Compensation Arrangement") (A) the Company Stock Plan, (B) the
treatment of the Company Options in accordance with the terms of this
Agreement, the Company Stock Plan and any other applicable Employee Plan, (C)
the terms of _Sections 3.7(d)_ ,  _7.1_ and _7.2_ of this Agreement and (D)
each other Employee Plan, in each case as in effect as of the date of
this Agreement, which resolutions have not been rescinded, modified or
withdrawn in any way and (y) has taken all other actions necessary to satisfy
the requirements of the non-exclusive safe harbor under Rule 14d-10(d)(2)
under the Exchange Act with respect to the foregoing arrangements and the
transactions contemplated by this Agreement. The Company Compensation
Committee is (or was, at each time it acted as described in this Section
4.19(k)) composed solely of "independent directors" within the meaning of
Rule 14d-10(d)(1) of the Exchange Act.

  



  

   

\- 34 - 
--- 

 


--- 

    



  

4.20 _Labor Matters_.

  



  

(a) Neither the Company nor any of its Subsidiaries is a party to any
collective bargaining agreement, labor union contract, or trade
union agreement (each a "Collective Bargaining Agreement"), and, to the
Knowledge of the Company, no collective Bargaining Agreement is being
negotiated with respect to any employee of the Company or any of its
Subsidiaries.

  



  

(b) (i) To the Knowledge of the Company, there are no activities or
proceedings of any labor or trade union to organize any employees of the
Company or any of its Subsidiaries; (ii) there is no strike, lockout,
slowdown, work stoppage, grievance or other labor dispute against or
affecting the Company or any of its Subsidiaries pending or, to the Knowledge
of the Company, threatened and during the last three years there has not been
any such action; (iii) neither the Company nor any of its Subsidiaries is
engaging in, or has within the last three years engaged in, any unfair labor
practice; and (iv) neither the Company nor any of its Subsidiaries has
received written or oral communication during the past three years of the
intent of any Governmental Authority responsible for the enforcement of labor
or employment laws to conduct an investigation of or affecting the Company or
any of its Subsidiaries and, to the Knowledge of the Company, no such
investigation is in progress.

  



  

(c) The Company and its Subsidiaries have complied in all material respects
with applicable Laws and Orders with respect to employment (including
applicable Laws regarding wage and hour requirements, correct classification
of independent contractors and of employees as exempt and non-exempt,
immigration status, discrimination in employment, workers' compensation,
employee health and safety, and collective bargaining).

  



  

(d) Except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a material impact on the Company or its
Subsidiaries, the Company and each of its Subsidiaries have withheld all
amounts required by applicable Law to be withheld from the wages, salaries,
and other payments to employees, and are not, to the Knowledge of the Company,
liable for any arrears of wages or any taxes or any penalty for failure to
comply with any of the foregoing. Neither the Company nor any of its
Subsidiaries is liable for any material payment to any trust or other fund or
to any Governmental Authority, with respect to unemployment
compensation benefits, social security or other benefits for employees (other
than routine payments to be made in the ordinary course of
business consistent with past practice).

  



  

(e) No current employee of the Company or any of its Subsidiaries has
provided notice of termination of employment with the Company or its
Subsidiaries, as applicable, and, to the Knowledge of the Company, no such
employee intends to terminate such employment, including in connection with
or as a result of the transactions contemplated by this Agreement.

  



  

4.21 _Permits_. The Company and its Subsidiaries have, and are in compliance
with the terms of, all permits, licenses, authorizations, consents, approvals
and franchises from Governmental Authorities required to own, lease and
operate their respective properties and to conduct their businesses as
currently conducted ("Permits"), and no suspension or cancellation of any such
Permits is pending or, to the Knowledge of the Company, threatened, except
for such noncompliance, suspensions or cancellations that have not had,
individually or in the aggregate, a Company Material Adverse Effect.

  



  

   

\- 35 - 
--- 

 


--- 

    



  

4.22 _Compliance with Laws_.

  



  

(a) The Company and each of its Subsidiaries are in compliance in all
material respects with all Law and Orders applicable to the Company and its
Subsidiaries. To the Knowledge of the Company, as of the date hereof, the
Company and each of its Subsidiaries are in material compliance with the
applicable laws and regulations of the FDA. Notwithstanding the foregoing, no
representation or warranty is made in this _Section 4.22_ with respect to (a)
compliance with the Exchange Act, to the extent such compliance is covered in
_Section 4.6_ and _Section 4.9_ , (b) intellectual property and related
matters, (c) applicable laws with respect to Taxes, (d) ERISA and other
employee benefit-related matters, (e) labor law matters or (f) Environmental
Laws.

  



  

(b) Key Products have been developed, tested, manufactured and stored, as
applicable, in compliance in all material respects with applicable Law
including, where applicable, the Federal Food, Drug and Cosmetic Act and
applicable regulations issued by the FDA, including, as applicable, those
requirements relating to the FDA's, EMA's and other Governmental Authorities'
current good manufacturing practices and good laboratory practices, and good
clinical practices.

  



  

(c) _Section 4.22_ of the Company Disclosure Letter contains a complete and
accurate list of all Registrations. Complete and accurate copies of all
Registrations, and all material correspondence with the FDA or other
applicable Governmental Authorities with respect to the Registrations, have
been made available to Parent. The Company and its Subsidiaries have never
imported for sale, exported for sale, marketed for sale, sold, offered for
sale, distributed for sale, processed for sale or packaged for sale any
products.

  



  

(d) The clinical trials conducted or otherwise sponsored by the Company and
its Subsidiaries with respect to Key Products were conducted and, if still
pending are being conducted, in all material respects in accordance with all
applicable clinical trial protocols, informed consents and applicable
requirements of applicable Law, including, where applicable, the FDA's good
clinical practices and good laboratory practices regulations. The Company
owns or has the right to use all data collected in the course of such
clinical trials, including the right to use such data in submissions to the
FDA, the EMA or other Governmental Authorities. The Company has the right to
transfer (including transfer of the right to use) all data collected in the
course of such clinical trials to Parent.

  



  

(e) Neither the FDA nor the EMA has commenced, or, to the knowledge of the
Company, threatened to initiate, any action (A) to place a clinical hold
order on, or otherwise terminate, delay or suspend, any proposed or ongoing
clinical investigation conducted or proposed to be conducted by the Company
or (B) alleging any material violation of the Federal Food, Drug and Cosmetic
Act, as well as applicable Laws of the FDA, the EMA and other applicable
Governmental Authorities of all countries in which Key Products are being
studied or proposed for marketing. No such termination or suspension has
occurred and no such action has been commenced or, to the knowledge of the
Company, threatened, except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.

  



  

(f) The Company has made available to Parent complete, true and correct
copies of all substantive correspondence (including letters,
memoranda, emails and formal summaries of meetings, phone calls,
conversations and teleconferences whether written or electronic) to or
from the FDA, EMA or other applicable Governmental Authorities and the
Company or its Subsidiaries or any Person acting for or on behalf of the
Company or its Subsidiaries including relating to clinical trials or proposed
clinical trials of Key Products, of the Company or its Subsidiaries, data
from such trials, preclinical testing of such Key Products, testing required
or recommended for approval of such Key Products, the manufacture of such Key
Products, inspection of facilities, audit reports or the pricing of or
reimbursement for such product candidates, including Key Products (whether
for commercial sale or compassionate or similar use).

  



  

   

\- 36 - 
--- 

 


--- 

    



  

(g) None of the Company, or any officer, employee or, to the Knowledge of the
Company, agent of the Company, has with respect to Key Products, of the
Company or its Subsidiaries, made any untrue statement or a material fact or
fraudulent statement to the FDA or any other Governmental Authority or failed
to disclose a material fact required to be disclosed to the FDA or any other
Governmental Authority. Neither the Company nor any of the Company
Subsidiaries, nor, to the knowledge of the Company, any director, officer,
employee or agent of the Company or any of the Company Subsidiaries, has been
convicted of any crime or engaged in any conduct for which debarment is
mandated by 21 U.S.C.  335a(a) or any similar Law or authorized by 21 U.S.C.
 335a(b) or any similar Law.

  



  

(h) The Company has not withdrawn or suspended Key Product, in the United
States or outside the United States (whether voluntarily or otherwise) since
January 2, 2012. No Legal Proceedings in the United States and outside of the
United States (whether completed or pending) seeking the withdrawal or
suspension of any Key Product, are pending or, to the Knowledge of the
Company, threatened against the Company.

  



  

4.23 _Environmental Matters_. Except for such matters as have not had,
individually or in the aggregate, a Company Material Adverse Effect:

  



  

(a) The Company and its Subsidiaries are, and have been, in compliance with
all applicable Environmental Laws, which compliance includes the possession
and maintenance of, and compliance with, all Permits required under applicable
Environmental Laws for the operation of the business of the Company and its
Subsidiaries as presently conducted.

  



  

(b) Neither the Company nor any of its Subsidiaries has transported,
produced, processed, manufactured, generated, used, treated, handled, stored
or Released any Hazardous Substances, at or from any property that the Company
or any of its Subsidiaries has at any time owned, operated, occupied or
leased.

  



  

(c) Neither the Company nor any of its Subsidiaries is a party to or is the
subject of any pending, or to the Knowledge of the Company threatened Legal
Proceeding alleging any Liability or responsibility under or noncompliance
with any Environmental Law or seeking to impose any financial responsibility
for any investigation, cleanup, removal, containment or any other remediation
or compliance under any Environmental Law. Neither the Company nor any of its
Subsidiaries is subject to any Order or agreement by or with any
Governmental Authority or third party imposing any material liability or
obligation with respect to any of the foregoing.

  



  

(d) There has been no Release of or exposure to any Hazardous Substances that
could reasonably be expected to form the basis of any claim against or
Liability of the Company or any of its Subsidiaries under any Environmental
Law.

  



  

(e) Neither the Company nor any of its Subsidiaries has retained or assumed,
either contractually or by operation of law, any liabilities or obligations
that could reasonably be expected to form the basis of any claim against or
Liability of the Company or any of its Subsidiaries under any Environmental
Law.

  



  

   

\- 37 - 
--- 

 


--- 

    



  

4.24 _Litigation_. As of the date hereof, there is no Legal Proceeding
pending or, to the Knowledge of the Company, threatened in writing against or
affecting the Company, any of its Subsidiaries or any of the respective
properties of the Company or any of its Subsidiaries that, individually or in
the aggregate, is material to the Company or any of its Subsidiaries, taken as
a whole. Neither the Company nor any of its Subsidiaries, taken as a whole,
is subject to any outstanding material Order.

  



  

4.25 _Insurance_. Except as has not had, individually or in the aggregate, a
Company Material Adverse Effect, all policies of insurance maintained by the
Company or any of its Subsidiaries are in full force and effect, no notice of
cancellation has been received with respect to such policies (other than in
connection with ordinary renewals), and there is no existing default or event
which, with the giving of notice or lapse of time or both, would constitute a
default, by any insured thereunder. As of the date of this Agreement, there
is no material claim pending or threatened against such policies as to which
coverage has been questioned, denied or disputed by the underwriters of such
policies. _Section 4.25_ of the Company Disclosure Letter contains a complete
and accurate list of all material insurance policies maintained by, or on
behalf of, Company or any of its Subsidiaries and sets forth the
annual premium of the Company's existing DandO Insurance.

  



  

4.26 _Related Party Transactions_. Except (a) for indemnification,
compensation, employment or other similar arrangements between the Company or
any of its Subsidiaries, on the one hand, and any director or officer thereof,
on the other hand, (b) as set forth in _Section 4.26_ of the Company
Disclosure Letter and (c) as disclosed in the Company SEC Reports filed prior
to the date hereof, there are no transactions, agreements, arrangements or
understandings between the Company or any of its Subsidiaries, on the one
hand, and any Affiliate (including any director or officer) thereof, but not
including any wholly-owned Subsidiary of the Company, on the other hand,
within the three-year period preceding the date of this Agreement, in each
case, that would be required to be disclosed pursuant to Item 404 of
Regulation S-K under the Securities Act in the Company's Form 10-K or proxy
statement pertaining to an annual meeting of stockholders.

  



  

4.27 _Brokers_. Except for Torreya Capital, a division of Financial West
Investment Group, Inc. and Deutsche Bank Securities Inc. ("Deutsche Bank"),
there is no financial advisor, investment banker, broker, finder, agent or
other Person that has been retained by or is authorized to act on behalf of
the Company, any of its Subsidiaries or the Company Board (or any committee
thereof), or that otherwise based upon arrangements made by or on behalf of
the Company, who is entitled to any financial advisor's, investment banking,
brokerage, finder's or other fee or commission in connection with the
transactions contemplated by this Agreement. The Company has made available
to Parent complete and correct copies of all Contracts between the Company and
each of Financial West Investment Group, Inc. and Deutsche Bank.

  



  

4.28 _Opinion of Financial Advisor_. The Company Board has received the
opinion of Deutsche Bank (the "Fairness Opinion") to the effect that, as of
the date hereof and subject to the limitations, qualifications, assumptions
and conditions set forth therein, the Merger Consideration to be paid to the
holders of Company Common Stock (other than Parent or any Affiliate of
Parent) in connection with the Offer and the Merger is fair from a financial
point of view to such holders. It is agreed and understood that such opinion
is for the benefit of the Company Board and may not be relied upon by Parent
or Acquisition Sub. The Company will deliver or make available to Parent for
informational purposes a signed copy of the Fairness Opinion as soon as
possible following the date hereof.

  



  

4.29 _Milestone and Royalty Payments_. _Section 4.29_ of the Company
Disclosure Letter contains a complete and accurate list of (a) all milestone,
development or similar payments, both scheduled and unscheduled, and (b) all
royalty or similar payments (including applicable percentages), in each case,
which remain outstanding as of the date hereof, and the applicable time or
trigger event upon which each such payment will be made and the product
candidates to which such payments relate.

  



  

   

\- 38 - 
--- 

 


--- 

    



  

ARTICLE V 
  _REPRESENTATIONS AND WARRANTIES OF PARENT AND ACQUISITION SUB_

  



  

Parent and Acquisition Sub hereby represent and warrant to the Company
jointly and severally as follows:

  



  

5.1 _Organization; Good Standing_. Parent is a corporation duly organized,
validly existing and in good standing under Danish Law and has the requisite
corporate power and authority to conduct its business as it is presently being
conducted and to own, lease or operate its respective properties and assets.
Acquisition Sub is a corporation duly organized and validly existing under
Delaware Law and has the requisite corporate power and authority to conduct
its business as it is presently being conducted and to own, lease or operate
its respective properties and assets. Each of Parent and Acquisition Sub is
duly qualified to do business and is in good standing (to the extent either
such concept is recognized under applicable Law) in each jurisdiction where
the character of its properties owned or leased or the nature of its
activities make such qualification necessary, except where the failure to be
so qualified or in good standing would not, individually or in the aggregate,
prevent or materially delay the consummation by Parent and Acquisition Sub of
the transactions contemplated hereby or the performance by Parent and
Acquisition Sub of their respective covenants and obligations hereunder.

  



  

5.2 _Corporate Power; Enforceability_. Each of Parent and Acquisition Sub has
the requisite corporate power and authority to execute and deliver this
Agreement and the CVR Agreement (if applicable), to perform their respective
covenants and obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby. The execution and delivery by
Parent and Acquisition Sub of this Agreement and the CVR Agreement (if
applicable), the performance by Parent and Acquisition Sub of their respective
covenants and obligations hereunder and thereunder and the consummation by
Parent and Acquisition Sub of the transactions contemplated hereby and
thereby have been duly authorized by all necessary corporate or other action
on the part of Parent and Acquisition Sub (other than the adoption of this
Agreement by Parent as sole stockholder of Acquisition Sub which shall occur
immediately after the execution and delivery hereof), and no other corporate
or other proceeding on the part of Parent or Acquisition Sub is necessary to
authorize the execution and delivery by Parent and Acquisition Sub of this
Agreement and the CVR Agreement (if applicable), the performance by Parent
and Acquisition Sub of their respective covenants and obligations hereunder
and thereunder or the consummation by Parent and Acquisition Sub of the
transactions contemplated hereby and thereby (other than the adoption of this
Agreement by Parent as sole stockholder of Acquisition Sub which shall occur
immediately after the execution and delivery hereof). This Agreement and the
CVR Agreement (if applicable) has been (or will be) duly executed and
delivered by each of Parent and Acquisition Sub and, assuming the due
authorization, execution and delivery by the other party thereto, constitutes
a legal, valid and binding obligation of each of Parent and Acquisition Sub,
enforceable against each in accordance with its terms, subject to the
Enforceability Exception.

  



  

5.3 _Non-Contravention_. The execution and delivery by Parent and Acquisition
Sub of this Agreement and the CVR Agreement (if applicable), the
performance by Parent and Acquisition Sub of their respective covenants and
obligations hereunder and thereunder and the consummation of the Offer, the
Merger and the other transactions contemplated hereby and thereby do not and
will not (a) violate or conflict with any provision of the certificate of
incorporation, by-laws or other organizational documents of Parent or
Acquisition Sub, (b) violate, conflict with, or result in the breach of or
constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or result in the termination or modification
of, or the acceleration of the performance or obligation required by, or
result in a right of termination, modification or acceleration under any note,
bond, mortgage, indenture, lease, license, contract, agreement or other
instrument or obligation to which Parent or Acquisition Sub is a party or by
which Parent, Acquisition Sub or any of their properties or assets may be
bound, (c) subject to the filings and Consents referred to in _Section 5.4,_
violate or conflict with any Law or Order applicable to Parent or Acquisition
Sub or by which any of their properties or assets are bound (assuming the
adoption of this Agreement by Parent as sole stockholder of Acquisition Sub
which shall occur immediately after the execution and delivery hereof) or (d)
result in the creation of any Lien (other than Permitted Liens) upon any of
the properties or assets of Parent or Acquisition Sub, except in the case of
each of _clauses (b)_ , _(c) _ and _(d)_ above, for such violations,
conflicts, defaults, terminations, modifications, accelerations or Liens
which would not, individually or in the aggregate, prevent or materially
delay the consummation by Parent and Acquisition Sub of the transactions
contemplated hereby and thereby or the performance by Parent and Acquisition
Sub of their respective covenants and obligations hereunder and thereunder.

  



  

   

\- 39 - 
--- 

 


--- 

    



  

5.4 _Required Governmental Approvals_. No Consent of any Governmental
Authority is required on the part of Parent, Acquisition Sub or any of their
Affiliates in connection with the execution and delivery by Parent and
Acquisition Sub of this Agreement and the CVR Agreement (if applicable), the
performance by Parent and Acquisition Sub of their respective covenants and
obligations hereunder and thereunder and the consummation by Parent and
Acquisition Sub of the transactions contemplated hereby and thereby,
except (a) the filing of the Certificate of the Merger with the Secretary of
State of the State of Delaware, and such filings with
Governmental Authorities to satisfy the applicable Laws of states in which
the Company and its Subsidiaries are qualified to do business, (b) such
filings and approvals as may be required by any federal or state securities
Laws, including compliance with any applicable requirements of the Exchange
Act, including the Schedule TO and the Offer Documents, (c) Consents required
under, and compliance with any other applicable requirements of the HSR Act
and any applicable foreign Antitrust Laws, and (d) such other Consents, the
failure of which to obtain would not, individually or in the aggregate,
prevent or materially delay the consummation by Parent and Acquisition Sub of
the transactions contemplated hereby and thereby or the performance by Parent
and Acquisition Sub of their respective covenants and obligations hereunder
and thereunder.

  



  

5.5 _Litigation_. As of the date hereof, there is no Legal Proceeding pending
or, to the knowledge of Parent, threatened in writing against or
affecting Parent or Acquisition Sub or any of their Subsidiaries or any of
their respective properties that would, individually or in the aggregate,
prevent or materially delay the consummation by Parent and Acquisition Sub of
the transactions contemplated hereby or the performance by Parent and
Acquisition Sub of their respective covenants and obligations hereunder.
Neither Parent nor Acquisition Sub is subject to any outstanding Order that
would, individually or in the aggregate, prevent or materially delay the
consummation by Parent and Acquisition Sub of the transactions contemplated
hereby or the performance by Parent and Acquisition Sub of their respective
covenants and obligations hereunder.

  



  

5.6 _Information Supplied_.

  



  

(a) Each document required to be filed by Parent or Acquisition Sub with the
SEC in connection with the Offer (the "Parent Disclosure Documents")
(including the Schedule TO and the Offer Documents), and any amendments or
supplements thereto, when filed, distributed or disseminated, as applicable,
will comply as to form in all material respects with the applicable
requirements of the Exchange Act.

  



  

(b) The Parent Disclosure Documents, at the time of the filing of such Parent
Disclosure Documents or any supplement or amendment thereto and at the time
of any distribution or dissemination thereof and at the time of the
consummation of the Offer, will not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make
the statements made therein, in the light of the circumstances under which
they were made, not misleading. The representations and warranties contained
in this _Section 5.6_ will not apply to statements included in, or omissions
from, the Parent Disclosure Documents based upon information furnished to
Parent or Acquisition Sub by or on behalf of the Company or any Affiliate of
the Company or known to the Company but not known to Parent or Acquisition
Sub.

  



  

   

\- 40 - 
--- 

 


--- 

    



  

(c) The information with respect to Parent or Acquisition Sub that Parent or
Acquisition Sub furnishes to the Company expressly for use in the Offer
Documents and the Company Disclosure Documents (including the Schedule 14D-9),
at the time such document is filed with the SEC, at any time such document is
amended or supplemented or at the time such document is first published, sent
or given to the Company Stockholders, will not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in the light of the circumstances under
which they were made, not misleading.

  



  

5.7 _Ownership of Company Capital Stock_.

  



  

(a) None of Parent or Acquisition Sub is, or at any time during the last
three (3) years has been, an "interested stockholder" of the Company as
defined in Section 203 of the DGCL. Prior to and as of the date of this
Agreement, neither Parent nor Acquisition Sub has taken, or authorized or
permitted any Representatives of Parent or Acquisition Sub to take, any action
that would cause either Parent or Acquisition Sub to be deemed an "interested
stockholder" as defined in Section 203 of the DGCL or otherwise render
Section 251(h) of the DGCL inapplicable to the Merger.

  



  

(b) As of the date hereof, neither Parent nor any of its Subsidiaries owns
(beneficially or otherwise) any shares of Company Common Stock or Company
Securities or Subsidiary Securities (or any other economic interest through
derivative securities or otherwise in the Company or any Subsidiary of the
Company) except pursuant to this Agreement.

  



  

5.8 _Brokers_. No agent, broker, finder or investment banker is entitled to
any brokerage, finder's or other fee or commission payable by the Company in
connection with the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of Parent or Acquisition Sub.

  



  

5.9 _Operations and Ownership of Acquisition Sub_. Acquisition Sub has been
formed solely for the purpose of engaging in the transactions
contemplated hereby and, prior to the Effective Time, Acquisition Sub will
not have engaged in any other business activities and will not have incurred
any Liabilities or obligations other than incident to its formation and other
than as contemplated by this Agreement. Parent indirectly owns, beneficially
and of record, all the outstanding shares of capital stock of Acquisition Sub,
free and clear of all Liens.

  



  

5.10 _Available Funds_.

  



  

(a) Parent has sufficient funds to consummate the Offer and the Merger on the
terms contemplated by this Agreement, and, at the Offer Closing and the
Effective Time, Parent will have available, and will make available to
Acquisition Sub, all of the funds necessary for the acquisition of all shares
of Company Common Stock pursuant to the Offer and the consummation of the
Merger and the other transactions contemplated hereby.

  



  

   

\- 41 - 
--- 

 


--- 

    



  

(b) Neither Parent or Acquisition Sub, or any of their respective Affiliates,
is a party to or otherwise bound by any Contracts, or has any formal or
informal arrangements or other understandings (whether or not binding), with
any stockholder, director, officer or other employee of the Company or any of
its Subsidiaries concerning any investments to be made in or contributions to
be made to Parent or Acquisition Sub in connection with the Merger and/or any
other transactions contemplated by this Agreement.

  



  

5.11 _Stockholder and Management Arrangements_. As of the date hereof,
neither Parent nor Acquisition Sub, nor any of their respective
Affiliates, is a party to any Contracts, or has made or entered into any
formal or informal arrangements or other understandings (whether or not
binding), with any stockholder, director, officer or other Affiliate of the
Company or any of its Subsidiaries relating to this Agreement, the Offer, the
Merger or any other transactions contemplated by this Agreement, or the
Surviving Corporation or any of its Subsidiaries, businesses or operations
(including as to continuing employment or compensation) from and after
the Effective Time. Parent and Acquisition Sub have delivered to the Company
complete and correct copies of any such Contract.

  



  

5.12 _No Other Company Representations or Warranties_. Except for the
representations and warranties set forth in _ARTICLE IV_ , Parent and
Acquisition Sub hereby acknowledge and agree that (a) neither the Company or
any of its Subsidiaries, nor any of their respective Affiliates,
stockholders, directors, officers, employees, agents, representatives or
advisors, nor any other Person, has made or is making (and neither Parent nor
Acquisition Sub is relying on) any other express or implied representation or
warranty with respect to the Company or any of its Subsidiaries or their
respective business or operations, including with respect to the accuracy or
completeness of any information provided or made available to Parent,
Acquisition Sub or any of their respective Affiliates, stockholders,
directors, officers, employees, agents, representatives or advisors, or any
other Person, and (b) other than as set forth in the last sentence of this
_Section 5.12_ , neither the Company nor any of its Subsidiaries, nor or any
of their respective Affiliates, stockholders, directors, officers, employees,
agents, representatives or advisors, nor any other Person, will have or be
subject to any liability or indemnification obligation or other obligation of
any kind or nature to Parent, Acquisition Sub or any of their respective
Affiliates, stockholders, directors, officers, employees, agents,
representatives or advisors, or any other Person, resulting from the
delivery, dissemination or any other distribution to Parent, Acquisition Sub
or any of their respective Affiliates, stockholders, directors, officers,
employees, agents, representatives or advisors, or any other Person, or the
use by Parent, Acquisition Sub or any of their respective Affiliates,
stockholders, directors, officers, employees, agents, representatives or
advisors, or any other Person, of any such information provided or made
available to any of them by the Company or any of its Subsidiaries, or any of
their respective Affiliates, stockholders, directors, officers, employees,
agents, representatives or advisors, or any other Person, including any
information, documents, estimates, projections, forecasts or other forward-
looking information, business plans or other material provided or made
available to Parent, Acquisition Sub or any of their respective Affiliates,
stockholders, directors, officers, employees, agents, representatives or
advisors, or any other Person, in "data rooms," confidential information
memoranda or management presentations in anticipation or contemplation of the
Merger or any other transactions contemplated by this Agreement.
Notwithstanding anything to the contrary, nothing in this Agreement shall be
construed to limit or relieve in any way the Company, its Subsidiaries, or any
of their respective Affiliates, Representatives or any other Person of any
liability to Parent or Acquisition Sub, arising out of fraud.

  



  

5.13 _Non-Reliance on Company Estimates, Projections, Forecasts, Forward-
Looking Statements and Business Plans_. In connection with the due
diligence investigation of the Company by Parent and Acquisition Sub and
their respective Affiliates, stockholders, directors, officers, employees,
agents, representatives or advisors, Parent and Acquisition Sub and their
respective Affiliates, stockholders, directors, officers, employees, agents,
representatives and advisors have received and may continue to receive after
the date hereof from the Company and its Affiliates, stockholders, directors,
officers, employees, agents, representatives and advisors certain
estimates, projections, forecasts and other forward-looking information, as
well as certain business plan information, regarding the Company and its
business and operations. Parent and Acquisition Sub hereby acknowledge and
agree (a) that there are uncertainties inherent in attempting to make such
estimates, projections, forecasts and other forward-looking statements, as
well as in such business plans, with which Parent and Acquisition Sub are
familiar, (b) that Parent and Acquisition Sub are taking full
responsibility for making their own evaluation of the adequacy, accuracy and
completeness of all estimates, projections, forecasts and other forward-
looking information, as well as such business plans, so furnished to them
(including the reasonableness of the assumptions underlying such estimates,
projections, forecasts, forward-looking information or business plans), and
(c) subject to the last sentence in _Section 5.12_ , Parent and Acquisition
Sub will have no claim against the Company or any of its Subsidiaries, or any
of their respective Affiliates, stockholders, directors, officers, employees,
agents, representatives or advisors, or any other Person, with respect
thereto. Accordingly, Parent and Acquisition Sub hereby acknowledge and agree
that none of the Company or any of its Subsidiaries, nor any of their
respective Affiliates, stockholders, directors, officers, employees, agents,
representatives or advisors, nor any other Person, has made or is making any
express or implied representation or warranty with respect to such estimates,
projections, forecasts, forward-looking statements or business plans
(including the reasonableness of the assumptions underlying such estimates,
projections, forecasts, forward-looking statements or business plans).

  



  

   

\- 42 - 
--- 

 


--- 

    



  

ARTICLE VI 
  _COVENANTS OF THE COMPANY_

  



  

6.1 _Interim Conduct of Business_.

  



  

(a) Except (i) as expressly required or permitted by this Agreement, (ii) as
required by applicable Law, (iii) as set forth in _Section 6.1_ of the
Company Disclosure Letter, or (iv) as approved by Parent in writing (which
approval will not be unreasonably withheld, conditioned or delayed), at all
times during the period commencing upon the execution and delivery of this
Agreement and continuing until the earlier to occur of the termination of
this Agreement pursuant to _Section 10.1_ and the Effective Time, each of the
Company and each of its Subsidiaries shall (A) carry on its business in the
usual, regular and ordinary course in substantially the same manner as
heretofore conducted, including by using commercially reasonable efforts to
continue current plans to launch the Key Product, and (B) use its
commercially reasonable efforts, consistent with past practices and policies,
to preserve substantially intact its business organization and keep available
the services of its current officers and employees and preserve the
current relationships of the Company and each of its Subsidiaries with
customers, suppliers, licensors and other Persons whom the Company or any of
its Subsidiaries has significant business relations.

  



  

(b) Except (w) as expressly required or permitted by this Agreement, (x) as
required by applicable Law, (y) as set forth in _Section 6.1 _ of the Company
Disclosure Letter, or (z) as approved by Parent in writing (which approval
will not be unreasonably withheld, conditioned or delayed), at all times
during the period commencing upon the execution and delivery of this Agreement
and continuing until the earlier to occur of the termination of this
Agreement pursuant to _Section 10.1_ and the Effective Time, the
Company shall not do any of the following and shall not permit any of its
Subsidiaries to do any of the following:

  



  

(i) amend its certificate of incorporation or by-laws or comparable
organizational documents;

  



  

(ii) issue, sell, grant, encumber, deliver or agree or commit to issue, sell,
grant, encumber or deliver (whether through the issuance or granting of
options, warrants, commitments, subscriptions, stock appreciation rights,
phantom stock or other rights to purchase or otherwise) any Company
Securities or any Subsidiary Securities, except (A) for the issuance and sale
of shares of Company Common Stock pursuant to Company Options outstanding on
the date hereof upon the exercise thereof on the terms in effect on the
date hereof, and (B) pursuant to requirements of Contracts of the Company or
any of its Subsidiaries set forth on _Section 6.1(b)(ii) _ of the Company
Disclosure Letter and in existence on the date of this Agreement and on the
terms in effect on the date hereof;

  



  

   

\- 43 - 
--- 

 


--- 

    



  

(iii) directly or indirectly acquire, repurchase or redeem any Company
Securities or Subsidiary Securities, except in connection with Tax
withholdings and exercise price settlements upon the exercise of Company
Options outstanding on the date hereof to the extent permitted by the terms
of the Company Stock Plan or any applicable award agreement as in effect on
the date of this Agreement;

  



  

(iv) (A) split, combine, subdivide or reclassify any shares of capital stock,
or (B) declare, set aside or pay any dividend or other distribution (whether
in cash, shares or property or any combination thereof) in respect of any
shares of capital stock, or make any other actual, constructive or deemed
distribution in respect of the shares of capital stock, except for cash
dividends made by any direct or indirect wholly-owned Subsidiary of the
Company to the Company or one of its wholly-owned Subsidiaries;

  



  

(v) form any Subsidiary, or enter into any joint venture, partnership,
limited liability or similar arrangement;

  



  

(vi) make any capital expenditures, except such capital expenditures that do
not exceed $25,000 individually or, when added to all other capital
expenditures made since January 1, 2014, $100,000 in the aggregate;

  



  

(vii) propose or adopt a plan of complete or partial liquidation,
dissolution, consolidation, restructuring, recapitalization or other
reorganization of the Company or any of its Subsidiaries, except for (A) the
transactions contemplated by this Agreement or (B) the dissolution or
reorganization of a wholly-owned Subsidiary of the Company in the ordinary
course of business;

  



  

(viii) (A) incur, assume or guarantee any Indebtedness, issue or guarantee
any warrants or other rights to acquire Indebtedness or enter into any
arrangement having the economic effect of any of the foregoing, other than (1)
Indebtedness not in excess of $100,000 in aggregate outstanding at any time
and (2) short-term borrowings incurred in the ordinary course of business
consistent with past practice not in excess of $25,000 in aggregate or (B)
make any loans, advances or capital contributions, or investments in, any
other Person, other than (1) to or in the Company or any of its Subsidiaries
or (2) business expense advances in the ordinary course of business
consistent with past practice to employees of the Company or any of its
Subsidiaries;

  



  

(ix) except as may be required by applicable Law or the terms of any Employee
Plan or Contract as in effect on the date hereof, (A) enter into, adopt,
amend (including acceleration of vesting or payment), waive any rights under,
modify or terminate any Employee Plan (or any award thereunder) or Contract
or any other bonus, profit sharing, incentive, compensation, change in
control, severance, retention, termination, option, appreciation right,
performance unit, stock equivalent, share purchase agreement, pension,
retirement, deferred compensation, employment, severance or other employee
benefit agreement, trust, plan, fund or other arrangement for
the compensation, benefit or welfare of any current or former director,
officer, employee, independent contractor or consultant in any manner or (B)
increase the compensation or benefits of, or grant any loan to, any current or
former director, officer, employee, independent contractor or consultant, pay
or agree to pay any special bonus or special remuneration to any current or
former director, officer, employee, independent contractor or consultant, or
pay or agree to pay any benefit to any current or former director, officer,
employee, independent contractor or consultant;

  



  

   

\- 44 - 
--- 

 


--- 

    



  

(x) hire or promote any employee of the Company or any of its Subsidiaries
(whether or not in the ordinary course of business) or terminate the
employment of any such employee, other than due to such employee's death or
disability or for cause (as determined by the Company or its Subsidiary, as
applicable, in its reasonable discretion consistent with past practice);

  



  

(xi) commence any Legal Proceeding, except with respect to (A) routine
matters in the ordinary course of business consistent with past practice or
(B) in such cases where the Company reasonably determines in good faith, after
consultation with outside legal counsel, that the failure to commence suit
would result in a material impairment of a valuable aspect of its business
(provided the Company consults with Parent and considers in good faith the
views and comments of Parent with respect to such Legal Proceedings prior to
commencement thereof);

  



  

(xii) pay, discharge, satisfy or settle any pending or threatened Legal
Proceeding or Liability, except for the payment, discharge, satisfaction or
settlement of any Legal Proceeding or Liability that (1) is reflected or
reserved against in the Company Balance Sheet or (2) is incurred since the
Company Balance Sheet Date, is not in excess of $100,000 per claim or
$1,000,000 in the aggregate and does not relate to the transactions
contemplated hereby, involve the issuance of Company Securities or Subsidiary
Securities or include any material restrictions on or obligation (other than
the payment of money) to be performed by the Company or its Subsidiaries;

  



  

(xiii) except as may be required as a result of a change in applicable Law or
in GAAP, make any material change in any of the accounting principles or
practices used by it;

  



  

(xiv) (A) make or change any material Tax election, (B) settle or compromise
any material U.S. federal, state, local or non-U.S. income Tax liability that
is disputed, (C) change any material method of Tax accounting or (D) consent
to any extension or waiver of any limitation period with respect to any claim
or assessment for material Taxes, except, in each case, in the ordinary
course of business consistent with past practice;

  



  

(xv) in a single transaction or a series of related transactions (A) acquire
(by merger, consolidation or acquisition of stock or assets or otherwise) any
other Person or any division, business or equity interest therein in excess of
$250,000 individually or $500,000 in the aggregate or (B) acquire, dispose
of, transfer, lease, pledge or otherwise encumber or subject to any Lien
(other than Permitted Liens) any properties or assets (including equipment
purchases) of the Company or its Subsidiaries with a fair market value or
otherwise at a price (i) in excess of $250,000 individually or $500,000 in the
aggregate or (ii) that are otherwise material, individually or in the
aggregate, to the Company and its Subsidiaries, taken as a whole, other than
the disposition of obsolete or worn-out equipment, in the ordinary course of
business consistent with past practice; or

  



  

(xvi) sell, lease (as lessor), license, abandon, let lapse, covenant not to
assert, fail to continue to prosecute or otherwise dispose of or subject to
any Lien (other than Permitted Liens) any Company Intellectual Property
Rights, except for (i) immaterial, non-exclusive licenses contained in
service contracts that are granted in the ordinary course of business
consistent with past practice and incidental to such service contracts and
(ii) abandonments of Company Intellectual Property Rights in the ordinary
course of business consistent with past practice; _provided_ , _however_ ,
that prior to abandoning any Company Intellectual Property Rights, the
Company shall consult with Parent;

  



  

(xvii) permit any material insurance policy naming the Company or any of its
Subsidiaries or its or their Representatives as a beneficiary or loss payee
to be cancelled or terminated;

  



  

   

\- 45 - 
--- 

 


--- 

    



  

(xviii) enter into or become bound by, or permit any of the assets owned or
used by it to become bound by, any Contract that if existing as of the date
of this Agreement, would have been a Material Contract, or amend or
prematurely terminate, or waive or exercise any material right or remedy
under, any Material Contract; or

  



  

(xix) agree or commit to take any of the actions described in clauses (i)
through (xviii) of this _Section 6.1_.

  



  

(c) Notwithstanding the foregoing, nothing in this Agreement is intended to
give Parent, directly or indirectly, the right to control or direct
the business or operations of the Company or its Subsidiaries at any time
prior to the Effective Time. Prior to the Effective Time, the Company and its
Subsidiaries shall exercise, consistent with the terms and conditions of this
Agreement, complete control and supervision over their own business and
operations.

  



  

6.2 _No Solicitation_.

  



  

(a) The Company and its Subsidiaries shall, and shall cause their
Representatives to, immediately (i) cease any and all existing discussions or
negotiations with any Persons conducted heretofore with respect to any
proposal that constitutes or would reasonably be expected to lead to an
Acquisition Proposal, (ii) request the prompt return or destruction of all
confidential information previously furnished to any Person within the last
12 months for the purposes of evaluating a possible Acquisition Proposal and
(iii) prohibit any third party from accessing any physical or electronic data
room relating to a possible Acquisition Proposal.

  



  

(b) Subject to _Section 6.2(c)_ and _Section 10.1(d)_ , at all times during
the period commencing upon the execution and delivery of this Agreement and
continuing until the earlier to occur of the termination of this Agreement
pursuant to _Section 10.1_  and the Effective Time, the Company and its
Subsidiaries shall not, nor shall they authorize, direct or permit any of
their respective directors, officers or other employees, controlled
affiliates, or any investment banker, attorney or other authorized agent
or representative (collectively, "Representatives") to, directly or
indirectly, (i) solicit, initiate or knowingly induce the making, submission
or announcement of, or knowingly encourage or assist, an Acquisition Proposal
or any inquiries that would reasonably be expected to lead to an Acquisition
Proposal, (ii) furnish to any Person (other than Parent, Acquisition Sub or
any designees of Parent or Acquisition Sub) any non-public information
relating to the Company or any of its Subsidiaries, in any such case to
knowingly induce or facilitate the making, submission or announcement of, or
to knowingly encourage or assist, an Acquisition Proposal or any inquiries or
the making of any proposal that would reasonably be expected to lead to an
Acquisition Proposal, (iii) participate or engage in discussions or
negotiations with any Person with respect to an Acquisition Proposal, (iv)
approve, endorse or recommend, or propose publicly to approve, endorse or
recommend, an Acquisition Proposal, or (v) approve, authorize the entry into
or enter into any Contract contemplating or otherwise relating to an
Acquisition Transaction (other than an Acceptable Confidentiality Agreement
pursuant to _Section 6.2(c)_ ); _provided_ , _however_ , that nothing in
this  _Section 6.2(b)_ shall prohibit the Company or its Representatives from
contacting in writing any Persons or groups of Persons who have made an
unsolicited Acquisition Proposal after the date of this Agreement solely to
request clarification of the terms and conditions thereof so as to determine
whether such Acquisition Proposal is, or could reasonably be expected to lead
to, a Superior Proposal, and any such actions shall not be a breach of this
_Section 6.2_. Without limiting the foregoing, it is agreed that any
violation of the restrictions set forth in the preceding sentence by any
Representative of the Company or any of its Subsidiaries, whether or not such
Person is purporting to act on behalf of the Company or its Subsidiary or
otherwise, shall be deemed to be a breach of this _Section 6.2(b)_ by the
Company; _provided_ , that, in the case of any violation by any
Representative that is not a director, officer or other employee of the
Company or any of its Subsidiaries, only a material violation thereby shall
be so deemed a breach.

  



  

   

\- 46 - 
--- 

 


--- 

    



  

(c) Notwithstanding anything to the contrary set forth in this _Section 6.2_
or elsewhere in this Agreement, if the Company Board (or any
committee thereof) determines in good faith (after consultation with outside
legal counsel) that the failure to take any of the following actions would
reasonably be expected to be inconsistent with its fiduciary duties to the
Company Stockholders under applicable Law, prior to the Offer Closing, the
Company, the Company's Subsidiaries, the Company's Representatives and the
Company's Subsidiaries' Representatives may, upon providing Parent 24 hours'
prior written notice of its intent to take such actions (i) participate or
engage in discussions or negotiations with any Person or group of Persons that
has made an unsolicited Acquisition Proposal that the Company Board (or any
committee thereof) determines in good faith, after consultation with its
outside financial advisor and outside legal counsel, either constitutes or
could reasonably be expected to lead to a Superior Proposal, (ii) grant a
waiver, amendment or release under any standstill agreement (or standstill
provision of any agreement) for the purpose of allowing any Person or group
of Persons to make an Acquisition Proposal and/or (iii) furnish to any Person
or group of Persons that has made an unsolicited Acquisition Proposal that
the Company Board (or any committee thereof) determines in good faith, after
consultation with its outside financial advisor and outside legal counsel,
either constitutes or could reasonably be expected to lead to a Superior
Proposal any non-public information relating to the Company and/or any of its
Subsidiaries and/or afford to any such Person or group of Persons access to
the business, properties, assets, books, records or other non-public
information, or to any personnel, of the Company and/or any of its
Subsidiaries, in each case under this _clause (iii)_ pursuant to
an Acceptable Confidentiality Agreement (a copy of which shall be provided by
the Company to Parent within 24 hours of execution);  _provided_ , _however_
, that in the case of any action taken pursuant to the preceding _clauses (i)_
or _(iii)_ , the Acquisition Proposal in question shall not have resulted
from a breach of _Section 6.2(a)_ , _Section 6.2(b)_ or  _Section 6.2(d_ )
and (A) the Company gives Parent at least one (1) Business Day prior written
notice of the identity of such Person or group of Persons and the material
terms of such Acquisition Proposal (and, if such Acquisition Proposal is in
written form, the Company shall give Parent a copy thereof), and (B)
contemporaneously with or prior to furnishing or making available any non-
public information or access to such Person or group of Persons, the Company
furnishes or makes available such non-public information or access to Parent
(which may be by posting such information to a "virtual data room" available
to Parent and its Representatives) to the extent such information has not
been previously furnished or made available to Parent.

  



  

(d) If the Company becomes aware of any receipt by the Company of (i) any
Acquisition Proposal, (ii) any request for information that would reasonably
be expected to lead to an Acquisition Proposal, or (iii) any inquiry with
respect to, or which would reasonably be expected to lead to, any Acquisition
Proposal, the Company shall promptly notify Parent (and in no event later than
48 hours after receipt thereof) of the material terms and conditions of such
Acquisition Proposal, request or inquiry, and the identity of the Person or
group of Persons making any such Acquisition Proposal, request or inquiry
(and, if such Acquisition Proposal, request or inquiry is in written form,
the Company shall give Parent a copy thereof). The Company shall keep Parent
reasonably informed of any material change in the status or terms of any such
Acquisition Proposal, request or inquiry (including by providing copies of
additional written materials relating thereto within 48 hours of receipt
thereof).

  



  

6.3 _Company Board Recommendation_.

  



  

(a) Neither the Company Board nor any committee thereof shall withhold,
withdraw, amend or modify in a manner adverse to Parent, or publicly propose
to withhold, withdraw, amend or modify in a manner adverse to Parent, the
Company Board Recommendation (a "Company Board Recommendation Change");
_provided_ , _however_ , that a "stop, look and listen" communication by the
Company Board (or any committee thereof) to the Company Stockholders pursuant
to Rule 14d-9(f) of the Exchange Act, or any substantially similar
communication, shall not in and of itself be deemed to be a Company Board
Recommendation Change. Notwithstanding the foregoing or anything to the
contrary set forth in this Agreement, at any time prior to the Offer Closing,
the Company Board (or any committee thereof) may effect a Company Board
Recommendation Change if, (i) (x) the Company Board (or any committee
thereof) receives an Acquisition Proposal not resulting from any breach of
_Section 6.2_ that it determines in good faith, after consultation with its
independent financial advisor and outside legal counsel, constitutes a
Superior Proposal and the Company Board (or any committee thereof) determines
in good faith (after consultation with outside legal counsel) that the failure
to effect a Company Board Recommendation Change would reasonably be expected
to be inconsistent with its fiduciary duties to the Company
Stockholders under applicable Law or (y) an Intervening Event occurs and as a
result thereof the Company Board (or any committee thereof) determines in
good faith (after consultation with outside legal counsel) that the failure to
effect a Company Board Recommendation Change would reasonably be expected to
be inconsistent with its fiduciary duties to the Company Stockholders under
applicable Law; (ii) the Company has notified Parent in writing that it
intends to effect a Company Board Recommendation Change, describing in
reasonable detail the reasons for such Company Board Recommendation Change (a
"Recommendation Change Notice") (it being agreed that the Recommendation
Change Notice and any amendment or update to such notice and the determination
to so deliver such notice, or update or amend public disclosures with respect
thereto shall not constitute a Company Board Recommendation Change for
purposes of this Agreement) and, if applicable, has provided Parent a summary
of any Superior Proposal and terms and conditions thereof (and a copy of any
definitive agreements related thereto); (iii) the Company shall have discussed
and negotiated in good faith, and shall have made its Representatives
available to discuss and negotiate in good faith, with Parent's
Representatives any proposed modifications to the terms and conditions of
this Agreement so that the failure to make such Company Board
Recommendation Change would no longer reasonably be expected to be
inconsistent with the Company Board's fiduciary duties (and, if
applicable, such Superior Proposal ceases to constitute a Superior Proposal)
during the period beginning at 5:00 p.m. Eastern Time on the day of delivery
by the Company to Parent of such Recommendation Change Notice and ending three
(3) Business Days later at 5:00 p.m. Eastern Time (it being understood and
agreed that any amendment to any material term or condition of any Superior
Proposal shall require a new Recommendation Change Notice and a new three (3)
Business Day period); and (iv) no earlier than the end of the three Business
Day period following receipt of the Recommendation Change Notice, the Company
Board (or any committee thereof) shall have determined in good faith (after
consultation with outside legal counsel), after considering the terms of any
proposed amendment or modification to this Agreement, that the failure to
effect a Company Board Recommendation Change would still reasonably be
expected to be inconsistent with its fiduciary duties to the Company
Stockholders under applicable Law and, if applicable, the Company Board (or
any committee thereof) determines in good faith, after consultation with its
independent financial advisor and outside legal counsel, after considering
the terms of any proposed amendment or modification to this Agreement, the
Acquisition Proposal that is subject of the Recommendation Change Notice
continues to constitute a Superior Proposal.

  



  

   

\- 47 - 
--- 

 


--- 

    



  

(b) Nothing in this Agreement shall prohibit the Company Board (or any
committee thereof) from (i) taking and disclosing to the Company
Stockholders a position contemplated by Rule 14e-2(a) under the Exchange Act
or complying with the provisions of Rule 14d-9 promulgated under the Exchange
Act, and/or (ii) making any disclosure to the Company Stockholders if the
Company Board (or any committee thereof) determines in good faith (after
consultation with its outside legal counsel) that the failure to make such
disclosure would reasonably be expected to be inconsistent with its fiduciary
duties to the Company Stockholders under applicable Law; _provided_ that any
Company Board Recommendation Change will be subject to the terms and
conditions of this Agreement.

  



  

   

\- 48 - 
--- 

 


--- 

    



  

6.4 _Access_.

  



  

(a) At all reasonable times during the period commencing upon the execution
and delivery of this Agreement and continuing until the earlier to occur of
the termination of this Agreement pursuant to _Section 10.1_ and the Effective
Time, the Company shall, and shall cause its Subsidiaries and Representatives
to, afford Parent and its financial advisors, business consultants, legal
counsel, accountants and other agents and representatives reasonable access
during normal business hours, upon reasonable written notice, to the
properties, books and records and personnel of the Company; _provided_ ,
_however_ , that the Company may restrict or otherwise prohibit access to any
documents or information to the extent that (i) any applicable Law requires
the Company to restrict or otherwise prohibit access to such documents or
information, (ii) access to such documents or information would give rise to
a material risk of waiving any attorney-client privilege, work product
doctrine or other privilege applicable to such documents or information,
(iii) access to such documents or information would violate any obligation of
confidentiality by the Company or a Subsidiary of the Company, or (iv) access
to a Contract to which the Company or any of its Subsidiaries is a party or
otherwise bound would violate or cause a default under, or give a third party
the right to terminate or accelerate the rights under, such Contract; and
_provided_ _further_ , that no information or knowledge obtained by Parent in
any investigation conducted pursuant to the access contemplated by this
_Section 6.4(a)_ shall affect or be deemed to modify any representation or
warranty of the Company set forth in this Agreement. Any investigation
conducted pursuant to the access contemplated by this  _Section 6.4(a)_ shall
be conducted in a manner that does not unreasonably interfere with the conduct
of the business of the Company and its Subsidiaries or create a risk of
damage or destruction to any property or assets of the Company or any of its
Subsidiaries. Any access to the Company's properties shall be subject to the
Company's reasonable security measures and insurance requirements and shall
not include the right to perform invasive testing. The terms and conditions of
the Confidentiality Agreement shall apply to any information obtained by
Parent or any of its financial advisors, business consultants, legal
counsel, accountants and other agents and representatives in connection with
any investigation conducted pursuant to the access contemplated by this
_Section 6.4(a)_.

  



  

(b) Unless prohibited by applicable Law, the Company shall (i) keep Parent
promptly informed of any communication, correspondence, filing or response
(in each case whether written or oral) with or from the FDA, EMA and any other
comparable Governmental Authority and provide copies of all such written
communications, correspondences, filings or responses, (ii) provide Parent
with a reasonable advance opportunity to review and comment upon, and
consider in good faith the views and comments of Parent prior to
submitting or making, or otherwise taking any other action with respect to,
any communication, correspondence, filing or response to the FDA, EMA or any
other comparable Governmental Authority, (iii) give Parent reasonable advance
notice of any in-person or telephonic meeting or conference with the FDA, EMA
or any other comparable Governmental Authority, (iv) consult with Parent in
advance of, and provide Parent an opportunity to participate in, each of such
meetings, and (v) promptly notify Parent of any data relating to the safety
or effectiveness of the Key Product not previously provided to Parent and keep
Parent promptly informed of, and consider Parent's views with respect to, the
status of the development and implementation of the launch of the Key Product.

  



  

6.5 _Section 16(b) Exemption_. The Company shall take all actions reasonably
necessary to cause the transactions contemplated by this Agreement and any
other dispositions of equity securities of the Company (including derivative
securities) in connection with the transactions contemplated by this
Agreement by each individual who is a director or executive officer (subject
to Section 16 of the Exchange Act) of the Company to be exempt under Rule
16b-3 promulgated under the Exchange Act.

  



  

6.6 _Stock Exchange Delisting_. Prior to the Merger Closing Date, the Company
shall cooperate with Parent and use commercially reasonable efforts to take,
or cause to be taken, all actions, and do or cause to be done all things,
reasonably necessary, proper or advisable on its part under applicable Laws
and rules and policies of the Nasdaq to cause the delisting of the Company and
the Company Common Stock from the Nasdaq as promptly as practicable after the
Effective Time and the deregistration of the Company Common Stock under the
Exchange Act as promptly as practicable after such delisting.

  



  

   

\- 49 - 
--- 

 


--- 

    



  

ARTICLE VII 
  _COVENANTS OF PARENT AND ACQUISITION SUB_

  



  

7.1 _Directors ' and Officers' Indemnification and Insurance_.

  



  

(a) The Surviving Corporation and its Subsidiaries shall (and Parent shall
cause the Surviving Corporation and its Subsidiaries to) honor and fulfill in
all respects the obligations of the Company and its Subsidiaries under (i) any
indemnification, expense advancement and exculpation provision set forth in
any certificate of incorporation or by-laws or comparable organizational
documents of the Company or any of its Subsidiaries as in effect on the date
of this Agreement, for a period of six years from the Effective Time for
actions taken by any of the Indemnified Persons prior to the Effective Time
and (ii) all indemnification agreements in effect as of the date of this
Agreement and set forth on _Section 7.1_ of the Company Disclosure Letter
between the Company or any of its Subsidiaries and any of their respective
current or former directors and officers and any person who becomes a
director or officer of the Company or any of its Subsidiaries prior to the
Effective Time, for the duration of the applicable agreement (the
"Indemnified Persons"). In addition, during the period commencing at the
Effective Time and ending on the sixth anniversary of the Effective Time, the
Surviving Corporation and its Subsidiaries shall (and Parent shall cause
the Surviving Corporation and its Subsidiaries to) cause the certificate of
incorporation and by-laws (and other similar organizational documents) of the
Surviving Corporation and its Subsidiaries to contain provisions with respect
to indemnification, exculpation and the advancement of expenses that are at
least as favorable to the Indemnified Persons as the indemnification,
exculpation and advancement of expenses provisions contained in the
certificate of incorporation and by-laws (or other similar
organizational documents) of the Company and its Subsidiaries as of the date
hereof, and during such six-year period, such provisions shall not be
repealed, amended or otherwise modified in any manner except as required by
applicable Law. Each Indemnified Person is, and the Indemnified Persons
collectively are, intended third party beneficiaries of this _Section 7.1_ and
each such Person shall have a right to enforce the rights hereunder as if
such person was a party to this Agreement.

  



  

(b) In addition to the provisions of _Section 7.1(a)_ , during the period
commencing at the Effective Time and ending on the sixth anniversary of the
Effective Time, to the fullest extent the Company would have been permitted to
do so under applicable Law (for the avoidance of doubt, subject to the
limitations on the Company's ability to indemnify its directors and officers
under Section 145 of the DGCL), Parent shall cause the Surviving Corporation
and its Subsidiaries to indemnify and hold harmless each Indemnified Person
from and against any reasonable out-of-pocket costs, fees and expenses
(including, subject to the limitations on retaining counsel set forth in the
third sentence of this _Section 7.1(b),_ reasonable attorneys' fees and
investigation expenses), judgments, fines, losses, claims, damages,
liabilities and amounts paid in settlement (in a settlement in respect
of which Parent has given its prior written consent, which shall not be
unreasonably withheld, delayed or conditioned) in connection with any claim,
proceeding, investigation or inquiry, whether civil, criminal, administrative
or investigative, to the extent such claim, proceeding, investigation or
inquiry arises out of or pertains to (i) any action or omission or alleged
action or omission in such Indemnified Person's capacity as a director,
officer, employee or agent of the Company or any of its Subsidiaries or other
Affiliates, or (ii) the Offer, the Merger, this Agreement or any of the
transactions contemplated by this Agreement;  _provided_ , _however_ , that
if, at any time prior to the sixth anniversary of the Effective Time, any
Indemnified Person delivers to Parent a written notice asserting a claim for
indemnification under this _Section 7.1(b)_ , then the claim asserted in such
notice shall survive the sixth anniversary of the Effective Time until such
time as such claim is fully and finally resolved. In addition, during the
period commencing at the Effective Time and ending on the sixth anniversary of
the Effective Time, to the fullest extent permitted by applicable Law, Parent
shall cause the Surviving Corporation and its Subsidiaries to advance, prior
to the final disposition of any claim, proceeding, investigation or inquiry
for which indemnification may be sought under this Agreement, promptly
following request by an Indemnified Person therefor, all reasonable out-of-
pocket costs, fees and expenses (including, subject to the limitations on
retaining counsel set forth in the third sentence of this _Section 7.1(b),_
reasonable attorneys' fees and investigation expenses) incurred by such
Indemnified Person in connection with any such claim,
proceeding, investigation or inquiry subject to receipt of an unsecured
undertaking to repay such amounts in the event that it is finally determined
that such Indemnified Person is not entitled to indemnification with respect
thereto; _provided_ , _however_ , that if, at any time prior to the sixth
anniversary of the Effective Time, any Indemnified Person delivers to Parent a
written notice asserting a claim for advancement under this _Section 7.1(b)_
, then the right to advancement asserted in such notice shall survive the
sixth anniversary of the Effective Time until such time as such claim is fully
and finally resolved. In the event of any such claim, proceeding,
investigation or inquiry, (i) Parent shall have the right to control the
defense thereof after the Effective Time (it being understood that, by
electing to control the defense thereof, none of Parent or any of its
Affiliates, including the Surviving Corporation, has waived any right to
object to the Indemnified Person's entitlement to indemnification hereunder
with respect thereto) , (ii) if Parent does not assume and control the defense
or if there exists or is reasonably likely to exist a conflict of interest
that would make it inappropriate for the same counsel to represent Parent and
the Indemnified Person, then such Indemnified Person shall be entitled to
retain his or her own counsel, (iii) only if (x) Parent does not assume and
control the defense or (y) there exists or is reasonably likely to exist a
conflict of interest that would make it inappropriate for the same counsel to
represent Parent and the Indemnified Person, the Surviving Corporation shall
pay all reasonable out-of-pocket fees and expenses of any counsel retained by
an Indemnified Person, promptly after statements therefor are received and
(iv) no Indemnified Person shall be liable for any settlement effected
without his or her prior express written consent (which shall not be
unreasonably withheld, delayed or conditioned). Notwithstanding anything to
the contrary set forth in this _Section 7.1(b) _ or elsewhere in this
Agreement, neither Parent nor any of its Affiliates (including the Surviving
Corporation) shall settle or otherwise compromise or consent to the entry of
any judgment or otherwise seek termination with respect to any claim,
proceeding, investigation or inquiry for which indemnification may be sought
by an Indemnified Person under this Agreement unless such
settlement, compromise, consent or termination (x) includes an unconditional
release of all Indemnified Persons from all liability arising out of such
claim, proceeding, investigation or inquiry that would not be indemnified by
the Surviving Corporation and its Subsidiaries, and (y) does not include any
statement as to admission of fault, culpability or a failure to act by or on
behalf of any Indemnified Person.

  



  

   

\- 50 - 
--- 

 


--- 

    



  

(c) Prior to the Effective Time, the Company shall, in consultation with
Parent, and, if the Company is unable to, Parent shall (or shall cause the
Surviving Corporation to) obtain and fully pay for "tail" prepaid insurance
policies with a claims period of at least six years from and after the
Effective Time from an insurance carrier with the same or better rating as the
Company's current insurance carrier with respect to directors' and officers'
liability insurance and fiduciary insurance (collectively, "DandO Insurance"),
for the Indemnified Persons, with terms, conditions, retentions and levels of
coverage at least as favorable, in the aggregate, as the Company's existing
DandO Insurance with respect to matters existing or occurring prior to the
Effective Time (including with respect to acts or omissions occurring in
connection with this Agreement and the consummation of the transactions
contemplated hereby); _provided_ , _however_ , that in no event will the
Company or Parent be required, and the Company shall not be permitted, to
expend for such policies pursuant to this _Section 7.1_  an annualized
premium amount in excess of 200% of the annual premiums currently paid by the
Company for such insurance and, if the annual premiums of such insurance
coverage exceed such amount, Parent or the Company may obtain a substantially
similar policy (from an insurance carrier with the same or better rating as
the Company's current insurance carrier) with the greatest coverage available
for a cost not exceeding such amount. If such "tail" prepaid insurance
policies have been obtained, Parent shall, and shall cause the Surviving
Corporation after the Effective Time to, maintain such policies in full force
and effect, for their full term, and to continue to honor its respective
obligations thereunder. If the Company fails to obtain such "tail" prepaid
insurance policies as of the Effective Time, the Surviving Corporation shall,
and Parent shall cause the Surviving Corporation to, continue to maintain in
effect, at no expense to the beneficiaries, for a period of at least
six years from and after the Effective Time for the Indemnified Persons, the
DandO Insurance (provided that Parent (or any successor) may substitute
therefor policies of at least the same terms, conditions, retentions and
levels of coverage and amounts which are, in the aggregate, as favorable to
the Indemnified Persons as provided in the existing policies as of the date of
this Agreement, from an insurance carrier with the same or better rating as
the Company's current insurance carrier); _provided_ , _however_ , that in no
event will Parent or the Surviving Corporation be required, and the Company
shall not be permitted, to expend for such policies pursuant to this _Section
7.1_ an annualized premium amount in excess of 200% of the annual premiums
currently paid by the Company for such insurance and, if the annual premiums
of such insurance coverage exceed such amount, Parent or the
Surviving Corporation shall, and the Company may, obtain a substantially
similar policy (from an insurance carrier with the same or better rating as
the Company's current insurance carrier) with the greatest coverage available
for a cost not exceeding such amount. Each Indemnified Person is, and the
Indemnified Persons collectively are, intended third party beneficiaries of
this _Section 7.1(c)_ , and each such Person shall have a right to enforce
the rights hereunder as if such person was a party to this Agreement.

  



  

   

\- 51 - 
--- 

 


--- 

    



  

(d) If Parent or the Surviving Corporation or any of its successors or
assigns shall (i) consolidate with or merge into any other Person and shall
not be the continuing or surviving corporation or entity of such consolidation
or merger, or (ii) transfer all or substantially all of its properties and
assets to any Person, then, and in each such case, proper provisions shall be
made so that the successors and assigns of Parent or the Surviving
Corporation, as the case may be, shall assume all of the obligations of Parent
and the Surviving Corporation set forth in this _Section 7.1_. Each
Indemnified Person is, and the Indemnified Persons collectively are, intended
third party beneficiaries of this _Section 7.1(d)_ , and each such Person
shall have a right to enforce the rights hereunder as if such person was a
party to this Agreement.

  



  

(e) The obligations set forth in this _Section 7.1_ shall not be terminated,
amended or otherwise modified in any manner that adversely affects any
Indemnified Person (and, if and to the extent applicable, their heirs and
representatives) without the prior written consent of such affected
Indemnified Person (and, if and to the extent applicable, their heirs and
representatives). Each of the Indemnified Persons (and, if and to the extent
applicable, their heirs and representatives) is intended to be third party
beneficiaries of this _Section 7.1_ , with full rights of enforcement as if a
party thereto. The rights of the Indemnified Persons (and, if and to the
extent applicable, their heirs and representatives) under this _Section 7.1_
shall be in addition to, and not in substitution for, any other rights that
such persons may have under the certificates of incorporation, by-laws or
other equivalent organizational documents of, or any and all indemnification
agreements of or entered into by, the Company or any of its Subsidiaries, or
applicable Law (whether at law or in equity).

  



  

(f) The obligations and liability of Parent, the Surviving Corporation and
the Surviving Corporation's Subsidiaries under this _Section 7.1_ shall be
joint and several.

  



  

(g) Nothing in this Agreement is intended to, shall be construed to or shall
release, waive or impair any rights to directors' and officers' insurance
claims under any policy that is or has been in existence with respect to the
Company or any of its Subsidiaries for any of their respective directors,
officers or other employees, it being understood and agreed that the
indemnification provided for in this _Section 7.1_ is not prior to or in
substitution for any such claims under such policies.

  



  

   

\- 52 - 
--- 

 


--- 

    



  

7.2 _Employee Matters_.

  



  

(a) Parent hereby acknowledges that a "change of control" (or similar phrase)
within the meaning of the Employee Plans and compensation arrangements, as
applicable, will occur as of the Effective Time, as applicable.

  



  

(b) From and after the Effective Time, the Surviving Corporation shall (and
Parent shall cause the Surviving Corporation to) honor all legally binding
Employee Plans and compensation arrangements in accordance with their terms as
in effect immediately prior to the Effective Time and unless otherwise
expressly terminated in accordance with their terms, such legally binding
compensation arrangements shall survive after the Effective Time, _provided_
that nothing in this sentence shall prohibit Parent or the Surviving
Corporation from amending or terminating, or from causing Parent or the
Surviving Corporation to amend or terminate, any such Employee Plans or
compensation arrangements or agreements in accordance with their terms or if
otherwise required by applicable Law.

  



  

(c) During the period commencing at the Effective Time and ending on December
31, 2014, the Surviving Corporation shall (and Parent shall cause the
Surviving Corporation to) either (i) maintain for the benefit of each
Continuing Employee the Employee Plans (other than equity-based benefits,
individual employment agreements and any retention or other special or non-
recurring bonus or incentive awards) (such Employee Plans, the "Company
Plans") at benefit levels that, taken as a whole, are
substantially comparable in the aggregate to those in effect at the Company
or its Subsidiaries on the date of this Agreement, and provide
compensation and benefits to each Continuing Employee under such Company
Plans, or (ii) provide compensation, benefits and severance payments (other
than equity-based benefits, individual employment agreements and any retention
or other special or non-recurring bonus or incentive awards) to each
Continuing Employee that, taken as a whole, are substantially comparable in
the aggregate to the compensation, benefits and severance payments (other
than equity-based benefits, individual employment agreements and any
retention or other special or non-recurring bonus or incentive awards)
provided to such Continuing Employee immediately prior to the Effective Time
("Comparable Plans"), or (iii) provide some combination of (i) and (ii) above
such that each Continuing Employee receives compensation, benefits and
severance payments (other than equity-based benefits, individual employment
agreements and any retention or other special or non-recurring bonus or
incentive awards) that, taken as a whole, are substantially comparable in the
aggregate to the compensation, benefits and severance payments (other than
equity-based benefits, individual employment agreements and any retention or
other special or non-recurring bonus or incentive awards) provided to such
Continuing Employee immediately prior to the Effective Time. During the
period commencing on January 1, 2015 and ending on the first anniversary
of the Effective Time, the Surviving Corporation shall (and Parent shall
cause the Surviving Corporation to) provide compensation, benefits and
severance payments (other than equity-based benefits, individual employment
agreements and any retention or other special or non-recurring bonus or
incentive awards) to each Continuing Employee that are substantially
comparable in the aggregate to the compensation, benefits and severance
payments (other than equity-based benefits, individual employment agreements
and any retention or other special or non-recurring bonus or incentive
awards) that are provided to similarly situated employees of Parent ("Parent
Plans"). In each case, base salary or wages as of immediately prior to the
Effective Time shall not be decreased for a period of one year following the
Effective Time for any Continuing Employee employed during that period.

  



  

(d) To the extent that a Company Plan, Comparable Plan or Parent Plan is made
available to any Continuing Employee on or following the Effective Time, the
Surviving Corporation shall (and Parent shall cause the Surviving Corporation
to) cause to be granted to such Continuing Employee credit for all service
with the Company and its Subsidiaries prior to the Effective Time for purposes
of eligibility to participate, vesting and entitlement to benefits where
length of service is relevant (including for purposes of vacation accrual and
severance pay entitlement); _provided, however,_ that such service need not be
credited to the extent that it would result in duplication of coverage or
benefits. In addition, and without limiting the generality of the foregoing:
(i) Parent shall cause to be waived or, where applicable, shall cause its
third-party insurance providers to waive, all eligibility waiting
periods, any evidence of insurability requirements and the application of any
pre-existing conditions limitations under such plans (such plans,
collectively, the "New Plans") to the extent coverage under any such New Plan
replaces coverage under a comparable Company Plan in which such Continuing
Employee participates immediately before the Effective Time (such plans,
collectively, the "Old Plans"), and only to the extent such waiting periods,
evidence of insurability requirements and pre-existing conditions limitations
were satisfied or did not apply to such Continuing Employee under the
corresponding Old Plan; and (ii) for purposes of each New Plan providing
medical, dental, pharmaceutical, vision and/or disability benefits to any
Continuing Employee, the Surviving Corporation shall cause all waiting
periods, pre-existing condition exclusions, evidence of insurability
requirements and actively-at-work or similar requirements of such New Plan to
be waived for such Continuing Employee and his or her covered dependents, to
the extent such waiting periods, pre-existing condition exclusions, evidence
of insurability requirements and actively-at-work requirements were satisfied
or did not apply to such Continuing Employee or his or her covered dependents
under the corresponding Old Plan, and the Surviving Corporation shall cause
any eligible expenses incurred by such Continuing Employee and his or
her covered dependents during the portion of the plan year of the Old Plan
ending on the date such employee's participation in the corresponding New
Plan begins to be given credit under such New Plan for purposes of satisfying
all deductible, coinsurance and maximum out-of-pocket requirements applicable
to such Continuing Employee and his or her covered dependents for the
applicable plan year as if such amounts had been paid in accordance with such
New Plan to the extent credited under the corresponding Old Plan and (iii)
credit the accounts of such Continuing Employee under any New Plan which is a
flexible spending plan with any unused balance in the account of such
Continuing Employee under the applicable Company Plan to the extent such
Continuing Employee commences participation in such New Plan in the same
calendar year as the unused balance was credited to the applicable Company
Plan. Any vacation or paid time off accrued but unused by a Continuing
Employee as of immediately prior to the Effective Time shall be credited to
such Continuing Employee following the Effective Time in accordance with the
practice and policies of the Company or its Subsidiaries, as applicable.

  



  

   

\- 53 - 
--- 

 


--- 

    



  

(e) Notwithstanding anything to the contrary set forth in this Agreement, no
provision of this Agreement, express or implied, shall be deemed to
(i) guarantee employment for any period of time for, or preclude the ability
of Parent or the Surviving Corporation to terminate, any Continuing Employee
for any reason, (ii) be an amendment to any Employee Plan or plan, program,
policy, agreement, arrangement or understanding of Parent or any of its
Subsidiaries or (iii) subject to applicable Law and subject to the limitations
and requirements specifically set forth in this _Section 7.2_ , require
Parent or the Surviving Corporation to continue any Company Plan,
Comparable Plan or Parent Plan or prevent the amendment, modification or
termination thereof after the Effective Time. This _Section 7.2 _ shall be
binding and inure solely to the benefit of each Party to this Agreement, and
nothing in this _Section 7.2,_  express or implied, is intended to confer
upon any other Person (including for the avoidance of doubt any current or
former director, officer, employee, independent contractor or consultant of
the Company or any of its Subsidiaries) any rights or remedies under or by
reason of this _Section 7.2_.

  



  

7.3 _Obligations of Acquisition Sub_. Parent shall take all action necessary
to cause Acquisition Sub and the Surviving Corporation to perform their
respective obligations under this Agreement.

  



  

7.4 _Other Actions by Parent and Acquisition Sub_. Parent shall, promptly
following the execution of this Agreement, approve and adopt this Agreement
in its capacity as sole stockholder of Acquisition Sub in accordance with
applicable Law and the certificate of incorporation and by-laws of
Acquisition Sub and deliver to the Company evidence of its vote or action by
written consent so approving and adopting this Agreement.

  



  

   

\- 54 - 
--- 

 


--- 

    



  

7.5 _Tax Matters_. All transfer, stamp, documentary, sales, use,
registration, value-added and other similar Taxes (including all
applicable real estate transfer Taxes and real property transfer gains Taxes
and including any filing and recording fees) and related amounts (including
any penalties, interest and additions to Tax) and all such reasonable costs
(including accounting and legal fees) associated with filing all Tax Returns
related to transfer Taxes incurred by the Company or any of its Subsidiaries
in connection with this Agreement and the other transactions contemplated
hereby ("Transfer Taxes") shall be paid by Parent. Parent shall be
responsible for filing all Tax Returns related to Transfer Taxes. All Parties
hereto shall use their commercially reasonable efforts to avail themselves of
any available exemptions from any such Transfer Taxes, and to cooperate with
the other Parties hereto in providing any information and documentation that
may be necessary to obtain such exemptions.

  



  

7.6 _CVRs_

  



  

(a) At or prior to the Offer Closing, Parent shall duly authorize, execute
and deliver the CVR Agreement with the Rights Agent.

  



  

(b) Parent and the Company shall cooperate, including by making changes to
the form of CVR Agreement attached hereto as _Exhibit B_ , as necessary to
ensure that the CVRs are not subject to registration under the Securities Act,
the Exchange Act or any applicable state securities or "blue sky" laws.

  



  

ARTICLE VIII 
  _ADDITIONAL COVENANTS OF ALL PARTIES_

  



  

8.1 _Reasonable Best Efforts to Complete_. Upon the terms and subject to the
conditions set forth in this Agreement and subject to _Section 8.2(d)_ , each
of Parent, Acquisition Sub and the Company shall use its reasonable best
efforts to take, or cause to be taken, all actions, and to do, or cause to be
done, and to assist and cooperate with the other Party or Parties hereto in
doing, all things reasonably necessary, proper or advisable under applicable
Law or otherwise to consummate and make effective, in the most expeditious
manner practicable, the transactions contemplated by this Agreement, including
using reasonable best efforts to: (i) cause the conditions set forth in
_Annex A_ and _ARTICLE IX_ to be satisfied; and (ii) obtain all necessary
actions or non-actions, waivers, consents, approvals, orders and
authorizations from Governmental Authorities and make all necessary
registrations, declarations and filings with Governmental Authorities, that
are necessary to consummate the Offer, the Merger and the
transactions contemplated hereby. In addition to the foregoing, neither
Parent or Acquisition Sub, on the one hand, nor the Company, on the other
hand, shall, subject to _Section 8.2(d)_ , take any action, or fail to take
any action, that is intended to, or has (or would reasonably be expected to
have) the effect of, preventing, impairing, delaying or otherwise adversely
affecting the consummation of the Offer or the Merger or the ability of such
Party to fully perform its obligations under this Agreement; _provided_ , 
_however_ , that, for the avoidance of doubt, no action permitted to be taken
pursuant to _Section 6.2_ or _Section 6.3_ shall be prohibited, or required
to be taken, by this sentence.

  



  

8.2 _Regulatory Filings_.

  



  

(a) Each of Parent and Acquisition Sub shall, and shall cause their
respective Affiliates to, and the Company shall, (x) file with the FTC and
the Antitrust Division of the DOJ a Notification and Report Form relating to
this Agreement and the transactions contemplated hereby as required by the
HSR Act as soon as practicable after the date of this Agreement but in no
event later than ten (10) Business Days following the execution and delivery
of this Agreement, and (y) file comparable pre-merger or post-merger
notification filings, forms and submissions with any foreign Governmental
Authority that is required by any other Antitrust Laws as soon as practicable
after the date of this Agreement but in no event later than ten (10) Business
Days following the execution and delivery of this Agreement. Each of Parent
and the Company shall use reasonable best efforts to (i) cooperate and
coordinate with the other in the making of such filings, (ii) supply the
other with any information that reasonably may be required in order to make
such filings, (iii) supply any additional information that reasonably may be
required or requested by the FTC, the DOJ or the Governmental Authorities of
any other applicable jurisdiction in which any such filing is made under any
other Antitrust Laws, and (iv) subject to _Section 8.2(d)_ , take all action
necessary to cause the expiration or termination of the applicable waiting
periods under the HSR Act or other Antitrust Laws as soon as practicable, and
to obtain any required consents under any other Antitrust Laws applicable to
the Offer or the Merger as soon as practicable, and to avoid any impediment to
the consummation of the Offer or the Merger under any Antitrust Laws,
including using reasonable best efforts to take all such action as reasonably
may be necessary to resolve such objections, if any, as the FTC, the DOJ, or
any other Governmental Authority or Person may assert under any
applicable Antitrust Laws with respect to the Offer or the Merger. Parent
shall pay all filing fees (and the Company shall not be required to pay any
filing fees) under the HSR Act and any fees or other payments to any
Governmental Authority in connection with any filings under the HSR Act or
such other filings as may be required under the applicable Antitrust Laws.

  



  

   

\- 55 - 
--- 

 


--- 

    



  

(b) Each of Parent and Acquisition Sub shall, and shall cause their
respective Affiliates to, and the Company shall, promptly inform the other
Parties of any communication from any Governmental Authority regarding any of
the transactions contemplated by this Agreement in connection with any
filings or investigations with, by or before any Governmental Authority
relating to this Agreement or the transactions contemplated hereby, including
any proceedings initiated by a private party. If any Party hereto or Affiliate
thereof shall receive a request for additional information or documentary
material from any Governmental Authority with respect to the transactions
contemplated by this Agreement pursuant to the HSR Act or any other Antitrust
Laws with respect to which any such filings have been made, then such Party
shall use its reasonable best efforts to make, or cause to be made, as soon as
reasonably practicable and after consultation with the other Party, an
appropriate response in compliance with such request. In connection with and
without limiting the foregoing, to the extent reasonably practicable and
unless prohibited by applicable Law or by the applicable Governmental
Authority, the Parties agree to (i) give each other reasonable advance notice
of all meetings with any Governmental Authority relating to the Offer or the
Merger, (ii) give each other an opportunity to participate in each of
such meetings, (iii) keep the other Parties reasonably apprised with respect
to any substantive communications with any Governmental Authority regarding
the Offer or the Merger, (iv) cooperate in the filing of any analyses,
presentations, memoranda, briefs, arguments, opinions or other written
communications explaining or defending the Offer or the Merger, articulating
any regulatory or competitive argument and/or responding to requests or
objections made by any Governmental Authority, (v) provide each other Party
with a reasonable advance opportunity to review and comment upon, and
consider in good faith the views of the other with respect to, all
written communications (including any analyses, presentations, memoranda,
briefs, arguments and opinions) with a Governmental Authority regarding the
Offer or the Merger, (vi) provide each other (or counsel of each Party, as
appropriate) with copies of all written communications to or from any
Governmental Authority relating to the Offer or the Merger, and (vii)
cooperate and provide each other with a reasonable opportunity to participate
in, and consider in good faith the views of the other with respect to,
all material deliberations with respect to all efforts to satisfy the
conditions set forth in _Section 9.1(a)_. Any such disclosures, rights to
participate or provisions of information by one Party to the others may be
made on a counsel-only basis to the extent required under applicable Law or
as appropriate to protect Confidential Information.

  



  

(c) Each of Parent, Acquisition Sub and the Company shall cooperate with one
another in good faith to (i) promptly determine whether any filings not
contemplated by _Section 8.2(a)_ are required to be or should be made, and
whether any other consents, approvals, permits or authorizations not
contemplated by _Section 8.2(a)_ are required to be or should be obtained,
from any Governmental Authority under any other applicable Law in connection
with the transactions contemplated hereby, and (ii) promptly make any
filings, furnish information required in connection therewith and seek to
obtain timely any such consents, permits, authorizations, approvals or
waivers that the Parties determine are required to be or should be made or
obtained in connection with the transactions contemplated hereby.

  



  

   

\- 56 - 
--- 

 


--- 

    



  

(d) Parent agrees (and the Company agrees except with respect to _clause
(ii)_ of this sentence), and shall cause each of its Subsidiaries, to take
any and all actions necessary to obtain any consents, clearances or approvals
required under or in connection with any domestic or foreign Antitrust Law,
and to enable all waiting periods under any Antitrust Law to expire, and to
avoid or eliminate each and every impediment under any Antitrust Law asserted
by any Governmental Authority, in each case, to cause the Merger and the
other transactions contemplated hereby to occur prior to the Outside Date,
including but not limited to (i) promptly complying with or modifying any
requests for additional information (including any second request) by any
Governmental Authority, (ii) if necessary to obtain clearance by any
Governmental Authority before the Outside Date, offering, negotiating,
committing to and effecting, by consent decree, hold separate order or
otherwise, the sale, divestiture, license or other disposition of any and all
of the capital stock, assets, rights, products or businesses of the Company
and its Subsidiaries, and any other structural or conduct restrictions on the
activities of the Company and its Subsidiaries and (iii) contesting, defending
and appealing any threatened or pending preliminary or permanent injunction
or other order, decree or ruling or statute, rule, regulation or
executive order that would adversely affect the ability of any Party hereto
to consummate the transactions contemplated hereby and taking any and all
other actions to prevent the entry, enactment or promulgation thereof;
_provided, however,_ that, notwithstanding anything in this Agreement to the
contrary, Parent and Acquisition Sub shall not be required, and the Company
shall not be permitted without the prior written consent of Parent, to
undertake any efforts or to take or offer or agree to take any action if the
taking of such efforts or action would reasonably be expected to result in a
Substantial Detriment.

  



  

(e) During the period from the date hereof and continuing until the earlier
to occur of the termination of this Agreement pursuant to _Section 10.1_ and
the Effective Time, except with the consent of the Company (which shall not be
unreasonably withheld, delayed or conditioned), Parent and its Affiliates
shall not do anything, including entering into any transaction, that would
reasonably be expected to prevent or delay any filings or approvals required
under the HSR Act or other applicable Antitrust Laws.

  



  

(f) The Company shall give prompt notice to Parent, and Parent shall give
prompt notice to the Company, (and will subsequently keep the other informed
on a current basis of any developments related to such notice) of (i) any
notice or other communication received by such party from any Governmental
Authority in connection with the Offer, the Merger or the other transactions
contemplated hereby or from any Person alleging that the consent of such
Person is or may be required in connection with the Offer, the Merger or the
other transactions contemplated hereby, (ii) its becoming aware of the
occurrence or existence of any fact, event or circumstance that is reasonably
likely to result in any of the conditions set forth in Article IX or Annex A
not being able to be satisfied prior to the Outside Date and (iii) any Legal
Proceedings commenced or, to such party's knowledge, threatened against,
relating to or involving or otherwise affecting such party or any of its
Subsidiaries which relate to the transactions contemplated hereby.

  



  

8.3 _No Company Stockholders Meeting_. The Merger shall be effected by
Parent, Acquisition Sub and the Company as soon as practicable following the
Offer Closing in accordance with _Section 3.2_ without a stockholders meeting
pursuant to Section 251(h) of the DGCL.

  



  

8.4 _Anti-Takeover Laws_. In the event that the restrictions of any state
anti-takeover or other similar Law are or become applicable to
this Agreement, the CVR Agreement or any of the transactions contemplated by
this Agreement or the CVR Agreement (other than, with respect to the Company,
as a result of the inaccuracy of the representations and warranties of Parent
and Acquisition Sub in _Section 5.7(a)_ ), the Company, Company Board, Parent
and Acquisition Sub shall use their respective reasonable best efforts to
ensure that the transactions contemplated by this Agreement and the CVR
Agreement may be consummated as promptly as practicable on the terms and
subject to the conditions set forth in this Agreement and the CVR Agreement
and to take all action necessary to render such Law inapplicable to this
Agreement, the CVR Agreement or any of the transactions contemplated by this
Agreement or the CVR Agreement or otherwise to minimize the effect of such
Law on this Agreement, the CVR Agreement and the transactions
contemplated hereby or thereby.

  



  

   

\- 57 - 
--- 

 


--- 

    



  

8.5 _Public Statements and Disclosure_. The initial press release relating to
this Agreement shall be a joint press release prepared and issued by the
Company and Parent, and thereafter, none of the Company, on the one hand, or
Parent and Acquisition Sub, on the other hand, shall issue any public release
or make any public announcement concerning this Agreement or the transactions
contemplated by this Agreement without the prior written consent of the other
(which consent shall not be unreasonably withheld, conditioned or delayed),
except as such release or announcement may be required by applicable Law or
the rules or regulations of any applicable United States securities exchange
or regulatory or Governmental Authority to which the relevant Party is subject
or submits, wherever situated, in which case the Party required to make the
release or announcement shall use its reasonable best efforts to allow the
other Party or Parties reasonable time to comment on such release or
announcement in advance of such issuance (it being understood that the final
form and content of any such release or announcement, as well as the timing of
any such release or announcement, shall be at the final discretion of the
disclosing Party); _provided_ , _however_ , that the restrictions set forth
in this _Section 8.5_ shall not apply to any release or announcement made or
proposed to be made (a) by the Company pursuant to _Section 6.3_ , relating
to any Acquisition Proposal or following a Company Board Recommendation Change
or (b) by the Parent or Acquisition Sub following a Company Board
Recommendation Change.

  



  

8.6 _Confidentiality_. Parent, Acquisition Sub and the Company hereby
acknowledge that Parent and the Company have previously executed the
Confidentiality Agreement, which will continue in full force and effect in
accordance with its terms; _provided_ , _however_ , that after the date
hereof until the earlier of (a) the Effective Time (at which time the
Confidentiality Agreement shall cease in its entirety to be in full force and
effect) and (b) the termination of this Agreement pursuant to _Section 10.1_ ,
paragraphs 5, 6, 7, 9 and 12 of the Confidentiality Agreement shall not be
applicable to Parent and its Subsidiaries (including Acquisition Sub).

  



  

8.7 _Certain Litigation_. Each Party hereto shall promptly advise the other
Parties of any litigation against such Party or any of its directors or its
officers (in their capacity as such) by any Company Stockholders (on their own
behalf or on behalf of the Company) relating to the Offer, the Merger, this
Agreement or any of the transactions contemplated hereby, and shall keep the
other Parties reasonably informed regarding any such litigation. Each Party
hereto shall give the other Parties the opportunity to consult with such
Party regarding the defense or settlement of any such stockholder litigation
and shall consider such other Parties' views with respect to such stockholder
litigation. No settlement of litigation against the Company or any of its
directors or officers shall be agreed to without Parent's written consent,
which consent shall not be unreasonably withheld, conditioned or delayed.

  



  

8.8 _Rule 14d-10(d) Matters._

  



  

(a) Notwithstanding anything in this Agreement to the contrary, the Company
and its Subsidiaries shall not, after the date hereof, enter into,
establish, amend or modify any plan, program, agreement or arrangement
pursuant to which compensation is paid or payable, or pursuant to which
benefits are provided, in each case to any current or future director, officer
or employee of the Company or its Subsidiaries unless, prior to such entry,
establishment, amendment or modification, the Company Compensation Committee
shall have taken all steps as may be necessary to (i) approve as an
Employment Compensation Arrangement each such plan, program, agreement or
arrangement and (ii) satisfy the requirements of the non-exclusive safe
harbor under Rule 14d-10(d)(2) under the Exchange Act with respect to such
plan, program, agreement, arrangement, understanding, payment or benefit. __

  



  

   

\- 58 - 
--- 

 


--- 

    



  

(b) In the event that, during the period beginning on the date of this
Agreement and ending not less than five days prior to the Offer Closing,
Parent requests that the Company Compensation Committee consider whether any
plan, program, agreement or arrangement that Parent would like to enter into,
establish, amend or modify pursuant to which compensation is paid or payable,
or pursuant to which benefits are provided, in each case to any current or
future director, officer or employee of the Company or its Subsidiaries (each
such plan, program, agreement or arrangement, a "Post-Signing Arrangement"),
would constitute an Employment Compensation Arrangement and provides the
Company with such information with respect to such Post-Signing Arrangement as
the Company may reasonably request, the Company Compensation Committee will
promptly, and in any event prior to the Offer Closing, consider such Post-
Signing Arrangement at a meeting duly called and held. In the event that,
following such consideration, the Company Compensation Committee believes in
good faith that such Post-Signing Arrangement constitutes an Employment
Compensation Arrangement, at such meeting the Company Compensation Committee
shall take all such steps as may be necessary to (i) approve as an
Employment Compensation Arrangement such Post-Signing Arrangement and (ii)
satisfy the requirements of the non-exclusive safe harbor under Rule
14d-10(d)(2) under the Exchange Act with respect to such Post-Signing
Arrangement.

  



  

8.9 _Directors_.

  



  

(a) Effective as of the Offer Closing and from time to time thereafter (as
long as Parent and its affiliates beneficially own a majority of the
outstanding shares of Company Common Stock), Acquisition Sub shall be entitled
to designate such number of directors on the Company Board as will give
Acquisition Sub, subject to compliance with Section 14(f) of the Exchange Act,
representation on the Company Board equal to at least that number of
directors, rounded up to the next whole number, which is the product of (i)
the total number of directors on the Company Board (giving effect to the
directors elected pursuant to this sentence) multiplied by (ii) the
percentage that (A) such number of shares of Company Common Stock so accepted
for payment and paid for by Acquisition Sub plus the number of shares of
Company Common Stock owned by Parent and Acquisition Sub or any direct or
indirect wholly-owned Subsidiary of Parent bears to (B) the total number of
such shares of Company Common Stock outstanding, and the Company shall, at
such time, cause Acquisition Sub's designees to be so elected; _provided,
however,_ that in the event that Acquisition Sub's designees are appointed or
elected to the Company Board, until the Effective Time the Company Board shall
have at least four directors who are members of the Company Board on the date
of this Agreement and independent directors for purposes of the continuing
listing requirements of Nasdaq, but who are not affiliates or employees of
Parent or any of its Subsidiaries (the "Independent Directors"); provided
further that, in such event, if the number of Independent Directors shall be
reduced below four for any reason whatsoever, any remaining Independent
Directors (or Independent Director, if there shall be only one remaining)
shall be entitled to designate persons to fill such vacancies who shall be
deemed to be Independent Directors for purposes of this Agreement or, if no
Independent Directors then remain, the other directors shall designate
four persons to fill such vacancies who are not, at the time of appointment,
officers, stockholders or affiliates of the Company, Parent or any of its
Subsidiaries and such persons shall be deemed to be Independent Directors for
purposes of this Agreement. Subject to applicable Law, the Company shall take
all action requested by Parent necessary to effect any such election,
including mailing to holders of Company Common Stock the Information
Statement containing the information required by Section 14(f) of the
Exchange Act and Rule 14f-1 promulgated thereunder, and the Company shall
make such mailing with the mailing of the Schedule 14D-9 (provided that
Parent and Acquisition Sub shall have provided to the Company on a timely
basis all information required to be included in the Information Statement
with respect to Acquisition Sub's designees to the Company Board in accordance
with Section 2.2(a)). Parent and Acquisition Sub will be solely responsible
for any information with respect to them and their nominees, officers,
directors and Affiliates required by Section 14(f) of the Exchange Act and
Rule 14f-1 promulgated thereunder. In connection with the foregoing, the
Company shall promptly, at the option of Acquisition Sub, either increase the
size of the Company Board or obtain the resignation of such number of its
current directors as is necessary to enable Acquisition Sub's designees to be
elected or appointed to the Company Board as provided above.

  



  

   

\- 59 - 
--- 

 


--- 

    



  

(b) After the appointment of Acquisition Sub's designees to the Company Board
pursuant to _Section 8.9(a)_ , and prior to the Effective Time, the approval
of a majority of the Independent Directors shall be required for the Company
to authorize: (i) any termination of, or any agreement to terminate, this
Agreement by or on behalf of the Company, (ii) any exercise or waiver of
any of the Company's rights or remedies under this Agreement, (iii) any
amendment to the Company Certificate of Incorporation, the Company By-laws
and other charter and organizational documents of the Company other than as
contemplated by this Agreement in connection with the Merger, (iv) any
extension of time for, or waiver by the Company of, the performance of any of
the obligations or other acts of Parent or Acquisition Sub under this
Agreement, (v) any agreement between the Company and any of the
Company's Subsidiaries, on the one hand, and Parent, Acquisition Sub or any
of their respective Affiliates, on the other hand or (vi) any amendment,
waiver or modification of this Agreement that would, or would be reasonably
likely to, adversely affect the rights of the holders of Company Common Stock
under this Agreement.

  



  

ARTICLE IX 
  _CONDITIONS TO THE MERGER_

  



  

9.1 _Conditions to Each Party 's Obligation to Effect the Merger_. The
respective obligations of each Party to effect the Merger shall be subject to
satisfaction or waiver at or prior to the Effective Time of the following
conditions:

  



  

(a) _No Legal Prohibition_. No Order (whether temporary, preliminary or
permanent in nature) issued by any court of competent jurisdiction or other
restraint or prohibition of any Governmental Authority of competent
jurisdiction shall be in effect, and no Law shall have been enacted, entered,
promulgated, enforced or deemed applicable by any Governmental Authority of
competent jurisdiction and remain in effect, that, in any such case,
prohibits or makes illegal the consummation of the Merger.

  



  

(b) _Acceptance of Tendered Shares_. Acquisition Sub shall have irrevocably
accepted for payment the shares of Company Common Stock validly tendered and
not validly withdrawn pursuant to the Offer; _provided_ , _however_ , that
neither Parent nor Acquisition Sub shall be entitled to assert the failure of
this condition if, in breach of this Agreement, Acquisition Sub fails to
irrevocably accept for payment any shares of Company Common Stock validly
tendered and not validly withdrawn pursuant to the Offer.

  



  

9.2 _Conditions to Company 's Obligation to Effect the Merger_. The
obligations of the Company to effect the Merger shall be subject to the CVR
Agreement being in full force and effect at the Effective Time.

  



  

ARTICLE X 
  _TERMINATION, AMENDMENT AND WAIVER_

  



  

10.1 _Termination. _ This Agreement may be validly terminated and the Offer,
the Merger and the other transactions contemplated by this Agreement may be
abandoned at any time prior to the Offer Closing only as follows (it being
understood and hereby agreed that this Agreement may not be terminated for
any other reason or on any other basis):

  



  

   

\- 60 - 
--- 

 


--- 

    



  

(a) by mutual written agreement of Parent and the Company;

  



  

(b) by either the Company or Parent in the event that the Offer Closing shall
not have occurred on or before August 29, 2014 (such date referred to herein
as the "Outside Date"); _provided_ , _however_ , that (i) the right to
terminate this Agreement pursuant to this _Section 10.1(b)_ shall not be
available to Parent if (A) Parent's or Acquisition Sub's actions or omissions
have been a principal cause of, or primarily resulted in, the failure of the
Offer Closing to occur on or before such date and such action or failure to
act constitutes a breach of this Agreement or (B) Parent or Acquisition Sub
is in material breach of this Agreement, and (ii) the right to terminate this
Agreement pursuant to this _Section 10.1(b)_ shall not be available to the
Company if (A) the Company's actions or omissions have been a principal cause
of, or primarily resulted in, the failure of the Offer Closing to occur on or
before such date and such action or failure to act constitutes a breach
of this Agreement or (B) the Company is in material breach of this Agreement;

  



  

(c) by either the Company or Parent if there shall be any Law enacted by a
Governmental Authority of competent jurisdiction after the date of this
Agreement remaining in effect that makes the acceptance for payment of or
payment for Company Common Stock validly tendered pursuant to the Offer
illegal or that prohibits the consummation of the Merger, or any court of
competent jurisdiction shall have issued a permanent injunction prohibiting
the acceptance for payment of or payment for Company Common Stock
validly tendered pursuant to the Offer or prohibiting the consummation of the
Merger and such injunction shall have become final and non-appealable; 
_provided, however,_ that in the case of an injunction a Party shall not be
permitted to terminate this Agreement pursuant to this _Section 10.1(c)_ if
the issuance of any such injunction is primarily attributable to the failure
of such Party (or any Affiliate of such Party) to perform in all material
respects any covenant or other obligation under this Agreement required to be
performed by such Party (or any Affiliate of such Party) at or prior to the
Effective Time;

  



  

(d) by the Company, prior to the Offer Closing in the event that (i) the
Company shall have received a Superior Proposal not resulting from any breach
of _Section 6.2_ ; (ii) the Company shall have notified Parent in writing that
it intends to enter into a definitive agreement with respect to such Superior
Proposal (a "Superior Proposal Notice"), which notice shall contain a
reasonably detailed description of all terms and conditions of the Superior
Proposal and attach a copy of all definitive agreements with respect to such
Superior Proposal (it being agreed that the Superior Proposal Notice and any
amendment or update to such notice and the determination to so deliver such
notice, or update or amend public disclosures with respect thereto shall not
constitute a Company Board Recommendation Change for purposes of this
Agreement); (iii) if requested in writing by Parent, the Company shall have
made its Representatives available to discuss and negotiate in good faith,
with Parent's Representatives any proposed modifications to the terms and
conditions of this Agreement during the period beginning at 5:00 p.m. Eastern
Time on the day of delivery by the Company to Parent of such Superior
Proposal Notice and ending three (3) Business Days later at 5:00 p.m. Eastern
Time (it being understood and hereby agreed that (1) such three (3) Business
Day period may be the same three (3) Business Day period contemplated by
_Section 6.3(a)_ if the Superior Proposal Notice also serves as a
Recommendation Change Notice and (2) any amendment to any material term or
condition of the definitive agreements provided in the Superior
Proposal Notice shall require a new Superior Proposal Notice and a new three
Business Day period); (iv) no earlier than the end of the three Business Day
period referred to in clause (iii), the Company Board (or any committee
thereof) shall have determined in good faith (after consultation with its
outside financial advisors and outside legal counsel), after considering the
terms of any proposed amendment or modification to this Agreement, that such
Superior Proposal remains a Superior Proposal and that failure to
terminate this Agreement pursuant to this _Section 10.1(d)_ would reasonably
be expected to be inconsistent with its fiduciary duties to the Company
Stockholders under applicable Law; (v) concurrently with the termination of
this Agreement, the Company pays Parent the Termination Fee payable to Parent
pursuant to _Section 10.3(c)_ and (vi) the Company Board approves, and the
Company concurrently with the termination enters into, a definitive agreement
providing for the implementation of such Superior Proposal;

  



  

   

\- 61 - 
--- 

 


--- 

    



  

(e) by Parent, in the event that (i) Parent and Acquisition Sub have not
breached any of their respective representations, warranties or covenants
under this Agreement in any material respect, and (ii) the Company shall have
breached any of its representations, warranties or covenants under this
Agreement such that the conditions set forth in _clauses (ii)_ or _(iii)_ of
paragraph (c) of _Annex A_ would not be satisfied and shall have failed to
cure such breach within ten (10) Business Days after the Company has received
written notice of such breach from Parent (it being understood that Parent
shall not be permitted to terminate this Agreement pursuant to this _Section
10.1(e)_ in respect of the breach set forth in any such written notice (x) at
any time during such ten (10) Business Day period, and (y) at any time after
such ten (10) Business Day period if the Company shall have cured such breach
during such ten (10) Business Day period);

  



  

(f) by Parent, in the event that (i) the Company Board (or any committee
thereof) shall have effected a Company Board Recommendation Change, (ii) a
tender or exchange offer for Company Common Stock that constitutes an
Acquisition Proposal (whether or not a Superior Proposal) is commenced by a
Person unaffiliated with Parent and, within ten (10) Business Days after the
public announcement of the commencement of such Acquisition Proposal, the
Company shall not have filed a Schedule 14D-9 pursuant to Rule 14e-2 and
Rule 14d-9 promulgated under the Exchange Act recommending that the Company
Stockholders reject such Acquisition Proposal and not tender any shares of
Company Common Stock into such tender or exchange offer, (iii) the Company
Board fails to publically reaffirm the Company Board Recommendation within
ten (10) Business Days of receipt of a written request by Parent to provide
such reaffirmation following receipt by the Company of an Acquisition
Proposal that is publicly announced or otherwise publicly known, (iv) the
Company breaches clauses (iv) or (v) of the first sentence of _Section
6.2(b)_ or (v) the Company materially and intentionally breaches any other
provision of _Section 6.2_ ;

  



  

(g) by the Company, in the event that (i) the Company has not breached any of
its representations, warranties or covenants under this Agreement in any
material respect and (ii) Parent or Acquisition Sub shall have breached in any
material respect (A) any of its representations or warranties under this
Agreement or (B) covenants or obligations hereunder, and, in either case, such
breach would or would reasonably be expected to individually or in the
aggregate with all other such breaches, prevent or materially impede, hinder
or delay the performance by Parent or Acquisition Sub of any of their
respective obligations under this Agreement or the consummation of the Offer
or the Merger and Parent or Acquisition Sub shall have failed to cure such
breach within ten (10) Business Days after Parent has received written notice
of such breach from the Company (it being understood that the Company shall
not be permitted to terminate this Agreement pursuant to this _Section
10.1(g)_ in respect of the breach set forth in any such written notice (A) at
any time during such ten (10) Business Day period, and (B) at any time after
such ten (10) Business Day period if Parent and Acquisition Sub shall have
cured such breach during such ten (10) Business Day period);

  



  

(h) by the Company, in the event that the Company has not breached any of its
representations, warranties or covenants under this Agreement in any material
respect and at any scheduled expiration date of the Offer, Acquisition Sub
fails to accept for payment shares of Company Common Stock validly tendered
and not validly withdrawn in the Offer subject to the terms of and in
accordance with  _Section 2.1_ and at such time all of the conditions set
forth in _Annex A_ are satisfied and no subsequent expiration date for the
Offer is established pursuant to an authorized extension of the Offer; or

  



  

(i) by either the Company or Parent, in the event that as of the expiration
of the Offer in accordance with its terms (subject to any extension of the
Offer pursuant to this Agreement), all of the Offer Conditions have been
satisfied or waived (to the extent waivable in accordance with the terms
hereof) except for the Minimum Tender Condition and conditions which by their
nature are to be satisfied at the expiration of the Offer; _provided_ that
the right to terminate this Agreement pursuant to this _Section 10.1(i) _
shall not be available to a Party if (A) such Party's actions or omissions
have been a principal cause of, or primarily resulted in, the failure of the
Minimum Tender Condition to be satisfied and such action or failure to act
constitutes a breach of this Agreement or (B) such Party is in material
breach of this Agreement.

  



  

   

\- 62 - 
--- 

 


--- 

    



  

10.2 _Notice of Termination; Effect of Termination_. Any proper and valid
termination of this Agreement pursuant to _Section 10.1_  shall be effective
immediately upon the delivery of written notice of the terminating Party to
the other Party or Parties hereto, as applicable. In the event of the
termination of this Agreement pursuant to _Section 10.1_ , this Agreement
shall be of no further force or effect without liability of any Party or
Parties hereto, as applicable (or any director, officer, employee,
affiliate, agent or other representative of such Party or Parties) to the
other Party or Parties hereto, as applicable, except (a) for the terms of
_ARTICLE I_ , the last sentence of _Section 2.1(f)_ , the last sentence of
_Section 2.2(b)_ , _Section 4.27_ , _Section 5.8_ , the last sentence of
_Section 6.4(a)_ , _Section 8.6_ , this _Section 10.2_ , _Section 10.3_ and
_ARTICLE XI_ , each of which shall survive the termination of this Agreement,
and (b) subject to _Section 10.3(g)_ , nothing in this Agreement shall
relieve any Party or Parties hereto, as applicable, from liability for any
knowing and intentional breach of, or fraud in connection with, this
Agreement.

  



  

10.3 _Fees and Expenses_.

  



  

(a) _General_. Except as set forth in _Sections 7.5_ and _8.2_ and this
Section _10.3_ , all fees and expenses incurred in connection with this
Agreement and the transactions contemplated hereby shall be paid by the Party
or Parties, as applicable, incurring such expenses whether or not the Offer
or the Merger is consummated.

  



  

(b) In the event that (i) this Agreement is validly terminated by Parent or
the Company pursuant to _Sections 10.1(b)_ , _10.1(e) _ or _10.1(i)_ , (ii)
subsequent to the date of this Agreement and at or prior to the time of the
termination of this Agreement a third party shall have publicly disclosed a
_bona fide_ Acquisition Proposal or the making or existence of such
proposal shall have otherwise become publicly known (and such Acquisition
Proposal shall not have been withdrawn prior to the time of the termination
of this Agreement) and (iii) at any time prior to the date that is fifteen
(15) months following the termination of this Agreement, the Company enters
into a definitive agreement with respect to an Acquisition Proposal or an
Acquisition Proposal is consummated, _provided_ , _however_ , that for the
purposes of this clause (b) all references to "20%" in the definition of
Acquisition Transaction shall be deemed to be references to "50%", then, in
any such case, the Company shall pay to Parent $18,550,000 (the "Termination
Fee"), less the amount of Parent Expenses previously reimbursed by the
Company pursuant to _Section 10.3(e)_ , by wire transfer of immediately
available funds to an account or accounts designated in writing by Parent,
within two (2) Business Days after the earlier of the entry into such
definitive agreement or the consummation of such transaction.

  



  

(c) In the event that this Agreement is terminated by the Company pursuant to
_Section 10.1(d)_ , the Company shall pay to Parent the Termination Fee, by
wire transfer of immediately available funds to an account or accounts
designated in writing by Parent, as a condition to the effectiveness of such
termination.

  



  

(d) In the event that this Agreement is terminated by Parent pursuant to
_Section 10.1(f)_ , the Company shall pay to Parent the Termination Fee, by
wire transfer of immediately available funds to an account or accounts
designated in writing by Parent, within two (2) Business Days after written
demand by Parent.

  



  

   

\- 63 - 
--- 

 


--- 

    



  

(e) In the event that this Agreement is terminated because of the failure to
satisfy the Minimum Tender Condition by Parent or the Company pursuant to
Sections _10.1(b)_ , _10.1(e)_ or _10.1(i)_ , the Company shall reimburse
Parent promptly upon demand, but in no event later than two (2) Business Days
after the date of such demand, by wire transfer of immediately available
funds, all reasonably documented out-of-pocket expenses (including all fees
and expenses of counsel, accountants, investment bankers, financing sources,
hedging counterparties, experts and consultants) ("Parent Expenses") incurred
by Parent, Acquisition Sub or their respective Affiliates in connection with
this Agreement and the transactions contemplated by this Agreement; 
_provided_ , that the Company shall not be obligated to reimburse Parent for
Parent Expenses in excess of $2,650,000. The reimbursement of Parent Expenses
pursuant to this _Section 10.3(e)_ shall not relieve the Company of any
subsequent obligation to pay any applicable Termination Fee pursuant to
_Section 10.3(b)_ (less the amount of Parent Expenses previously
reimbursed by the Company pursuant to this _Section 10.3(e)_ ).

  



  

(f) Each of the Company and Parent acknowledges and agrees that the
agreements contained in this _Section 10.3_ are an integral part of the
transactions contemplated by this Agreement, and that, without these
agreements, neither the Company nor Parent would have entered into this
Agreement; accordingly, if the Company fails promptly to pay the Termination
Fee or reimburse the Parent Expenses due pursuant to _Section 10.3_ , and, in
order to obtain such payment or reimbursement, as applicable, Parent commences
a Legal Proceeding that results in an award against the Company for such fee
or reimbursement, as applicable, the Company shall pay Parent its costs and
expenses (including reasonable attorneys' fees and expenses) in connection
with such Legal Proceeding, together with interest on the amount of the
applicable fee from the date such payment was required to be made until the
date of payment at the prime lending rate as published in _The Wall Street
Journal_ in effect on the date such payment was required to be made.

  



  

(g) In no event shall the Company be required to pay the Termination Fee on
more than one occasion. Notwithstanding anything to the contrary in this
Agreement, (x) if the Company pays the Termination Fee pursuant to _Section
10.3_ , then any such payment shall be the sole and exclusive remedy of
Parent and Acquisition Sub against the Company and its Subsidiaries and any of
their respective former, current or future officers, directors, partners,
equity holders, managers, members, Affiliates or successors and none of the
Company, any of its Subsidiaries or any of their respective former, current or
future officers, directors, partners, equity holders, managers, members,
Affiliates or successors shall have any further liability or obligation
relating to or arising out of this Agreement or the transactions contemplated
hereby, and (z) if Parent or Acquisition Sub receives any payments from
the Company in respect of any breach of this Agreement or reimbursement of
Parent Expenses, and thereafter Parent is entitled to receive the Termination
Fee under _Section 10.3_ , the amount of such Termination Fee shall be reduced
by the aggregate amount of any payments made by the Company to Parent or
Acquisition Sub in respect of any such breaches of this Agreement and
reimbursement of any Parent Expenses.

  



  

10.4 _Amendment_. This Agreement may be amended by the Parties at any time
before or after the Offer Closing shall have occurred; _provided_ , 
_however_ , that after the Offer Closing and subject to _Section 3.7(b)_ ,
there shall be no amendment that decreases the Merger Consideration. This
Agreement may not be amended except by an instrument in writing signed on
behalf of each of the Parties.

  



  

10.5 _Extension; Waiver_. At any time and from time to time prior to the
Effective Time, any Party or Parties hereto may, to the extent
legally allowed and except as otherwise set forth herein, (a) extend the time
for the performance of any of the obligations or other acts of the other
Party or Parties hereto, as applicable, (b) waive any inaccuracies in the
representations and warranties made to such Party or Parties hereto contained
herein or in any document delivered pursuant hereto and (c) waive compliance
with any of the agreements or conditions for the benefit of such Party or
Parties hereto contained herein (other than, for the avoidance of doubt, the
Minimum Tender Condition unless such waiver is consented to in writing by the
Company). Any agreement on the part of a Party or Parties hereto to any such
extension or waiver shall be valid only if set forth in an instrument in
writing signed on behalf of such Party or Parties, as applicable. Any delay
in exercising any right under this Agreement shall not constitute a waiver of
such right.

  



  

   

\- 64 - 
--- 

 


--- 

    



  

ARTICLE XI 
  _GENERAL PROVISIONS_

  



  

11.1 _Survival of Representations, Warranties and Covenants_. The
representations and warranties of the Company, Parent and Acquisition
Sub contained in this Agreement shall terminate at the Effective Time, and
only the covenants that by their terms survive the Effective Time shall so
survive the Effective Time in accordance with their respective terms.

  



  

11.2 _Notices_. All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly delivered and
received hereunder (i) four (4) Business Days after being sent by registered
or certified mail, return receipt requested, postage prepaid, (ii) one (1)
Business Day after being sent for next Business Day delivery, fees prepaid,
via a reputable nationwide overnight courier service, or (iii) immediately
upon delivery by email, by hand or by facsimile (with a written or electronic
confirmation of delivery), in each case to the intended recipient as set
forth below:

  



  

(a) if to Parent or Acquisition Sub to:

  



  

H. Lundbeck A/S

  

Ottiliavej 9; 2500

  

Valby, Denmark

  

  

     Attention:    | Mette Carlstedt 
---|--- 
     | Jacob Tolstrup 
   Facsimile No.:   | +4536438249 
     | +4536438280 
   Email address:  | meco@lundbeck.com 
     | jtl@lundbeck.com 
  



  

with a copy (which shall not constitute notice) to:

  



  

Cravath, Swaine andMoore LLP

  

Worldwide Plaza

  

825 Eighth Avenue

  

New York, NY 10019

     Attention:   | Faiza Saeed 
---|--- 
     | Ting S. Chen 
   Facsimile No.:  | (212) 474-3700 
   Email address:  | fsaeed@cravath.com 
     | tchen@cravath.com 
  



  

(b) if to the Company, to:

  



  

Chelsea Therapeutics International, Ltd.

  

3530 Toringdon Way, Suite 200

  

Charlotte, NC 28277

     Attention:   | Joseph Oliveto 
---|--- 
   Facsimile No.:  | (704) 752-1479 
   Email address:  | oliveto@chelsearx.com 
  



  

   

\- 65 - 
--- 

 


--- 

    



  

with a copy (which shall not constitute notice) to:

  



  

Morgan, Lewis and Bockius LLP

  

101 Park Avenue

  

New York, NY 10178

     Attention:  | Robert W. Dickey 
---|--- 
   Facsimile No.:   | (212) 309-6001 
   Email address:   | rdickey@morganlewis.com 
  



  

11.3 _Assignment_. No Party may assign either this Agreement or any of its
rights, interests, or obligations hereunder without the prior
written approval of the other Parties, and any assignment without such prior
written approval shall be null and void except that Parent and Acquisition
Sub may assign, in their sole discretion, any of or all their rights,
interests and obligations under this Agreement to any direct or indirect
wholly-owned subsidiary of Parent but no such assignment shall relieve Parent
or Acquisition Sub, as applicable, of any of their obligations under this
Agreement. Subject to the preceding sentence, this Agreement shall (i) be
binding upon the Parties hereto and their respective successors and permitted
assigns and (ii) shall inure to the benefit of the Parties hereto and their
respective successors and permitted assigns.

  



  

11.4 _Entire Agreement_. This Agreement and the CVR Agreement (including the
Annexes and Exhibits hereto and thereto) constitute the entire agreement
among the Parties with respect to the subject matter hereof and supersedes all
prior agreements and understandings, both written and oral, among the Parties
with respect to the subject matter hereof; _provided_ , _however_ , that
subject to _Section 8.6_ , the Confidentiality Agreement shall not be
superseded, shall survive any termination of this Agreement and shall
continue in full force and effect until the earlier to occur of (a) the
Effective Time and (b) the date on which the Confidentiality Agreement
expires in accordance with its terms or is validly terminated by the parties
thereto. EACH PARTY HERETO AGREES THAT, EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER PARENT, ACQUISITION SUB OR
ANY OF THEIR AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES OR REPRESENTATIVES,
ON THE ONE HAND, NOR THE COMPANY OR ANY OF ITS AFFILIATES, DIRECTORS,
OFFICERS, EMPLOYEES OR REPRESENTATIVES, ON THE OTHER HAND, MAKES ANY
REPRESENTATIONS OR WARRANTIES TO THE OTHER, AND EACH PARTY HEREBY DISCLAIMS
ANY OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED (INCLUDING ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE), OR
AS TO THE ACCURACY OR COMPLETENESS OF ANY OTHER INFORMATION, MADE (OR MADE
AVAILABLE) BY ITSELF OR ANY OF ITS REPRESENTATIVES, WITH RESPECT TO, OR IN
CONNECTION WITH, THE NEGOTIATION, EXECUTION OR DELIVERY OF THIS AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED HEREBY, NOTWITHSTANDING THE DELIVERY OR
DISCLOSURE TO THE OTHER OR THE OTHER'S REPRESENTATIVES OF ANY DOCUMENTATION
OR OTHER INFORMATION WITH RESPECT TO ANY ONE OR MORE OF THE FOREGOING.

  



  

11.5 _Third Party Beneficiaries_. This Agreement is not intended to, and
shall not, confer upon any other Person any rights or remedies hereunder,
except (a) for the provisions of _Section 7.1_ and (b) from and after the
Effective Time, the rights of holders of shares of the Company Common Stock
and other Company Securities to receive the Merger Consideration or other
consideration, as contemplated in _ARTICLE III_.

  



  

11.6 _Severability_. In the event that any provision of this Agreement, or
the application thereof, becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remainder of
this Agreement will continue in full force and effect and the application of
such provision to other persons or circumstances will be interpreted so as
reasonably to effect the intent of the Parties. The Parties further agree to
replace such void or unenforceable provision of this Agreement with a valid
and enforceable provision that will achieve, to the extent possible, the
economic, business and other purposes of such void or unenforceable provision.

  



  

   

\- 66 - 
--- 

 


--- 

    



  

11.7 _Specific Performance_. The Parties hereto agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise
breached and that in any such case any breach of this Agreement could not be
adequately compensated by monetary damages alone. Accordingly, the Parties
agree that, prior to the valid termination of this Agreement in accordance
with _Section 10.1_ , each Party shall be entitled to an injunction or
injunctions, or any other appropriate form of specific performance or
equitable relief, to prevent breaches of this Agreement and to enforce
specifically the terms and provisions hereof in any court of competent
jurisdiction, in each case in accordance with _Section 11.9_ , this being in
addition to any other remedy to which they are entitled under the terms of
this Agreement at law or in equity. Each Party hereto accordingly agrees not
to raise any objections to the availability of the equitable remedy of
specific performance to prevent or restrain breaches or threatened breaches
of, or to enforce compliance with, the covenants and obligations of such
Party under this Agreement all in accordance with the terms of this _Section
11.7_. Any Party seeking an injunction or injunctions to prevent breaches of
this Agreement and to enforce specifically the terms and provisions of
this Agreement shall not be required to post a bond or undertaking in
connection with such order or injunction sought in accordance with the terms
of this _Section 11.7_.

  



  

11.8 _Governing Law_. THIS AGREEMENT AND ANY LEGAL PROCEEDING (WHETHER AT
LAW, IN CONTRACT OR IN TORT) THAT MAY BE DIRECTLY OR INDIRECTLY BASED UPON,
RELATING TO OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE HEREOF OR THEREOF, SHALL
BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF
DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE
PRINCIPLES OF CONFLICTS OF LAWS THEREOF.

  



  

11.9 _Consent to Jurisdiction._

  



  

(a) Each of the Parties irrevocably submits to the exclusive jurisdiction of
the Court of Chancery of the State of Delaware or, if such court lacks
subject matter jurisdiction, the United States District Court sitting in New
Castle County in the State of Delaware or Delaware Superior Court, for the
purpose of any Legal Proceeding directly or indirectly based upon, relating to
or arising out of this Agreement or any transaction contemplated hereby or
the negotiation, execution or performance hereof or thereof, and each of the
Parties hereby irrevocably agrees that all claims in respect to such action or
proceeding shall be brought in, and may be heard and determined exclusively
in, such state or federal courts. Each of the Parties irrevocably and
unconditionally waives any objection to the laying of venue in, and any
defense of inconvenient forum to the maintenance of, any action or
proceeding so brought. Each of the Parties agrees that a final judgment in
any action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by Law.

  



  

(b) Each of the Parties irrevocably consents to the service of the summons
and complaint and any other process in any other action or
proceeding relating to the transactions contemplated by this Agreement, on
behalf of itself or its property, by personal delivery of copies of such
process to such Party at the addresses set forth in _Section 11.2_. Nothing in
this _Section 11.9_ shall affect the right of any Party to serve legal
process in any other manner permitted by Law.

  



  

   

\- 67 - 
--- 

 


--- 

    



  

11.10 _WAIVER OF JURY TRIAL_. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO
INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE
TO A TRIAL BY JURY IN ANY LITIGATION DIRECTLY OR INDIRECTLY BASED UPON,
RELATING TO OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY OR THE NEGOTIATION, EXECUTION OR PERFORMANCE HEREOF OR THEREOF. EACH
PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATION OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND
(IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

  



  

11.11 _Company Disclosure Letter References_. The Parties agree that the
disclosure set forth in any particular section or subsection of the Company
Disclosure Letter shall be deemed to be an exception to (or, as applicable, a
disclosure for purposes of) (i) the representations and warranties (or
covenants, as applicable) of the Company that are set forth in the
corresponding section or subsection of this Agreement, and (ii) any other
representations and warranties (or covenants, as applicable) of the Company
that are set forth in this Agreement as though fully set forth in such other
representation and warranty (or covenant, as applicable), but in the case of
this _clause (ii)_ only if the relevance of that disclosure as an exception to
(or a disclosure for purposes of) such other representations and warranties
(or covenants, as applicable) is reasonably apparent on the face of such
disclosure. No reference to or disclosure of any item or other matter in the
Company Disclosure Letter shall be construed as an admission or
indication that such item or other matter is material or that such item or
other matter is required to be referred to or disclosed in the Company
Disclosure Letter. The information set forth in the Company Disclosure Letter
is disclosed solely for the purposes of this Agreement, and no information
set forth therein shall be deemed to be an admission by any Party to any third
party of any matter whatsoever, including of any violation of Law or breach
of any agreement.

  



  

11.12 _Counterparts_. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the Parties and delivered to the other Parties, it being understood that
all Parties need not sign the same counterpart.

  

 _ _

  

 _[Remainder of Page Intentionally Left Blank]_

  



  

   

\- 68 - 
--- 

 


--- 

    



     

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed
by their respective duly authorized officers to be effective as of the date
first above written.

  



       | H. LUNDBECK A/S 
---|--- 
     |   | 
     | By:  | /s/ Ulf Wiinberg 
     | Name:  | Ulf Wiinberg 
     | Title:  | Chief Executive Officer 
     |   | 
     | By:  | /s/ Anders Gotzsche 
     | Name:  | Anders Gotzsche 
     | Title:  | Chief Financial Officer 
     |   | 
     | CHARLIE ACQUISITION CORP. 
     |   | 
     | By:  | /s/ Staffan Schuberg 
     | Name:  | Staffan Schuberg 
     | Title:  | President 
     |   | 
     | CHELSEA THERAPEUTICS I 
 NTERNATIONAL, LTD. 
     |   | 
     | By:  | /s/ Joseph Oliveto 
     | Name:   | Joseph Oliveto 
     | Title:   | President and Chief Executive Officer 
  



  

[Signature Page to the Agreement and Plan of Merger]

  



  

   


--- 

 


--- 

    



  

ANNEX A

  

 _Conditions to the Offer_

  



  

Notwithstanding any other term of the Offer or this Agreement, Acquisition
Sub shall not be required to, and Parent shall not be required to
cause Acquisition Sub to, accept for payment and pay for any shares of
Company Common Stock tendered pursuant to the Offer if: (a) there shall not
be validly tendered and not validly withdrawn prior to the expiration of the
Offer a number of shares of Company Common Stock (excluding shares of Company
Common Stock subject to notices of guaranteed delivery not delivered to or on
behalf of the Acquisition Sub) that when added to the number of shares owned
by Acquisition Sub represent a majority of the Fully Diluted Shares as of the
expiration of the Offer (the "Minimum Tender Condition"); (b) the waiting
period applicable to the purchase of shares of Company Common Stock pursuant
to the Offer and the consummation of the Merger under the HSR Act (or
any extension thereof) shall have neither expired nor terminated; or (c) any
of the following conditions shall have occurred and be continuing as of the
expiration of the Offer:

  



  

(i) (A) there shall be any Order (whether temporary, preliminary or permanent
in nature) issued by any court of competent jurisdiction or other restraint
or prohibition of any Governmental Authority of competent jurisdiction in
effect, or any Law enacted, entered, promulgated, enforced or deemed
applicable by any Governmental Authority of competent jurisdiction and
remaining in effect, that, in any such case, prohibits or makes illegal the
consummation of the Offer or the Merger or (B) there shall be pending any
Legal Proceeding brought by any Governmental Authority of competent
jurisdiction that has a substantial likelihood of success (1) seeking to make
illegal, restrain or prohibit the making or consummation of the Offer or the
Merger in accordance with the terms of this Agreement or (2) which, if
successful, would reasonably be expected to result in a Substantial Detriment;

  



  

(ii) (x) the representations and warranties of the Company contained in
_Section 4.7_ ( _Capitalization_ ), _Section 4.8(b)_  ( _Subsidiaries_ ), and
_Section 4.27_ ( _Brokers_ ) shall not be true and correct, except for any _de
minimis_ inaccuracies, as of such time (except to the extent made as of a
specific date, in which case as of such specific date only); (y) the
representations and warranties of the Company contained in the first sentence
of _Section 4.1_ ( _Organization_ ), _Section 4.2_  ( _Corporate Power;
Enforceability_ ), _Section 4.4_ ( _Voting Requirements_ ), _Section 4.5(a)_ (
_Non-Contravention_ ) and the second sentence of _Section 4.13(a)_ ( _Absence
of Certain Changes_ ) shall not be true and correct in all respects as of
such time (except to the extent made as of a specific date, in which case as
of such specific date only); or (z) all other representations and warranties
of the Company set forth in this Agreement shall not be true and correct
(disregarding all qualifications or limitations as to "materiality," "Company
Material Adverse Effect" and words of similar import set forth therein) as of
such time, except where the failure of such representations and warranties to
be so true and correct would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect and except,
in each case, to the extent such representations and warranties are made as
of a specific date (in which case such representations and warranties shall
not be true and correct (subject to such qualifications) as of such specific
date only);

  



  

(iii) the Company shall have failed to perform or comply in all material
respects with its obligations required to be performed or complied with by it
under this Agreement;

  



  

(iv) since the date of this Agreement, there shall have occurred any change,
circumstance, event or occurrence that has had or would reasonably be
expected to have a Company Material Adverse Effect; or

  



  

   


--- 

 


--- 

    



  

(v) this Agreement shall have been terminated in accordance with its terms.

  



  

On the date of the Offer Closing, the Company shall deliver to Parent a
certificate executed on behalf of the Company by the chief executive officer
or the chief financial officer of the Company certifying that none of the
conditions set forth in _clauses (c)(ii)_ , _(c)(iii)_ , and _(c)(iv)_ above
shall have occurred and be continuing as of the expiration of the Offer.

  



  

The term "Fully Diluted Shares" means, as of any time, the sum of (A) all
shares of Company Common Stock then issued and outstanding and (B) all
shares of Company Common Stock that the Company may be required to issue upon
the vesting (including vesting solely as a result of the consummation of the
Offer), conversion, settlement, or exercise of all then outstanding
options, warrants or securities convertible or exchangeable into shares of
Company Common Stock, or other rights to acquire or be issued shares of
Company Common Stock, regardless of the conversion or exercise price or other
terms and conditions thereof.

  



  

The foregoing conditions, other than the Minimum Tender Condition, are for
the sole benefit of Parent and Acquisition Sub and, subject to the terms and
conditions of this Agreement and the applicable rules and regulations of the
SEC, may be waived by Parent and Acquisition Sub in whole or in part at any
time and from time to time in their sole discretion (other than the Minimum
Tender Condition unless such waiver is consented to in writing by the
Company). The failure by Parent or Acquisition Sub at any time to exercise
any of the foregoing rights shall not be deemed a waiver of any such rights
and each such right shall be deemed an ongoing right which may be asserted at
any time and from time to time.

  



  

The capitalized terms used in this _Annex A_ and not defined in this _Annex
A_ shall have the meanings set forth in the Agreement and Plan of Merger,
dated as of May 7, 2014, by and among H. Lundbeck A/S, Charlie Acquisition
Corp. and Chelsea Therapeutics International, Ltd.

  



  

   


--- 

 


--- 

    



  

  

EXHIBIT A

    

  



  

  

AMENDED AND RESTATED

  



  

CERTIFICATE OF INCORPORATION

  



  

OF

  



  

SURVIVING CORPORATION

  



  



  



  

FIRST: The name of the corporation (hereinafter called the " _Corporation_
") is [NAME OF CORPORATION].

  



  

SECOND: The address, including street, number, city, and county, of the
registered office of the Corporation in the State of Delaware is [], and the
name of the registered agent of the Corporation in the State of Delaware at
such address is [].

  



  

THIRD: The purpose of the Corporation is to engage in any lawful act or
activity for which corporations may be organized under the General Corporation
Law of the State of Delaware.

  



  

FOURTH: The aggregate number of shares which the Corporation shall have
authority to issue is 1,000 shares of Common Stock, par value $0.01 per share.

  



  

FIFTH: In furtherance and not in limitation of the powers conferred upon it
by law, the Board of Directors of the Corporation is expressly authorized to
adopt, amend or repeal the By-laws of the Corporation.

  



  

SIXTH: The Corporation reserves the right to amend, alter, change or repeal
any provisions contained in this Certificate of Incorporation in the manner
now or hereafter prescribed by statute, and this Certificate of
Incorporation, and all rights conferred upon stockholders and directors
herein, are granted subject to this reservation.

  



  

SEVENTH: To the fullest extent permitted by the General Corporation Law of
the State of Delaware as it now exists and as it may hereafter be amended, no
director or officer of the Corporation shall be personally liable to the
Corporation or any of its stockholders for monetary damages for breach
of fiduciary duty as a director or officer; provided, however, that nothing
contained in this Article SEVENTH shall eliminate or limit the liability of a
director or officer (i) for any breach of the director's or officer's duty of
loyalty to the Corporation or its stockholders, (ii) for acts or omissions
not in good faith or which involve intentional misconduct or a knowing
violation of law, (iii) pursuant to Section 174 of the General Corporation
Law of the State of Delaware or (iv) for any transaction from which the
director or officer derived an improper personal benefit. No amendment to or
repeal of this Article SEVENTH shall apply to or have any effect on the
liability or alleged liability of any director or officer of the Corporation
for or with respect to any acts or omissions of such director or officer
occurring prior to such amendment or repeal.

  



  

   


--- 

 


--- 

    



  

EIGHTH: The Corporation shall, to the fullest extent permitted by Section
145 of the General Corporation Law of the State of Delaware, as the same may
be amended and supplemented, indemnify any and all persons whom it shall have
power to indemnify under said Section from and against any and all of the
expenses, liabilities or other matters referred to in or covered by said
Section. Such indemnification shall be mandatory and not discretionary. The
indemnification provided for herein shall not be deemed exclusive of any other
rights to which those indemnified may be entitled under any By-laws,
agreement, vote of stockholders or disinterested directors or otherwise, both
as to action in his or her official capacity and as to action in another
capacity while holding such office, and shall continue as to a person who has
ceased to be a director, officer, employee or agent and shall inure to the
benefit of the heirs, executors and administrators of such a person. Any
repeal or modification of this Article EIGHTH shall not adversely affect any
right to indemnification of any persons existing at the time of such repeal
or modification with respect to any matter occurring prior to such repeal or
modification.

  



  

The Corporation shall to the fullest extent permitted by the General
Corporation Law of the State of Delaware advance all costs and expenses
(including without limitation, attorneys' fees and expenses) incurred by any
director or officer within 15 days of the presentation of same to the
Corporation, with respect to any one or more actions, suits or proceedings,
whether civil, criminal, administrative or investigative, so long as the
Corporation receives from the director or officer an unsecured undertaking to
repay such expenses if it shall ultimately be determined that such director
or officer is not entitled to be indemnified by the Corporation under the
General Corporation Law of the State of Delaware. Such obligation to advance
costs and expenses shall be mandatory, and not discretionary, and
shall include, without limitation, costs and expenses incurred in asserting
affirmative defenses, counterclaims and cross claims. Such undertaking to
repay may, if first requested in writing by the applicable director or
officer, be on behalf of (rather than by) such director or officer, provided
that in such case the Corporation shall have the right to approve the party
making such undertaking.

  



  

NINTH: Unless and except to the extent that the By-laws of the Corporation
shall so require, the election of directors of the Corporation need not be by
written ballot.

    

  



  

   


--- 

 


--- 

    



  

Exhibit B

  



  

  

FORM OF CONTINGENT VALUE RIGHTS AGREEMENT

  



  

THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [], 2014 (this "
_Agreement_ "), is entered into by and between H. Lundbeck A/S, a Danish
corporation (" _Parent_ "), and [], a [ _Jurisdiction_ ] [ _Type of Entity_
], as Rights Agent.

  



  

RECITALS

  



  

WHEREAS, Parent, Charlie Acquisition Corp., a Delaware corporation ("
_Acquisition Sub_ "), and Chelsea Therapeutics International, Ltd., a
Delaware corporation (the " _Company_ "), have entered into an Agreement and
Plan of Merger dated as of May 7, 2014 (as it may be amended or supplemented
from time to time pursuant to the terms thereof, the " _Merger Agreement_
"), pursuant to which Acquisition Sub (a) has made a tender offer (the "
_Offer_ ") to acquire all of the outstanding shares of common stock, par
value $0.0001 per share, of the Company (" _Company Common Stock_ ") and (b)
following acceptance of the shares of Company Common Stock pursuant to the
Offer, will merge with and into the Company, with the Company surviving the
Merger as a subsidiary of Parent;

  



  

WHEREAS, pursuant to the Merger Agreement, in each of the Offer and the
Merger, Parent has agreed to provide to Company's stockholders and holders of
Company Options the right to receive contingent cash payments as hereinafter
described; and

  



  

WHEREAS, pursuant to this Agreement, the maximum potential amount payable per
CVR is $1.50.

  



  

NOW, THEREFORE, in consideration of the foregoing and the consummation of the
transactions referred to above, Parent and Rights Agent agree, for the equal
and proportionate benefit of all Holders (as hereinafter defined), as follows:

  



  

1. DEFINITIONS

  



  

1.1. _Definitions_. Capitalized terms used but not otherwise defined herein
shall have the meanings ascribed to them in the Merger Agreement. As used in
this Agreement, the following terms shall have the following meanings:

  



  

" _2015 Sales Milestone_ " means the achievement of aggregate worldwide
(other than Japan, Korea, China and Taiwan) Net Sales of the Product in
excess of $100,000,000 during the period commencing January 1, 2015 to and
including December 31, 2015.

  



  

" _2016 Sales Milestone_ " means the achievement of aggregate worldwide
(other than Japan, Korea, China and Taiwan) Net Sales of the Product in
excess of $200,000,000 during the period commencing on January 1, 2016 to and
including December 31, 2016.

  



  

" _2017 Sales Milestone_ " means the achievement of aggregate worldwide
(other than Japan, Korea, China and Taiwan) Net Sales of the Product in
excess of $300,000,000 during the period commencing on January 1, 2017 to and
including December 31, 2017.

  



  

" _Acting Holders_ " means, at the time of determination, Holders of at least
40% of the outstanding CVRs as set forth on the CVR Register.

  



  

" _Assignee_ " has the meaning set forth in _Section 6.3_.

  



  

   


--- 

 


--- 

    



  

" _Board of Directors_ " means the board of directors of Parent.

  



  

" _Board Resolution_ " means a copy of a resolution certified by the
secretary or an assistant secretary (or other comparable officer) of Parent to
have been duly adopted by the Board of Directors and to be in full force and
effect on the date of such certification, and delivered to the Rights Agent.

  



  

" _Business Day_ " means any day, other than a Saturday, Sunday and any day
which is a legal holiday under the laws of the State New York or is a day on
which banking institutions located in the State of New York are authorized or
required by law or other governmental action to close.

  



  

" _Compound_ " means droxidopa.

  



  

" _CVRs_ " means the rights of Holders to receive contingent cash payments
pursuant to the Merger Agreement and this Agreement.

  



  

" _CVR Register_ " has the meaning set forth in _Section 2.3(b)_.

  



  

" _CVR Shortfall_ " has the meaning set forth in _Section 4.4(b)_.

  



  

" _Distribution Services_ " means all distribution and invoicing activities
between and among a party or the parties, on the one hand, and its or their
customers and third-party distributors (including wholesalers and specialty
pharmacies), on the other hand, related to the Product, including receipt and
entry of orders, pick, pack and ship operations, completion and provision of
sales documentation, order delivery, warehousing, inventory control and
management, handling of returns, customer relations, billing, credit and
collection activities, and any other distribution and invoicing activities.

  



  

" _Governmental Entity_ " means any government, any governmental or
regulatory entity or body, department, commission, board, agency
or instrumentality, and any court, tribunal or judicial body of competent
jurisdiction, in each case whether federal, state, county, provincial, and
whether local or foreign.

  



  

" _Holder_ " means a Person in whose name a CVR is registered in the CVR
Register at the applicable time.

  



  

" _ICC_ " has the meaning set forth in _Section 6.6_.

  



  

" _Independent Accountant_ " means an independent certified public accounting
firm of nationally recognized standing designated either (a) jointly by the
Acting Holders and Parent, or (b) if such parties fail to make a designation,
jointly by an independent public accounting firm selected by Parent and an
independent public accounting firm selected by the Acting Holders.

  



  

" _Milestone Notice_ " has the meaning set forth in _Section 2.4_.

  



  

" _Milestone Payment_ " means, as applicable and without any aggregation,

  



  

(a) with respect to the 2015 Sales Milestone, an amount equal to (i) 0.5
_multiplied_ _by_ (ii)(A) the aggregate worldwide (other than Japan, Korea,
China and Taiwan) Net Sales of the Product during the period commencing
January 1, 2015 to and including December 31, 2015 _minus_ (B) $100,000,000
_divided_ _by_ (iii) the aggregate number of CVRs issued in connection with
the Merger; _provided_ that the such payments shall not exceed $0.50 per CVR.

  



  

   

2 
--- 

 


--- 

    



  

(b) with respect to the 2016 Sales Milestone, an amount equal to (i) 0.5
_multiplied_ _by_ (ii)(A) the aggregate worldwide (other than Japan, Korea,
China and Taiwan) Net Sales of the Product during the period commencing
January 1, 2016 to and including December 31, 2016  _minus_ (B) $200,000,000
_divided_ _by_ (iii) the aggregate number of CVRs issued in connection with
the Merger;  _provided_ that such payments shall not exceed $0.50 per CVR.

  



  

(c) with respect to the 2017 Sales Milestone, an amount equal to (i) 0.5
_multiplied_ _by_ (ii)(A) the aggregate worldwide (other than Japan, Korea,
China and Taiwan) Net Sales of the Product during the period commencing
January 1, 2017 to and including December 31, 2017  _minus_ (B) $300,000,000
_divided_ _by_ (iii) the aggregate number of CVRs issued in connection with
the Merger;  _provided_ that such payments shall not exceed $0.50 per CVR.

  



  

" _Net Sales_ " means the gross amount invoiced by or on behalf of the
relevant Selling Entity for the Product sold to third parties other than any
other Selling Entity, less the Permitted Deductions, all calculated on an
accrual basis, as determined in accordance with the applicable Selling
Entity's usual and customary accounting methods consistent with the treatment
of other branded prescription products commercialized by the applicable
Selling Entity, which shall be in accordance with United States generally
accepted accounting principles or International Financial Reporting
Standards, as applicable, including the accounting methods for translating
activity denominated in foreign currencies into United States dollar amounts.
In the case of any sale of the Product between or among the Company, its
Affiliates, licensees and sublicensees, for resale, Net Sales shall be
calculated as above only on the value charged or invoiced on the first bona
fide arm's-length sale thereafter to a third party. For the avoidance of
doubt, in the case of any sale of the Product between or among the Company,
its Affiliates, licensees and sublicensees where such Affiliate or
licensee is an end-user of, and does not further sell, the Product, Net Sales
shall be calculated on the value charged or invoiced to such Affiliate,
licensee or sublicensee. In the case of any sale for value other than
exclusively for money (but excluding any compassionate use, early access,
indigent patient and patient assistance or discount programs) on bona fide
arm's-length terms (which has the effect of reducing the invoiced amount
below what it would have been in the absence of such non-monetary
consideration), Net Sales shall be calculated at the average Net Sales price
charged to third parties for cash sales of the Product in the jurisdiction of
sale during the relevant reporting period unless such sales in the
jurisdiction during the relevant period were only de minimis cash sales, in
which case at the fair market value as determined by comparable markets.
Notwithstanding the foregoing, the following (including whether such amounts
actually exist or are deemed to exist for purposes of calculation) shall not
be included in Net Sales: (i) Product provided for administration to patients
enrolled in clinical trials or for other research purposes, (ii)
Product distributed through a not-for-profit organization or otherwise at no
or nominal charge to eligible patients in conjunction with any compassionate
use, early access, indigent patient or patient assistance program or (iii)
Product used for test marketing, promotional or sampling purposes.

  



  

" _Net Sales Statement_ " means a written statement of Parent, certified by
the Chief Financial Officer of Parent, setting forth Net Sales for the
applicable period and with reasonable detail (a) an itemized calculation of
the gross amounts invoiced by the Selling Entities for the Product sold to
third parties other than any other Selling Entity, (b) an itemized calculation
of the Permitted Deductions, and (c) to the extent that sales for the Product
are recorded in currencies other than United States dollars, the
exchange rates used for conversion of such foreign currency into United
States dollars. The Net Sales Statement shall be calculated in
accordance with International Financial Reporting Standards and shall be
derived from the audited financial statements of Parent.

  



  

" _Officer 's Certificate_" means a certificate signed by the chief executive
officer, president, chief financial officer, any vice president, the
controller, the treasurer or the secretary, in each case of Parent, in his or
her capacity as such an officer, and delivered to the Rights Agent.

  



  

   

3 
--- 

 


--- 

    



  

" _Permitted Deductions_ " means the following deductions as accrued by a
Selling Entity in accordance with United States generally accepted accounting
principles or International Financial Reporting Standards, as applicable:

  



  

(1) trade, cash and quantity discounts;

  



  

(2) amounts repaid, reimbursed or credited by reasons of defects, recalls,
withdrawals, returns, rebates or allowances of goods or because of
retroactive price reductions or billing corrections specifically identifiable
to the Product;

  



  

(3) chargebacks, discounts, credits, rebates (or the equivalent thereof) and
other amounts paid on sale of the Product, including such payments mandated
by programs of Governmental Entities;

  



  

(4) chargebacks, discounts, credits, rebates (or the equivalent thereof) and
administrative fees paid to medical healthcare organizations,
group purchasing organizations, pharmacies, formularies, large employers,
national accounts, long-term care organizations, insurers, Governmental
Entities and programs (including Medicare and the Veterans Health
Administration and other federal, state and local agencies), trade customers
or other organizations similar to the foregoing in line with approved contract
terms or other normal and customary understandings and arrangements
(including, as part of bundling or other forms of multi-product purchase
arrangements);

  



  

(5) tariffs, duties, excise, sales, value-added and other Taxes (other than
Taxes based on net income) and charges of Governmental Entities;

  



  

(6) transportation, freight, postage, importation, shipping insurance and
other handling expenses;

  



  

(7) distribution commissions and fees (including fees related to services
provided pursuant to distribution service agreements with
wholesalers, specialty pharmacy fees, fee-for-service wholesaler fees and
inventory management fees) payable to any third party providing
Distribution Services to the Selling Entities;

  



  

(8) costs of samples distributed by either specialty pharmacies or sales
representatives;

  



  

(9) deductions for uncollectible amounts on previously sold Products;

  



  

(10) discounts and provisions pursuant to compassionate use, early access,
indigent patient, co-pay reimbursement or assistance and patient
assistance or discount programs and coupon discounts;

  



  

(11) the portion of the annual fee on prescription drug manufacturers imposed
by the Patient Protection and Affordable Care Act, Pub. L. No. 111-148, that
the applicable Selling Entity allocates to sales of the Product, as
applicable, in accordance with the applicable Selling Entity's standard
policies and procedures consistently applied across its products, as
applicable.

  



  

For the avoidance of doubt, if a single item falls into more than one of the
categories set forth in clauses (1) through (13) above, such item shall not
be deducted more than once.

  



  

" _Permitted Transfer_ " means a transfer of CVRs (a) upon death of a Holder
by will or intestacy; (b) pursuant to a court order; (c) by operation of law
(including by consolidation or merger) or without consideration in connection
with the dissolution, liquidation or termination of any corporation, limited
liability company, partnership or other entity; or (d) in the case of CVRs
held in book-entry or other similar nominee form, from a nominee to a
beneficial owner and, if applicable, through an intermediary, as allowable
by the Depositary Trust Company.

  



  

   

4 
--- 

 


--- 

    



  

" _Product_ " means any pharmaceutical product that contains Compound as the
sole active pharmaceutical ingredient and is intended for
intravenous, intramuscular, subcutaneous, oral or sublingual administration,
including, in each case, all formulations and line extensions thereof.

  



  

" _Review Request Period_ " has the meaning set forth in _Section 4.4_.

  



  

" _Rights Agent_ " means the Rights Agent named in the first paragraph of
this Agreement, until a successor Rights Agent becomes such pursuant to the
applicable provisions of this Agreement, and thereafter "Rights Agent" shall
mean such successor Rights Agent.

  



  

" _Rules_ " has the meaning set forth in _Section 6.6_.

  



  

" _Sales Milestones_ " means, collectively, the 2015 Sales Milestone, the
2016 Sales Milestone and the 2017 Sales Milestone.

  



  

" _Selling Entity_ " means Parent, any Assignee, and each of their controlled
Affiliates (including, from and after the Effective Time, the
Company), licensees and sublicensees.

  



  

1.2. _Rules of Construction_. Except as otherwise explicitly specified to the
contrary, (a) references to a Section means a Section of this Agreement
unless another agreement is specified, (b) the word "including" (in its
various forms) means "including without limitation," (c) references to a
particular statute or regulation include all rules and regulations thereunder
and any successor statute, rules or regulation, in each case as amended or
otherwise modified from time to time, (d) words in the singular or plural
form include the plural and singular form, respectively, (e) references to a
particular Person include such Person's successors and assigns to the extent
permitted by this Agreement and (f) all references to dollars or "$" refer
to United States dollars.

  



  

2. CONTINGENT VALUE RIGHTS

  



  

2.1. _CVRs_. The CVRs represent the rights of Holders to receive contingent
cash payments pursuant to this Agreement. The initial Holders shall be
determined pursuant to the terms of the Merger Agreement.

  



  

2.2. _Nontransferable_. The CVRs may not be sold, assigned, transferred,
pledged, encumbered or in any other manner transferred or disposed of, in
whole or in part, other than through a Permitted Transfer.

  



  

2.3. _No Certificate; Registration; Registration of Transfer; Change of
Address_.

  



  

(a) The CVRs shall not be evidenced by a certificate or other instrument.

  



  

(b) The Rights Agent shall keep a register (the " _CVR Register_ ") for the
purpose of registering CVRs and transfers of CVRs as herein provided. The
CVRs shall, in the case of the holders of shares of Company Common Stock
immediately prior to the Effective Time, be registered in the names and
addresses of the holder as set forth in the applicable letter of transmittal
accompanying the shares of Company Common Stock surrendered by the holder
thereof in connection with the Offer or the Merger pursuant to the Merger
Agreement and in a denomination equal to the number of shares of Company
Common Stock so surrendered.

  



  

   

5 
--- 

 


--- 

    



  

(c) Subject to the restrictions on transferability set forth in _Section 2.2_
, every request made to transfer a CVR must be in writing and accompanied by
a written instrument of transfer and other requested documentation in form
reasonably satisfactory to the Rights Agent pursuant to its guidelines, duly
executed by the Holder thereof, the Holder's attorney duly authorized in
writing, the Holder's personal representative or the Holder's survivor, and
setting forth in reasonable detail the circumstances relating to
the transfer. Upon receipt of such written notice, the Rights Agent shall,
subject to its reasonable determination that the transfer instrument is in
proper form and the transfer otherwise complies with the other terms and
conditions of this Agreement (including the provisions of _Section 2.2_ ),
register the transfer of the CVRs in the CVR Register. Parent and Rights Agent
may require payment of a sum sufficient to cover any stamp or other Tax or
governmental charge that is imposed in connection with any such registration
of transfer. The Rights Agent shall have no duty or obligation to take any
action under any section of this Agreement that requires the payment by a
Holder of a CVR of applicable Taxes or charges unless and until the Rights
Agent is satisfied that all such Taxes or charges have been paid. All duly
transferred CVRs registered in the CVR Register shall be the valid
obligations of Parent and shall entitle the transferee to the same benefits
and rights under this Agreement as those held immediately prior to the
transfer by the transferor. No transfer of a CVR shall be valid until
registered in the CVR Register.

  



  

(d) A Holder may make a written request to the Rights Agent to change such
Holder's address of record in the CVR Register. The written request must be
duly executed by the Holder. Upon receipt of such written notice, the Rights
Agent shall, subject to its reasonable determination that the transfer
instrument is in proper form, promptly record the change of address in the CVR
Register.

  



  

2.4. _Payment Procedures_.

  



  

(a) On or before March 31 of each of 2016, 2017 and 2018, Parent shall
deliver to the Rights Agent (i) a notice (the " _Milestone Notice_ ")
indicating whether the applicable Sales Milestone was achieved with respect to
the previous year, (ii) if such Sales Milestone was achieved, cash equal to
the aggregate amount necessary to pay the applicable Milestone Payment to all
Holders pursuant to _Section 4.2_ , and (iii) the Net Sales Statement for the
year ended December 31 of the previous year along with any letter of
instruction required by the Rights Agent. Parent shall also deliver to the
Rights Agent on or before July 31st during 2015, 2016 and 2017, a Net Sales
Statement with respect to the first six months during such calendar year.

  



  

(b) The Rights Agent shall promptly, and in any event within ten (10)
Business Days of receipt of a Milestone Notice and/or a Net Sales Statement
as well as any letter of instruction required by the Rights Agent, send each
Holder at its registered address a copy of such Milestone Notice and/or Net
Sales Statement. If a Milestone Payment is payable to the Holders, then at the
time the Rights Agent sends a copy of the Milestone Notice to the Holders,
the Rights Agent shall also pay the applicable Milestone Payment to each of
the Holders (the amount which each Holder is entitled to receive shall be the
applicable Milestone Payment _multiplied_ _by_ the number of CVRs held by
such Holder as reflected on the CVR Register) (i) by check mailed to the
address of such Holder reflected in the CVR Register as of the close of
business on the date of the Milestone Notice or (ii) with respect to any such
Holder that is due an amount in excess of $1,000,000 in the aggregate who
have provided the Rights Agent wiring instructions in writing as of the close
of business on the date of the Milestone Notice, by wire transfer of
immediately available funds to the account specified on such instructions.

  



  

(c) Parent shall be entitled to deduct or withhold, or cause the Rights Agent
to deduct or withhold, from any Milestone Payment otherwise payable
pursuant to this Agreement such amounts as may be required to be deducted or
withheld therefrom under the Code, the Treasury Regulations thereunder, or
any other applicable Tax Law, as may be determined by Parent or the Rights
Agent. Prior to making any such Tax withholdings or causing any such Tax
withholdings to be made with respect to any Holder, Parent shall instruct the
Rights Agent to solicit IRS Form W-9s from Holders eligible for Tax
withholding within a reasonable amount of time in order to provide the
opportunity for the Holder to provide any necessary Tax forms (including an
IRS Form W-9 or an applicable IRS Form W-8) in order to avoid or reduce such
withholding amounts. To the extent such amounts are so deducted or withheld,
such amounts shall be treated for all purposes under this Agreement as having
been paid to the person to whom such amounts would otherwise have been paid,
and prior to the 15th day of February in the year following any payment of
such Taxes by Parent or the Rights Agent, Parent shall deliver (or shall
cause the Rights Agent to deliver) to the person to whom such amounts would
otherwise have been paid the original Form 1099 or other reasonably
acceptable evidence of such withholding.

  



  

   

6 
--- 

 


--- 

    



  

(d) Any portion of any Milestone Payment that remains undistributed to the
Holders nine months after the date of the Milestone Notice shall be
delivered by the Rights Agent to Parent, upon demand, and any Holder shall
thereafter look only to Parent for payment of such Milestone Payment, without
interest, but such Holder shall have no greater rights against Parent than
those accorded to general unsecured creditors of Parent under applicable law.

  



  

(e) Neither Parent nor the Rights Agent shall be liable to any person in
respect of any Milestone Payment delivered to a public official in
compliance with any applicable state, federal or other abandoned property,
escheat or similar law. If, despite Parent's and/or the Rights Agent's
commercially reasonable efforts to deliver a Milestone Payment to the
applicable Holder, such Milestone Payment has not been paid prior to the date
on which such Milestone Payment would otherwise escheat to or become the
property of any Governmental Entity, any such Milestone Payment shall, to the
extent permitted by applicable Law, immediately prior to such time become
the property of Parent, free and clear of all claims or interest of any
person previously entitled thereto. In addition to and not in limitation of
any other indemnity obligation herein, Parent agrees to indemnify and hold
harmless Rights Agent with respect to any liability, penalty, cost or expense
Rights Agent may incur or be subject to in connection with transferring such
property to Parent.

  



  

(f) Except to the extent any portion of any Milestone Payment is required to
be treated as imputed interest pursuant to applicable Law, the Holders and
the parties hereto agree to treat the CVRs received with respect to shares of
Company Common Stock pursuant to the Merger Agreement for all U.S. federal
and applicable state and local income Tax purposes as additional consideration
paid at the Effective Time for shares of Company Common Stock pursuant to the
Merger Agreement and none of the Holders and the parties hereto will take
any position to the contrary on any U.S. federal and applicable state and
local income Tax Return or for other U.S. federal and applicable state and
local income Tax purposes except as required by applicable Law. The Company
shall report imputed interest on the CVRs pursuant to Section 483 of the
Code. The Holders and the parties hereto agree that the Milestone Payments
paid in respect of each CVR that was received with respect to Company Options
pursuant to the Merger Agreement, for all U.S. federal and applicable
state and local income Tax purposes, constitute wages in the year in which
the applicable Milestone Payment is made, and none of the Holders and the
parties hereto will take any position contrary on any U.S. federal and
applicable state and local income Tax Return or for other U.S. federal and
applicable state and local income Tax purposes except as required by
applicable Law.

  



  

2.5. _No Voting, Dividends or Interest; No Equity or Ownership Interest in
Parent_.

  



  

(a) The CVRs shall not have any voting or dividend rights, and interest shall
not accrue on any amounts payable on the CVRs to any Holder.

  



  

   

7 
--- 

 


--- 

    



  

(b) The CVRs shall not represent any equity or ownership interest in Parent
or in any constituent company to the Merger or any of their
respective Affiliates.

  



  

3. THE RIGHTS AGENT

  



  

3.1. _Certain Duties and Responsibilities_. The Rights Agent shall not have
any liability for any actions taken, suffered or omitted to be taken in
connection with this Agreement, except to the extent of its gross negligence,
bad faith or willful or intentional misconduct.

  



  

3.2. _Certain Rights of Rights Agent_. The Rights Agent undertakes to perform
such duties and only such duties as are specifically set forth in
this Agreement, and no implied covenants or obligations shall be read into
this Agreement against the Rights Agent. In addition:

  



  

(a) the Rights Agent may rely and shall be protected and held harmless by
Parent in acting or refraining from acting upon any resolution,
certificate, statement, instrument, opinion, report, notice, request,
direction, consent, order or other paper or document believed by it in good
faith to be genuine and to have been signed or presented by the proper party
or parties;

  



  

(b) whenever the Rights Agent shall deem it desirable that a matter be proved
or established prior to taking, suffering or omitting any action
hereunder, the Rights Agent may rely upon an Officer's Certificate, which
certificate shall be full authorization and protection to the Rights Agent,
and the Rights Agent shall, in the absence of gross negligence, bad faith or
willful or intentional misconduct on its part, incur no liability and be held
harmless by Parent for or in respect of any action taken, suffered or omitted
to be taken by it under the provisions of this Agreement in reliance upon
such certificate;

  



  

(c) the Rights Agent may engage and consult with counsel of its selection and
the written advice of such counsel or any opinion of counsel shall be full
and complete authorization and protection and shall be held harmless by Parent
in respect of any action taken, suffered or omitted by it hereunder in good
faith and in reliance thereon;

  



  

(d) the permissive rights of the Rights Agent to do things enumerated in this
Agreement shall not be construed as a duty;

  



  

(e) the Rights Agent shall not be required to give any note or surety in
respect of the execution of such powers or otherwise in respect of the
premises;

  



  

(f) the Rights Agent shall not be liable for or by reason of, and shall be
held harmless by Parent with respect to any of the statements of fact
or recitals contained in this Agreement or be required to verify the same,
but all such statements and recitals are and shall be deemed to have been
made by the Parent only;

  



  

(g) the Rights Agent shall have no liability and shall be held harmless by
Parent in respect of the validity of this Agreement or the execution
and delivery hereof (except the due execution and delivery hereof by the
Rights Agent and the enforceability of this Agreement against the Rights
Agent assuming the due execution and delivery hereof by Parent); nor shall it
be responsible for any breach by the Parent of any covenant or condition
contained in this Agreement;

  



  

(h) Parent agrees to indemnify Rights Agent for, and hold Rights Agent
harmless against, any loss, liability, claim, demands, suits or expense
arising out of or in connection with Rights Agent's duties under this
Agreement, including the reasonable out-of-pocket costs and expenses of
defending Rights Agent against any claims, charges, demands, suits or loss,
unless such loss has been determined by a court of competent jurisdiction to
be a result of Rights Agent's gross negligence, bad faith or willful or
intentional misconduct;

  



  

   

8 
--- 

 


--- 

    



  

(i) Rights Agent shall not be liable for consequential damages under any
provision of this Agreement or for any consequential damages arising out of
any act or failure to act hereunder in the absence of gross negligence, bad
faith or willful or intentional misconduct on its part;

  



  

(j) Parent agrees (i) to pay the fees and expenses of the Rights Agent in
connection with this Agreement as agreed upon in writing by the Rights Agent
and Parent on or prior to the date hereof, and (ii) to reimburse the Rights
Agent for all Taxes and governmental charges, reasonable out-of-pocket
expenses and other charges of any kind and nature incurred by the Rights Agent
in the execution of this Agreement (other than Taxes imposed on or measured
by the Rights Agent's net income and franchise or similar Taxes imposed on it
(in lieu of net income Taxes)). The Rights Agent shall also be entitled to
reimbursement from Parent for all reasonable and necessary out-of-pocket
expenses paid or incurred by it in connection with the administration by the
Rights Agent of its duties hereunder; and

  



  

(k) No provision of this Agreement shall require the Rights Agent to expend
or risk its own funds or otherwise incur any financial liability in
the performance of any of its duties hereunder or in the exercise of its
rights if there shall be reasonable grounds for believing that repayment of
such funds or adequate indemnification against such risk or liability is not
reasonably assured to it.

  



  

3.3. _Resignation and Removal; Appointment of Successor_.

  



  

(a) The Rights Agent may resign at any time by giving written notice thereof
to Parent specifying a date when such resignation shall take effect,
which notice shall be sent at least 60 days prior to the date so specified
but in no event shall such resignation become effective until a successor
Rights Agent has been appointed. Parent has the right to remove Rights Agent
at any time by a Board Resolution specifying a date when such removal shall
take effect but no such removal shall become effective until a successor
Rights Agent has been appointed. Notice of such removal shall be given by
Parent to Rights Agent, which notice shall be sent at least 60 days prior to
the date so specified.

  



  

(b) If the Rights Agent provides notice of its intent to resign, is removed
or becomes incapable of acting, Parent, by a Board Resolution, shall as soon
as is reasonably possible appoint a qualified successor Rights Agent who shall
be a stock transfer agent of national reputation or the corporate trust
department of a commercial bank. The successor Rights Agent so appointed
shall, forthwith upon its acceptance of such appointment in accordance with
_Section 3.4_ , become the successor Rights Agent.

  



  

(c) Parent shall give notice of each resignation and each removal of a Rights
Agent and each appointment of a successor Rights Agent by mailing
written notice of such event by first-class mail to the Holders as their
names and addresses appear in the CVR Register. Each notice shall include the
name and address of the successor Rights Agent. If Parent fails to send such
notice within ten Business Days after acceptance of appointment by a
successor Rights Agent, the successor Rights Agent shall cause the notice to
be mailed at the expense of Parent.

  



  

3.4. _Acceptance of Appointment by Successor_. Every successor Rights Agent
appointed hereunder shall execute, acknowledge and deliver to Parent and to
the retiring Rights Agent an instrument accepting such appointment and a
counterpart of this Agreement, and thereupon such successor Rights Agent,
without any further act, deed or conveyance, shall become vested with all the
rights, powers, trusts and duties of the retiring Rights Agent. On request of
Parent or the successor Rights Agent, the retiring Rights Agent shall
execute and deliver an instrument transferring to the successor Rights Agent
all the rights, powers and trusts of the retiring Rights Agent.

  



  

   

9 
--- 

 


--- 

    



  

4. COVENANTS

  



  

4.1. _List of Holders_. Parent shall furnish or cause to be furnished to the
Rights Agent in such form as Parent receives from the Company's
transfer agent (or other agent performing similar services for the Company),
the names and addresses of the Holders within 30 Business Days of the
Effective Time.

  



  

4.2. _Payment of Milestone Payments_. If a Sales Milestone has been achieved
in accordance with this Agreement, Parent shall, promptly (but in any event
no later than three Business Days) following the delivery of the Milestone
Notice, deposit with the Rights Agent, for payment to the Holders in
accordance with _Section 2.4_ , the aggregate amount necessary to pay the
applicable Milestone Payment to all Holders.

  



  

4.3. _Books and Records_. Parent shall, and shall cause its subsidiaries to,
keep true, complete and accurate records in sufficient detail to enable the
Holders and their consultants or professional advisors to determine the
amounts payable hereunder.

  



  

4.4. _Audits_.

  



  

(a) Upon the written request of the Acting Holders provided to Parent within
90 days following the date on which the Holders are delivered the year end
Net Sales Statement in each of 2016, 2017 and 2018 pursuant to _Section
2.4(a)_ of this Agreement (the " _Review Request Period_ "), Parent shall
permit, and shall cause its controlled Affiliates to permit, the Independent
Accountant to have access during normal business hours to such of the records
of the Company or, to the extent available to Parent, other applicable
Selling Entity as may be reasonably necessary to verify the accuracy of the
Net Sales Statement and the figures underlying the calculations set forth
therein, including all written materials related to any sale transaction
reasonably requested by such Independent Accountant. The Independent
Accountant, acting as an expert and not as an arbitrator, shall be charged to
come to a final determination with respect to those specific items in the Net
Sales Statement that the Acting Holders and Parent disagree on and submit to
it for resolution, and the scope of the disputes to be resolved by the
Independent Accountant shall be limited to such specific items. All other
items in the Net Sales Statement that the Acting Holders and Parent do not
submit, prior to the end of the Review Request Period, to the Independent
Accountant for resolution shall be deemed to be agreed by the Acting
Holders and Parent and the Independent Accountant shall not be charged with
calculating or validating those agreed upon items. If issues are submitted to
the Independent Accountant for resolution, Parent shall, and shall cause its
controlled Affiliates to, furnish to the Independent Accountant such access,
work papers and other documents and information related to those disputed
issues as the Independent Accountant may request and as are available to
Parent. The Independent Accountant shall disclose to Parent and the Acting
Holders any matters directly related to their findings to the extent necessary
to verify the accuracy or completeness of the Net Sales Statements. The fees
charged by such accounting firm shall be paid by Parent.

  



  

(b) If the Independent Accountant concludes that there was a shortfall in the
amount of any Milestone Payment paid to the Holders, Parent shall
promptly pay to the Rights Agent (for further distribution to the Holders) or
to the Holders the amount of any such shortfall, plus interest on such amount
at the "prime rate" as published in the Wall Street Journal or similar
reputable data source from time to time calculated from when the applicable
Milestone Payment should have been paid, as applicable, to the date of actual
payment (such amount including interest being the " _CVR Shortfall_ "). The
CVR Shortfall shall be paid within ten Business Days of the date the
Independent Accountant delivers to Parent and the Acting Holders the
Independent Accountant's written report. The decision of the Independent
Accountant shall be final, conclusive and binding on Parent and the Holders,
shall be non-appealable and shall not be subject to further review. The
decision of the Independent Accountant under this _Section 4.4_ shall
constitute an expert determination under the law governing expert
determination and not an arbitration.

  



  

   

10 
--- 

 


--- 

    



  

(c) If, upon the expiration of the Review Request Period, the Acting Holders
have not requested a review of the Net Sales Statement in accordance with
this  _Section 4.4_ , the calculations set forth in the Net Sales Statement
shall be final, binding and conclusive upon the Holders, shall be non-
appealable and shall not be subject to further review.

  



  

(d) Each person seeking to receive information from Parent in connection with
a review pursuant to this _Section 4.4_ shall enter into, and shall cause its
accounting firm to enter into, a reasonable and mutually satisfactory
confidentiality agreement with Parent or any controlled Affiliate obligating
such party to retain all such information disclosed to such party in
confidence pursuant to such confidentiality agreement.

  



  

(e) The parties hereto agree that, if Parent or its Affiliates have exercised
audit rights under any license or distribution agreement prior to the
Acting Holders' request for an audit under this _Section 4.4_ and under such
license or distribution agreement Parent and its Affiliates cannot request
another audit, the results of Parent's prior audit of such licensee or
distributor shall be used for purposes of the audit requested by the Acting
Holders under this _Section 4.4_ and that Parent shall not have any
further obligation to provide access to an Independent Accountant with
respect to such licensee until such time as Parent may again exercise its
rights of audit under the license agreement with such licensee.

  



  

5. AMENDMENTS

  



  

5.1. _Amendments without Consent of Holders_.

  



  

(a) Without the consent of any Holders or the Rights Agent, Parent, when
authorized by a Board Resolution, at any time and from time to time, may
enter into one or more amendments hereto, for any of the following purposes:

  



  

(i) to evidence the succession of another Person as a successor Rights Agent
and the assumption by any such successor of the covenants and obligations of
the Rights Agent herein;

  



  

(ii) to add to the covenants of Parent such further covenants, restrictions,
conditions or provisions as Parent shall consider to be for the protection of
the Holders; _provided_ that, in each case, such provisions do not adversely
affect the interests of the Holders;

  



  

(iii) to cure any ambiguity, to correct or supplement any provision herein
that may be defective or inconsistent with any other provision herein, or to
make any other provisions with respect to matters or questions arising under
this Agreement; _provided_ that, in each case, such provisions do not
adversely affect the interests of the Holders;

  



  

(iv) as may be necessary or appropriate to ensure that the CVRs are not
subject to registration under the Securities Act, the Exchange Act or any
applicable state securities or "blue sky" laws;

  



  

   

11 
--- 

 


--- 

    



  

(v) to reduce the number of CVRs, in the event any Holder agrees to renounce
such Holder's rights under this Agreement in accordance with _Section 6.4_ ;

  



  

(vi) to evidence the assignment of this Agreement by Parent as provided in
_Section 6.3_ ; or

  



  

(vii) any other amendments hereto for the purpose of adding, eliminating or
changing any provisions of this Agreement, unless such addition,
elimination or change is adverse to the interests of the Holders.

  



  

(b) Promptly after the execution by Parent and the Rights Agent of any
amendment pursuant to the provisions of this _Section 5.1_ , Parent
shall mail (or cause the Rights Agent to mail) a notice thereof by first
class mail to the Holders at their addresses as they appear on the CVR
Register, setting forth such amendment.

  



  

5.2. _Amendments with Consent of Holders_.

  



  

(a) Subject to _Section 5.1_ (which amendments pursuant to _Section 5.1_ may
be made without the consent of the Holders or the Rights Agent), with the
consent of the Holders of not less than a majority of the outstanding CVRs,
whether evidenced in writing or taken at a meeting of the Holders, Parent,
when authorized by a Board Resolution, and the Rights Agent may enter into one
or more amendments hereto for the purpose of adding, eliminating or changing
any provisions of this Agreement, even if such addition, elimination or
change is materially adverse to the interest of the Holders.

  



  

(b) Promptly after the execution by Parent and the Rights Agent of any
amendment pursuant to the provisions of this _Section 5.2_ , Parent
shall mail (or cause the Rights Agent to mail) a notice thereof by first
class mail to the Holders at their addresses as they appear on the CVR
Register, setting forth such amendment.

  



  

5.3. _Execution of Amendments_. In executing any amendment permitted by this
_Section_ 5, the Rights Agent shall be entitled to receive, and shall be
fully protected in relying upon, an opinion of counsel selected by Parent
stating that the execution of such amendment is authorized or permitted by
this Agreement. The Rights Agent may, but is not obligated to, enter into any
such amendment that affects the Rights Agent's own rights, privileges,
covenants or duties under this Agreement or otherwise.

  



  

5.4. _Effect of Amendments_. Upon the execution of any amendment under this
_Section _5, this Agreement shall be modified in accordance therewith, such
amendment shall form a part of this Agreement for all purposes and
every Holder shall be bound thereby.

  



  

6. OTHER PROVISIONS OF GENERAL APPLICATION

  



  

6.1. _Notices to Rights Agent and Parent_. All notices and other
communications hereunder shall be in writing and shall be deemed to have been
duly delivered and received hereunder (i) four Business Days after being sent
by registered or certified mail, return receipt requested, postage prepaid,
(ii) one Business Day after being sent for next Business Day delivery, fees
prepaid, via a reputable nationwide overnight courier service, or (iii)
immediately upon delivery by email, by hand or by facsimile (with a written
or electronic confirmation of delivery), in each case to the intended
recipient as set forth below:

  



  

   

12 
--- 

 


--- 

    



  

If to the Rights Agent, to it at:

  



  

[] 
 [Address] 
 Attn: []

  

Facsimile: []

  

Email: []

  



  

With a copy to: 
  
 [] 
 [Address] 
 Attn: []

  

Facsimile: []

  

Email: []

  



  

If to Parent, to it at: 
  
 H. Lundbeck A/S

  

Ottiliavej 9; 2500

  

Valby, Denmark

     Attention:  | Mette Carlstedt 
---|--- 
     | Jacob Tolstrup 
   Facsimile:  | +453648249 
     | +453648280 
   Email address:  | meco@lundbeck.com 
     | jtl@lundbeck.com 
  



  

with a copy to: 
  
 Cravath, Swaine and Moore LLP 
 825 Eighth Avenue 
 New York, NY 10019

     Attention:   | Faiza Saeed 
---|--- 
     | Ting S. Chen 
   Facsimile:  | (212) 474-3700 
   Email:  | fsaeed@cravath.com 
     | tchen@cravath.com 
  



  

The Rights Agent or Parent may specify a different address or facsimile
number by giving notice in accordance with this _Section 6.1_.

  



  

6.2. _Notice to Holders_. Where this Agreement provides for notice to
Holders, such notice shall be sufficiently given (unless otherwise
herein expressly provided) if in writing and mailed, first-class postage
prepaid, to each Holder affected by such event, at the Holder's address as it
appears in the CVR Register, not later than the latest date, and not earlier
than the earliest date, if any, prescribed for the giving of such notice. In
any case where notice to Holders is given by mail, neither the failure to mail
such notice, nor any defect in any notice so mailed, to any particular Holder
shall affect the sufficiency of such notice with respect to other Holders.

  



  

6.3. _Parent Successors and Assigns_. Parent may assign, in its sole
discretion and without the consent of any other party, any or all of its
rights, interests and obligations hereunder (i) to one or more direct or
indirect wholly-owned subsidiaries of Parent or (ii) to any
purchaser, licensee or sublicensee of substantial rights to the Product that
is a company in the pharmaceutical industry (each, an " _Assignee_ "); 
_provided_ that the Assignee agrees to assume and be bound by all of the terms
of this Agreement. Any such Assignee may thereafter assign, in its sole
discretion and without the consent of any other party, any or all of its
rights, interests and obligations hereunder to one or more additional
Assignees who agree to assume and be bound by all of the terms of this
Agreement; _provided_ ,  _however_ , that in connection with any assignment
to an Assignee pursuant to clause (i) of the first sentence of this
_Section 6.3_ and, only if the Assignee does not have net assets of at least
$1,000,000,000 as shown on its most recently prepared financial statements,
clause (ii) of the first sentence of this _Section 6.3_ , Parent (or the other
assignor) shall agree to remain liable for the performance by each Assignee
(and such other assignor, if applicable) of all obligations of Parent
hereunder, with such Assignee substituted for Parent under this Agreement.
This Agreement will be binding upon, inure to the benefit of and
be enforceable by Parent's successors and each Assignee. Subject to
compliance with the requirements set forth in this _Section 6.3_ relating to
assignments, this Agreement shall not restrict Parent's, any Assignee's or any
of their respective successors' ability to merge or consolidate with, or
sell, issue, license or dispose of its stock or other equity interests or
assets to, any other Person, or spin-off or split-off. Each of Parent's
successors and assigns shall, by a supplemental contingent
consideration payment agreement or other acknowledgement executed and
delivered to the Rights Agent, expressly assume payment of amounts on all the
CVRs and the performance of every duty and covenant of this Agreement on the
part of Parent to be performed or observed.

  



  

   

13 
--- 

 


--- 

    



  

6.4. _Benefits of Agreement_. Nothing in this Agreement, express or implied,
shall give to any Person (other than the Rights Agent, Parent, Parent's
successors and assignees, and the Holders, each of whom is intended to be, and
is, a third party beneficiary hereunder) any benefit or any legal or
equitable right, remedy or claim under this Agreement or under any covenant or
provision herein contained, all such covenants and provisions being for the
sole benefit of the Rights Agent, Parent, Parent's successors and
assignees, and the Holders. The Holders of CVRs shall have no rights except
the contractual rights as are expressly set forth in this
Agreement. Notwithstanding anything to the contrary contained herein, any
Holder may at any time agree to renounce, in whole or in part, whether or not
for consideration, such Holder's rights under this Agreement by written notice
to the Rights Agent and Parent, which notice, if given, shall be irrevocable,
and Parent may, in its sole discretion, at any time offer consideration to
Holders in exchange for their agreement to irrevocably renounce their rights
hereunder.

  



  

6.5. _Governing Law_. This Agreement, the CVRs and all actions arising under
or in connection therewith (whether sounding in contract, tort or otherwise)
shall be governed by and construed in accordance with the laws of the State of
Delaware, regardless of the laws that might otherwise govern under applicable
principles of conflicts of laws thereof.

  



  

6.6. _Arbitration_. Any dispute, controversy or claim (including any claim
for breach hereof) based upon, relating to or arising out of this
Agreement or any transaction contemplated hereby shall be resolved by binding
arbitration conducted in accordance with the Rules of Arbitration (" _Rules_
") of the International Chamber of Commerce (the " _ICC_ "). The arbitration
will be conducted by a panel of three arbitrators, each of whom shall be
independent and a lawyer or retired judge with at least fifteen years
experience in the pharmaceutical industry or with mergers and acquisitions.
No later than fifteen days after an arbitration proceeding is commenced under
this _Section 6.6_ , Parent will nominate one arbitrator and the Holder (or,
if more than one Holder is a party to the arbitration proceeding, all such
Holders collectively) will nominate one arbitrator, and the two so nominated
arbitrators shall select the third arbitrator. If the two arbitrators cannot
or fail to agree upon the third arbitrator within fifteen days of their
confirmation by the ICC, the third arbitrator shall be appointed by the ICC in
accordance with the Rules. The arbitration shall be administered by the ICC
acting through its International Court of Arbitration. The arbitration will be
conducted in the English language and the place of the arbitration will be
the city of New York, New York. Hearings will be conducted in New York, New
York, or at such other location as mutually agreed by Parent and the Holder or
Holders that are party to the arbitration proceeding. The arbitration award
shall be final, conclusive, binding and non-appealable and shall not be
subject to further review by any court. The arbitrator shall have no power to
amend or supplement the terms of this Agreement or act ex aequo et bono.
Judgment upon the award may be entered in any court having jurisdiction
thereof. Each party shall bear his, her or its own costs of any such
arbitration. Notwithstanding anything to the contrary in this _Section 6.6_ ,
any dispute, controversy or claim relating to the accuracy of the Net Sales
Statement or the determination of any Milestone Payment or CVR Shortfall shall
be resolved in accordance with the provisions of _Section 4.4_ and not
subject to the arbitration provisions of this _Section 6.6_.

  



  

   

14 
--- 

 


--- 

    



  

6.7. _Severability_. In the event that any provision of this Agreement, or
the application thereof, becomes or is declared by a court of competent
jurisdiction to be illegal, void or unenforceable, the remainder of this
Agreement shall continue in full force and effect and the application of such
provision to other persons or circumstances shall be interpreted so as
reasonably to effect the intent of the parties. The parties further agree to
replace such void or unenforceable provision of this Agreement with a valid
and enforceable provision that will achieve, to the extent possible, the
economic, business and other purposes of such void or unenforceable provision.

  



  

6.8. _Counterparts and Signature_. This Agreement may be executed in one or
more counterparts, all of which shall be considered one and the
same agreement and shall become effective when one or more counterparts have
been signed by each party and delivered to the other party, it being
understood that all parties need not sign the same counterpart.

  



  

6.9. _Termination_. This Agreement shall be terminated and of no force or
effect, the parties hereto shall have no liability hereunder (other than with
respect to monies due and owing by Parent to Rights Agent), and no payments
shall be required to be made, upon the earlier to occur of (a) the mailing by
the Rights Agent to the address of each Holder as reflected in the CVR
Register the full amount of all potential Milestone Payments required to be
paid under the terms of this Agreement and (b) in the event the applicable
Milestone Notice indicates that the 2017 Sales Milestone has not been
achieved, the expiration of the applicable Review Request Period,
unless there has been a request for an audit pursuant to _Section 4.4_ prior
to the end of the Review Request Period, in which case until such audit has
been completed and any CVR Shortfall determined to be payable as a result of
such audit, if applicable, has been paid.

  



  

6.10. _Entire Agreement_. This Agreement and the Merger Agreement (including
the annexes and exhibits hereto and thereto) constitute the entire agreement
among the parties with respect to the subject matter hereof and supersedes all
prior agreements and understandings, both written and oral, among the parties
with respect to the subject matter hereof. If and to the extent that any
provision of this Agreement is inconsistent or conflicts with the Merger
Agreement, this Agreement shall govern and be controlling.

  



  

[ _REMAINDER OF PAGE INTENTIONALLY LEFT BLANK_ ]

  



     

   

15 
--- 

 


--- 

    



  

IN WITNESS WHEREOF, each of the parties has caused this Agreement to be
executed on its behalf by its duly authorized officers as of the day and
year first above written.

  



       | H. LUNDBECK A/S 
---|--- 
     |   | 
     | By:   | 
     | Name: 
     | Title: 
     |   | 
     | [RIGHTS AGENT] 
     |   | 
     | By:   | 
     | Name: 
     | Title: 
  



  

[Signature Page to Contingent Value Rights Agreement]

    



  

   


--- 

    



       '

